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ABSTRACT 
This work investigated the use of polyanhydride microspheres as drug delivery 
carriers for therapeutic proteins. The specific polyanhydrides investigated were poly(sebacic 
anhydride) and copolymers of poly[ 1,6-bis(p-carboxyphenoxy)hexane] (poly(CPH)) and 
poly(SA), 20:80 (CPH:SA), 50:50 (CPH:SA), and 80:20 (CPH:SA). The model protein 
bovine serum albumin (BSA) was encapsulated in poly(SA), 20:80 (CPH:SA), 50:50 
(CPH:SA), and 80:20 (CPH:SA) microspheres to determine the feasibility of using 
polyanhydrides as protein carriers. Poly(SA) and 20:80 (CPH:SA) microspheres were found 
to stabilize the encapsulated BSA and were used for all future studies. The compatibility of 
three proteins (ovalbumin, lysozyme, and tetanus toxoid) with polyanhydride or polyester 
degradation products was investigated. This work provided a rational approach for selecting 
compatible protein/polymer systems prior to encapsulating a protein in a polymeric 
microspheres. The role of the microsphere fabrication process on protein stability was 
studied by encapsulating ovalbumin in microspheres fabricated by four different fabrication 
techniques (water-oil-water, water-oil-oil, soli-oil-oil, and a cryogenic atomization method). 
The in vitro release kinetics, encapsulation efficiencies, and structural stability of the 
encapsulated and released ovalbumin were investigated. The cryogenic atomization method 
was used in future applications. The therapeutic protein, uterocalin, was encapsulated in 
polyanhydride microspheres and its biological activity upon release in vitro was measured. 
Uterocalin released from poly(SA) and 20:80 (CPH.SA) microspheres was biologically 
active. This work demonstrates that polyanhydrides microspheres are suitable drug delivery 





Between 1980 and 2001 the food and drug administration (FDA) approved 554 new 
therapeutic drugs [1]. Small molecular weight drugs made up the majority of the new 
therapeutics approved (504), followed by recombinant proteins (40), and monoclonal 
antibodies (10). As recombinant DNA practices have become more routine, the number of 
recombinant DNA products entering the market has increased. With the increasing number 
of therapeutic proteins being marketed in United States each year more research is being 
directed towards developing superior methods of delivering proteins. Unlike low molecular 
weight drugs, proteins are complex three-dimensional molecules, whose functionality 
depends on their higher-order structure [2], Proteins are prone to chemical (e.g., 
deamidation, oxidation) and physical (aggregation, precipitation, and adsorption) alterations 
[2-5]. The mechanisms by which proteins undergo structural alterations are protein specific; 
but, there are known factors that decrease the stability of proteins such as elevated 
temperature and moisture [3, 4, 6, 7], Parenteral administration remains the most common 
method of delivering proteins; however, this method often provides no method of stabilizing 
the shelf life of the protein or increasing the half-life of the protein in vivo [8]. 
Controlled delivery devices are more advantageous than traditional methods of 
administering drugs. Traditional drug delivery requires repeat administration to maintain 
therapeutic levels. Repeat administration results in poor patient compliance and peak 
concentrations of the drug. If administered too frequently, fatal concentrations of the drug 
2 
may occur, while infrequent administration may result in the inability to maintain therapeutic 
levels of the drug. Figure 1.1 illustrates the in vivo drug concentration during traditional drug 
administration. Controlled delivery devices that initially elevate the drug concentration in 
the serum to therapeutic values and maintain that concentration for a prolonged period 
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Time 
Figure 1.1. Schematic demonstrating the in vivo concentration of a drug administered by 
traditional methods. 
A vehicle that can be delivered via parenteral administration and is capable of 
preserving the function of native proteins while simultaneously providing controlled release 
in vivo is needed. The ability of biodegradable polymers to meet these requirements is being 
investigated. The biodegradable polymer that has received the most attention as a protein 
delivery vehicle is poly(D,L-lactide-co-glycolide) (PLGA). PLGA has been used to 
encapsulate and release numerous model and therapeutic proteins, such as bovine serum 
albumin (BSA) [9-16], lysozyme [15, 17, 18], recombinant human growth hormone (rhGH) 
[19-22], and recombinant human insulin like growth factor-1 (rhIGF-I) [23-25]. Because 
3 
PLGA is a bulk-eroding polymer, as soon as it is exposed to an aqueous environment the 
encapsulated protein is exposed to elevated moisture content. This increase in moisture can 
cause covalent aggregation of the encapsulated protein [6, 7]. The addition of excipients 
(e.g., trehalose or dextran) is needed to help prevent covalent aggregation of the encapsulated 
protein [12, 13, 26]. As PLGA degrades, the pH within the polymeric device drops 
significantly, providing a less than ideal microclimate for the protein [27]. Co-encapsulating 
basic moieties, such as antacids, are needed to stabilize the encapsulated protein [9]. 
Polyanhydrides are biodegradable polymers that have also been investigated as 
protein carriers [28]. Polyanhydrides are more hydrophobic than PLGA. Polyanhydrides are 
surface eroding polymers as a result of their increased hydrophobicity. By eroding from the 
surface inward the moisture level that an encapsulated protein is exposed to is minimized, 
reducing moisture induced protein aggregation [29-32]. As polyanhydrides degrade, the pH 
surrounding the degrading device does not drop as severely as in PLGA, providing a more 
suitable microclimate for encapsulated and released proteins [31]. 
For parenteral formulations, microspheres are the most commonly used controlled 
delivery vehicle to encapsulated proteins or low molecular weight drugs. Microspheres can 
be fabricated by three different procedures: hot melt, solvent removal, and spray drying [33-
40]. The hot melt procedure is not advantageous when encapsulating proteins, because the 
elevated temperatures needed to melt the polymer can denature proteins. Solvent removal, 
either oil-in-oil (O/O) or water-in-oil-in-water (W/O/W) (also known as the double emulsion 
methods), and spray drying can be performed at or below room temperature. While spray 
drying requires the use of an atomizer the solvent removal techniques require no special 
equipment. Care must be taken when encapsulating proteins using a solvent removal 
4 
technique because the presence of a water/oil interface can cause protein inactivation (e.g., 
denaturation) [41]. 
When encapsulating a protein in a polymer microsphere, there are three stages in 
which the protein must maintain its stability: microsphere fabrication, storage, and release of 
the protein from the eroding microspheres. A detailed understanding of each of these 
considerations is needed before any polymer can be used clinically for the delivery of 
proteins. Maintaining the functionality of the protein during the encapsulation process 
requires an understanding of how a specific protein denatures, and one must avoid those 
conditions during the microsphere fabrication process. Once the protein has been 
successfully encapsulated within a polymer matrix, it is necessary to characterize the 
interactions between the polymer matrix and the protein. By characterizing the interactions, 
it is possible to determine if the function of the protein has been altered (e.g., through non-
covalent interactions) and if the shelf life of the protein has been extended. Finally, it is 
important to be able to control the release of the protein from the device by understanding: 
how the release of the protein will be influenced by the protein distributed within the 
microsphere, how the protein interacts with the degradation products of the polymer, and 
how the microenvironment surrounding the microsphere affects the stability and diffusion of 
the released protein. 
The overall objective of this research is to demonstrate that polyanhydrides can be 
used to stabilize and provide a controlled release of proteins. Rational strategies that can be 
generalized and applied to several different protein/polymer systems will be developed. This 
will be accomplished by meeting the following specific goals: 
1. Demonstrate the feasibility of using polyanhydrides microspheres as protein carriers. 
2. Discern the compatibility of proteins with biodegradable polymer degradation 
products. 
3. Study the role of microsphere fabrication methods on protein stability. 
4. Apply the insights gained from specific goals 1, 2, and 3 to design uterocalin-loaded 
polyanhydride microspheres to expedite cell migration for applications for 
applications in wound healing. 
The polymers to be used in this work are poly(sebacic anhydride) (poly(SA)) and 
copolymers of poly[l,6-bis-p(carboxyphenoxy)hexane] (poly((CPH)) and poly(SA). The 
repeat units of poly(SA) and poly(CPH) are shown in Figure 1.2. 
a. 
O O 
II I X II 
-c-hcHr)rc-o-
b. 
Figure 1.2. The chemical structures of (a) poly(sebacic anhydride) (poly(SA)) and (b) 
poly[ 1,6-bis-p(carboxyphenoxy)hexane] (poly(CPH)). 
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CHAPTER 2 
ENGINEERING SURFACE-ERODIBLE POLYANHYDRIDES WITH TAILORED 
MICROSTRUCTURE FOR CONTROLLED DELIVERY 
A paper published in: H.S. Nalwa, editor. Handbook of nanostructured biomaterials and their 
applications in nanotechnology. Stevenson Ranch: American Scientific Publishers, 2005. p. 
108-141. Amy S. Determan1'2 and Balaji Narasimhan2'3 
2.1 Introduction 
This chapter summarizes the literature concerning polyanhydride synthesis, 
characterization, and degradation. A section describing mechanisms of protein inactivation 
is included, as well as a review of protein-loaded microsphere systems including fabrication 
and characterization techniques, followed by a section discussing release of proteins from 
polymeric microspheres. 
2.2 Polymer Synthesis 
Butcher and S lade first synthesized polyanhydrides in 1909 [1]. Twenty years later, 
Hill and Carothers studied aliphatic polyanhydrides for use in textiles. They soon discovered 
that polyanhydrides are hydrolytically unstable (e.g., water) making them a poor choice for 
textiles [2, 3]. It was not until the 1980's when Langer suggested using polyanhydrides as 
drug delivery devices that a practical use for polyanhydrides was identified [4], Since the 
1 Graduate student; primary author and researcher 
2 Department of Chemical and Biological Engineering, Iowa State University 
3 Major professor; corresponding author 
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1980's, two polyanhydrides, poly(sebacic anhydride) (poly(SA)) and poly(l,3-bis(p-
carboxyphenoxy) propane) (poly(CPP)), have been approved for human use by the U.S. food 
and drug administration (FDA) [5]. Table 2.1 shows the monomer structure of poly(SA) and 
poly(CPP) and other prevalent polyanhydrides used in medial applications. 
Polyanhydrides have been synthesized by melt polycondensation, in solution, and as 
ring opening reactions. Melt polycondensation reactions typically lead to higher molecular 
weight polymers than any of the other routes of polymerization and are most often 
employed. Melt polycondensation reactions cannot be used if the monomer to be 
polymerized is heat sensitive; hence alternative routes of polymerization are discussed. 
Table 2.1 : Common anhydride monomers used for drug delivery systems 
Structure Chemical Name (Abbreviation) 
O O n = 4 adipic anhydride (AA) n = 5 azelaic anhydride 
n = 6 suburic anhydride 
n = 8 sebacic anhydride (SA) 
n = 10 docecanedioic anhydride (DD) 
o-(-ch2-^o 
o 
"| n = 1 p-carboxyphenoxy methane (CRM) 
O n = 3 p-carboxyphenoxy propane (CPP) 
n = 4 p-carboxyphenoxy valeric anhydride (CPV) 
n = 1 p-carboxyphenoxy acetic anhydride (CPA) 
n = 4 p-carboxyphenoxy valeric anhydride (CPV) 
n = 8 p-carboxyphenoxy octanoic acid (CPO) 
n = 1 p-carboxyphenoxy acetic anhydride (CPA) 
n = 4 p-carboxyphenoxy valeric anhydride (CPV) 
n = 8 p-carboxyphenoxy octanoic acid (CPO) 
Phenylenedipropionic anhydride (POP) 
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Table 2.1 : Common anhydride monomers used for drug delivery systems (continued) 






Fumaric Acid (FA) 
1, 4'-cyclohexanedicarboxlyic anhydride (CHDA) 
Trimellitylimido-glycine (TMA-GLY) 
O O O O 
Pyromellitylimido-alanine (PMA-ALA) 
Trimellitylimido-tyrosine (TMA-TYR) 
2.2.1 Melt polycondensation 
Melt polycondensation reactions can be broken up into two separate steps. In the first 
step, dicarboxylic acids are refluxed with an excess amount of acetic anhydride resulting in 
prepolymers with a degree of polymerization ranging from 1 to 20. In the second step, the 
prepolymer is polymerized in a dry environment, under vacuum, and at elevated 
temperatures, typically 150-200 °C, Figure 2.1 [5]. 
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Figure 2.1. The mechanism of polymerizing anhydrides via melt condensation. Reprinted 
with permission from ref. [6], 
When synthesizing poly(SA) and poly l,6-bis(p-carboxyphenoxy)hexane 
(poly(CPH)), the diacids (e.g., sebacic acid and 1,6-bis(p-carboxyphenoxy)hexane), are 
allowed to reflux with acetic anhydride for 30 and 60 min, respectively. To purify the 
prepolymers, they are dissolved in chloroform and filtered. Sebacic acid is commercially 
available, however, CPH diacid is not. The chemistry outlining the synthesis of CPH diacid 
is similar to the procedure used by Conix for making CPP diacid [7], 
Briefly, CPH diacid is synthesized by adding sodium hydroxide, ^ -hydroxybenzoic 
acid, and water to a reaction vessel. The mixture is stirred and heated. Once it has started to 
reflux, dibromohexane is added dropwise to the vessel. The contents are then allowed to 
reflux overnight. The white precipitate is then filtered and dissolved in warm water and 
fuming sulfuric acid is added. This acidifies the precipitate and the dibasic acid is collected 
by filtration and dried under heat and vacuum. 
The second step of the melt polycondensation reaction is to polymerize the 
prepolymers. This is done under heat and vacuum. The polymerization of poly(SA) and 
poly(CPH) is done at 180 °C and at 3 xlO"1 torn The polymerization of both poly(SA) and 
poly(CPH) proceeds in a stepwise fashion. The molecular mass of the polymers is highly 
dependent on the strength of the vacuum and the purity of the diacids used in the formation 
of the prepolymers [5], 
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There are four variables that affect the molecular weight of a polymer made by melt 
polycondensation: the monomer purity, the temperature of the reaction, the length of the 
reaction, and the adequate removal of the condensation product [8], By taking advantage of 
these variables, pure prepolymers polymerized at 180 °C under a vacuum of 10"4 mm Hg for 
90 minutes, Domb and Langer [8] obtained polyanhydrides with weight-average molecular 
weights (Mw) above 100,000. By over heating or extending the length of time of the 
reaction, the polymers became susceptible to depolymerization, resulting in a lower 
molecular mass product. The removal of the acetic anhydride condensation products was 
essential to obtain high conversions. 
When catalysts such as cadmium acetate, calcium carbonate, earth metal oxides, and 
ZnEtz-HzO were used to synthesize polyanhydrides by melt condensation, higher molecular 
weight polymers were obtained in a shorter length of time [8], Because all of the catalysts 
except calcium carbonate are toxic, catalysts are rarely employed when synthesizing 
polyanhydrides for biomedical use. 
2.2.2 Solution polymerization 
One drawback of melt polycondensation reactions is that the polymerization must 
take place at elevated temperatures. Some monomers are heat sensitive (e.g., dipeptides and 
therapeutically active diacids) and others have such a high melting temperature that the 
product may be charred [9], thus, precluding the use of melt condensation reactions. An 
alternative to melt condensation reactions is solution polymerization in which the 
dicarboxylic acid is polymerized in one step at room temperature. Schotten-Baumann 
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condensation and dehydrative coupling are two common mechanisms for solution 
polymerization [9-12]. 
Schotten-Baumann condensation, shown in Figure 2.2, is essentially the 
dehydrochlorination between a diacid chloride and a dicarboxylic acid. The diacid and the 
base, such as triethylamine or tri-n-propylamine, are dissolved in an organic solvent. To this 
solution, the diacid chloride is added drop wise and allowed to stir at room temperature until 
the reaction is completed (~1 h). To precipitate the polymer petroleum ether is added. 
Polymers with number average molecular weight (Mn) in the range of 2000 to 5000 have 
been reported using Schotten-Baumann condensation [9]. 
hoVo/cAA,— iXWt + Base'HCI 
Figure 2.2. The Schotten-Baumann mechanism used to polymerize polyanhydrides via a 
solution polymerization. Reprinted with permission from ref. [6]. 
Polyanhydrides can also be polymerized in solution by using dehydrative coupling 
agents at room temperature. Mestres et al. [10] and Cabre-Castellvi et al. [11] reported the 
formation of anhydrides by reacting jV,Ar-bis[2-oxo-3-oxazolidinyl]phosphorodiamidic 
chloride with carboxylic acids. Leong et al. [9] later used bis[2-oxo-3-
oxazolidinyl]phosphinic chloride, jV-phenylphosphoroamidochloridate, and diphenyl 
chlorophosphate to synthesize polymeric anhydrides from dicarboxylic acids such as sebacic 
acid and 1,4-pheyhylenedipropionic acid. Bis[2-oxo-3-oxazolidinyl]phosphinic chloride and 
7V-phenylphosphoroamidochloridate were more effective coupling agents, resulting in 
polymers with Mn of 3000, while diphenyl chlorophosphate had a lower coupling activity 
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leading to discolored lower molecular weight polymers. One drawback of using coupling 
agents is the need of an additional separation step needed to remove the catalyst derivatives 
that form during the reaction. This procedure often leads to the hydrolysis of the polymer 
[9]-
Phosgene and disphosgene have also been used as coupling agents in the synthesis of 
polyanhydrides with the use of poly(4-vinylpyridine) (PVP) and K2CO3 as proton acceptors 
[12]. High molecular weight poly(SA) (Mn = 16000) was obtained when a heterogeneous 
acid acceptor (e.g., PVP) was used, as opposed to the lower molecular weight polymer that 
was obtained when the non-amine heterogeneous base K2CO3 was used. 
2.2.3 Ring opening reactions 
In the 1930's, Hill and Carothers studied aliphatic polyanhydrides formed using the 
diacids H00C-(C02)„-(C00H), (n ranged from 4 to 12) and the different transformations to 
which these polymers were susceptible [2, 3] . When the diacids were reacted with acetic 
anhydride linear low molecular weight polymers resulted (denoted a-anhydride). To 
increase the molecular weight of the a-anhydride, it was subjected to a molecular distillation. 
During this process a higher molecular weight polymer formed (co-anhydride) and cyclic 
monomers and dimers were distilled off (|3-anhydride). The (3-anhydride was converted to a 
higher molecular weight polymer on standing (Figure 2.3). Using an aniline reaction, Hill 
and Carothers [3] were able to determine if the products were cyclic monomers, dimers, or 
aliphatic polymers. When aniline was reacted with a monomer only one product resulted, 
acid monoanilide, however, when aniline was reacted with a dimer or a polymer there were 
three possible products: dibasic acid, acid monoanilide, and acid dianilide [2, 3], 
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Albertsson and Lundmark [13] synthesized poly(adipic anhydride) (poly(AA)) by 
first preparing oxepane-2,7-dione and depolymerizing it using two different ring opening 
mechanisms. In the first, the oxepane-2,7-dione prepared by reacting adipic acid with acetic 
anhydride was dissolved in methylene chloride and allowed to react with ZnCli (l%w) for 6 
h at room temperature. The resulting poly(AA) had a Mn of 1700 [14]. The second 
mechanism that they employed was to catalytically depolymerize oxepane-2,7-dione under 
vacuum. The concentration of the catalyst (stannous 2-ethylhexanoate), the reaction time, 
and temperature were all found to influence the depolymerization. The resulting poly(AA) 
had a Mn no greater than 5000. By studying the stannous 2-ethylhexanoate reaction with 1H-
NMR and infrared spectroscopy (IR), it was deduced that a non-ionic insertion 
polymerization mechanism was occurring initially in the reaction. However, after 2 h at 
80°C the anhydride exchange was the dominating reaction [13]. 
V 
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Figure 2.3. Mechanism of polyanhydride formation using ring opening polymerization. 
Reprinted with permission from ref. [6], 
More recently, poly(AA) has been synthesized by ring opening polymerization 
initiated by dibutylmagnesium, potassium poly(ethylene glycol)ate, and aluminum 
triisoporpoxide respectively [15-17], The highest molecular weight was achieved using 
aluminum triisopropoxide as the initiator, and a M„ of 58,000 was obtained [16]. The high 
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molecular weight polymer was polymerized in bulk at 80°C in the presence of the initiator 
and nicotine (nicotine acts as a Lewis base). 
2.3 Polymer Characterization 
In order to optimize the performance of polyanhydrides as biomaterials, their 
chemical composition, molecular weight, degree of crystallinity, and thermal properties need 
to be characterized. These are discussed below. 
2.3.1 Chemical composition 
When copolymerizing aliphatic and aromatic monomers there are three different 
covalent bonds that could result in the polymer backbone: aliphatic-aliphatic, aliphatic-
aromatic (or aromatic-aliphatic), and aromatic-aromatic [18, 19]. These different bonds are 
each represented in the 'H-NMR spectra of a copolymer, thus, making 'H-NMR a useful 
analytical technique for characterizing the chemical composition. In the model system 
poly(CPP:SA), the copolymer has a doublet at 8.1 and 8.0 ppm (J=8.7 Hz) and two triplets at 
2.6 and 2.4 ppm (J=7.4 Hz), while the SA monomer has one triplet at 2.4 ppm and the CPP 
monomer has one doublet at 8.1 ppm [19]. Figure 2.4 shows how the ^H-NMR spectra of 
poly(CPP:SA) changes as the ratio CPP to SA is varied. The additional peaks in the 
copolymer are attributed to long-range deshielding and shielding effects of the additional 
bonds found in the copolymer. The peak at 2.6 ppm is a result of the aliphatic-aromatic bond 
between CPP-SA in the copolymer that has undergone an upward shift, while the peak at 8.0 
ppm is a result of the aliphatic-aromatic bond between CPP-SA that undergoes a downward 
shift. Using the frequency of specific bonds between aliphatic and aromatic monomers the 
reactivity ratio of aliphatic and aromatic monomers, can be determined. A reactivity ratio of 
one for SA monomers with CPP and CPH has been reported [19, 20]. 
'H-NMR can also be used to determine the number average sequence length by 
integrating the area under peaks specific to each particular monomer. Thus,1 H-NMR can be 
used to: verify the percent conversion of the polymerization [21], determine the exact 
composition of copolymers [19,22, 23], monitor the rate of degradation [24], and determine 
the degree of randomness of the copolymer (e.g. if it has a block like or random sequence 
distribution). The sequence distribution is dependent on the ratio of monomers in the 
copolymer. In the CPP.SA and CPH:SA copolymer systems, the dominating monomer has a 
longer number average sequence length and the copolymer displays a block like sequence 
distribution [19, 23]. When no monomer dominates (50:50 (CPP:SA) or (CPH:SA)) the 
distribution of the monomers mimics an alternating copolymer. 
Fourier transform infrared (FTIR) and Raman spectroscopy have also been used to 
characterize homopolymers [9-12, 18, 21, 25-29], determine monomer content in copolymers 
[18, 20, 27, 30-32], study reactions between the anhydride bond and amines [33, 34], and 
study the degradation process of polyanhydrides [31, 35-38], Aliphatic polyanhydrides 
display an anhydride doublet at 1740 and 1810 cm"1, while aromatic polyanhydrides display 
an anhydride doublet at 1720 and 1780 cm"1, as shown in Figure 2.5. When aliphatic and 
aromatic polyanhydrides are copolymerized, two distinct peaks are observed at 1810 cm"1 
and 1780 cm"1, and a third distinct peak is observed between 1720-1740 cm"1. As the 
polyanhydrides undergo hydrolysis the anhydride doublet disappears and is replaced by a 
peak at 1700 cm"1 corresponding to carboxylic acid [39]. 
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Figure 2.4. 1 H NMR spectra of poly(CPP:SA) copolymers, from ref [19]. 
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FTIR was used to study the degradation properties of poly(fumaric anhydride:sebacic 
anhydride) poly(FA:SA) copolymers in three different buffers (0.1M citrate pH 4.2, 
phosphate pH 7.4, and tris pH 8.8 buffers) [36]. In this study, the ratio of the areas under the 
anhydride (1860-1775 cm"1) and carboxylic acid (1770-1675 cm"1) peaks were plotted as a 
function of time. From this information, the amount of free acid formation was also 
calculated. This study helped support the theory that crystalline regions degrade slower than 
amorphous regions and that polyanhydrides degrade faster in alkaline solutions [36]. 
Figure 2.5. FTIR spectra of aliphatic polyanhydride (SA) and aromatic polyanhydride 
(CPH). 
2.3.2 Molecular mass 
Gel permeation chromatography (GPC) and viscosity measurements have been used 
to determine the molecular weight of polyanhydrides [19]. The weight average molecular 
weight (Mw) ranges from 2,000 to 300,000 and the intrinsic viscosity (in chloroform) ranges 
from 0.13 to 1.25 dL/g. The viscosity of the polymers was measured using an Ubbelohde 
4 
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viscometer. The Mark-Houwink relationship for poly(CPP:SA) was determined from the 
viscosity data and the Mw values determined by using polystyrene standards. 
3.88x10-^/™ (1) 
From the Mark-Houwink relationship of polystyrene and poly(CPP:SA), a universal 
calibration curve was obtained that allows for direct determination of Mw of polyanhydrides 
without determining the viscosity of the polymer. All the experimental Mw data collected 
were found to fit equation 1 [19]. 
2.3.3 Crystallinity and thermal properties 
Differential scanning calorimetry (DSC) has been used to report the thermal 
properties of polyanhydrides. The glass transition temperature (Tg), the melting temperature 
(Tm), and the heat of fusion of the copolymers (CPH: SA), (CPP: SA), (FA: SA), 
trimellitylimidoglycine : CPH (TMA-gly:CPH), (TMA-gyl:SA), pyromellitylimidoalanine : SA 
(PMA-ala:SA), and (PMA-ala:CPH) and the individual homopolymers have been reported 
[22, 36, 40-42], A typical trend of the Tg is that as the chain length increases, the Tg 
decreases; this is a result of the increased molecular motion due to the increased flexibility of 
the polymer chain. It is essential to know the Tg and the Tm values for polyanhydrides 
because they are important parameters for fabricating drug delivery devices. For example, Tg 
is the minimum temperature needed for compression molding while Tm is the minimum 
temperature needed for injection molding or melt pressing [35]. The Tg and Tm for poly(SA) 
are 62°C and 79°C, respectively [40]. The Tg and Tm for poly(CPH) are 32°C and 140°C, 
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respectively [8]. The Tg and Tm of copolymers of poly(CPH) and poly(SA) fall between the 
values of the homopolymers [40]. 
The degree of crystallinity of polyanhydrides is an important factor in the rate of 
polymer erosion. The degree of crystallinity of both homopolymers and copolymers of 
polyanhydrides has been determined using X-ray diffraction [26, 36, 43,44], differential 
scanning calorimetry (DSC) [26, 36,44-46], small angle X-ray scattering (SAXS) [44, 47], 
and 'H-NMR [26]. X-ray diffraction can be used to determine the crystallinity of a polymer 
only when a clear separation between the amorphous halo and the crystalline pattern exists. 
When such a clear separation is not available, DSC and 'H-NMR methods are usually 
employed. 
The degree of crystallinity for the homopolymers poly(SA), poly(CPP), and 
poly(CPH) are 67%, 61%, and 20% respectively [26]. When these monomers are 
copolymerized, the more prevalent monomer in the copolymer determines the crystal 
structure, and when a non-crystalline monomer is polymerized with a crystalline monomer, a 
decrease in the crystallinity results [26, 40]. When an equal monomer ratio of SA and CPP 
were copolymerized, the resulting copolymer was amorphous; this was a direct result of the 
random presence of both monomer units in the polymer chain. However, when an equal 
monomer ratio of CPH and SA were copolymerized the resulting polymer had a degree of 
crystallinity between poly(SA) and poly(CPH); this was to be expected because poly(CPH) 
has a lower degree of crystallinity than poly(SA). Kipper et al. [48] used time-resolved 
SAXS to study the isothermal crystallization kinetics of homopolymers and copolymers of 
poly(CPH) and poly(SA). This work provided new insights on the crystal morphology via 
measurements of lamellar dimensions. 
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2.3.4 Stability 
The stability of aliphatic and aromatic polyanhydrides was examined in solution and 
solid state [49]. Aromatic polyanhydrides such as poly(CPH) and poly(CPP) maintained 
their original molecular weight both as a solid (under dry argon and under vacuum) and in 
solution for over a year. Aliphatic polyanhydrides, poly(SA), underwent molecular weight 
loss both in solution and in the solid state. Aliphatic-aromatic copolymers were found to 
undergo molecular weight loss according to their monomer content, the more aromatic 
monomer present the more stable the copolymer. The depolymerization of the aliphatic 
polyanhydrides followed first-order kinetics, with an activation energy of 7.5 kcal/mol. The 
depolymerization of the polymers was found not to be a result of hydrolysis but rather an 
internal anhydride exchange. This result was justified by the repolymerization of the 
depolymerized polymer, by heating to 180°C for 20 min. From 'H NMR data it was 
confirmed that the depolymerized polymer repolymerized. If it had undergone hydrolysis 
this would not have been possible [49]. 
Polyanhydrides that are to be used as drug delivery devices must be sterilized before 
they can be used in vivo. It is important that the sterilization process not alter the physical 
properties of the polymer, thus altering the polymers' degradation profile, y-irradiation and 
ethylene oxide are two methods that can be used to sterilize polyanhydrides [38, 50]. y-
irradiation at a dose of 2.5 Mrad was found not to affect the molecular weight of aliphatic 
polyanhydrides; however, the molecular weight of polymers containing an anhydride 
conjugated to unsaturated bonds did show molecular weight loss after undergoing y-
irradiation [50]. The decrease in molecular weight was due to the conversion of a fully 
unsaturated anhydride bond to a more stable half-saturated anhydride bond. This internal 
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anhydride exchange lead to the formation of low molecular weight polymer rings that 
hydrolyzed faster than the original polymer. 
Leach et al. [38] used ethylene oxide to sterilize double-walled microspheres of 
poly(CPP:SA) and poly(lactic acid). The sterilization caused some degradation of the 
polyanhydride core, as detected by an increase in oligomers and carboxylic acid groups by 
DSC and FTIR respectively. Prior to sterilization, 93% of the sample had a Mw greater than 
2000 and after the sterilization only 52% of the sample had a Mw greater than 2000. The 
sterilization was performed under humid conditions; thus, the polyanhydrides probably 
underwent hydrolysis due to the content of the medium and not the ethylene oxide [38]. 
2.3.5. Biocompatibility 
Polyanhydrides have been extensively studied as a potential biomaterial for site 
directed drug delivery. However, before polyanhydrides could be used clinically, their 
biological inertness had to be verified. The biocompatibility of polyanhydrides has been 
studied in the brains of rats, monkeys, and rabbits, subcutaneously in rats, and in the corneas 
of rabbits [33, 51-60], In all studies, the localized inflammatory response was minimal. The 
inflammatory response to the polyanhydride implants was comparable to other surgical 
implants, even when large doses (40 to 120 times greater than would be used in humans) 
were used [51, 55, 56]. 
Because the brain is protected from foreign substances or toxins by the blood brain 
barrier, it is exceptionally difficult to administer drugs to ailments located within the brain 
[61]. Due to the limited effectiveness of drugs on ailments such as brain cancer by 
traditional drug delivery methods, the use of site directed drug delivery in the brain using 
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polyanhydrides was investigated. After undergoing phase I, II, and III human clinical trials, 
the copolymer 20:80 poly(CPP:SA) became the first surface eroding polymer to be approved 
by the FDA for use in humans [62]. The polyanhydride implant is a wafer composed of 
20:80 poly(CPP:SA) encapsulating 1,3-bis (2-chloroethyl)-1 -nitrosourea (BCNU), a 
chemotherapeutic agent. It is marketed under the name Gliadel™ and is used for the 
treatment of glioblastoma multiforme, a fatal form of brain cancer [63]. 
Domb et al. [64] studied the in vivo elimination of a 20:80 poly(CPP:SA) implant in 
rat brains by radiolabelling each of the monomers separately. The majority of poly(SA), 
40%, exited the rat as CO2, with minimal excretion of polymer in urine (10%) and feces 
(2%). At the completion of the study (7 days), 10% of the radiolabelled polymer remained at 
the site of the implant with the remainder of the radiolabelled polymer in the process of being 
metabolized. Poly(CPP) was not expired as CO2. The main route of elimination for CPP in 
seven days was in urine (-1%) and feces (~3%). 
2.4 Structures 
The term "polyanhydride" describes a polymer containing an anhydride bond in each 
"mer" of its backbone, yet the term does not provide any additional information about the 
backbone. Polyanhydrides of varying structures, molecular weights, degrees of crystallinity, 
hydrophobicity, and mechanical strength have been synthesized. Each of these 
characteristics is a function of the polymer backbone. Several different polyanhydride 
structures, and the properties of these particular polymers will be discussed. 
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2.4.1 Aliphatic 
Poly(SA) is one of the most commonly studied polyanhydrides. It was first 
synthesized in 1932 by Hill and Carothers [3] and has since been approved by the FDA for 
use as a biomaterial. However, poly(SA) is only one of many saturated aliphatic 
polyanhydrides all of which have similar properties. Saturated aliphatic polyanhydrides are 
crystalline and rigid. The length of the diacid monomer influences the polymer's melting 
temperature, solubility in common organics, and the degradation time of the polymer. As the 
length of the diacid increases, the melting temperature of the polymer increases (the melting 
temperatures for aliphatic polyanhydrides are usually below 100°C). As the length of the 
diacid monomer increases, the solubility of the polymer in common organic solvents and the 
rate of degradation decreases [57]. Domb et al. [57] reported that enzymes do not affect the 
rate of degradation of aliphatic polyanhydrides; instead the rate was solely dependent on the 
rate of hydrolysis. Aliphatic polymers are degraded and eliminated from the body within 
weeks. Aliphatic polyanhydrides showed a decrease in molecular weight over a one year 
period when stored in either solid state or in an organic solution [18]. 
2.4.2 Aromatic 
Aromatic polyanhydrides are more hydrophobic than aliphatic polyanhydrides. The 
increase in hydrophobicity increases the polymer stability. Aromatic polyanhydrides studied 
for a year showed no molecular weight loss in either solid state or in an organic solvent [18]. 
The increase in hydrophobicity decreased the degradation rate of the polymers. The 
degradation rate of aromatic polymers was on the time scale of years [65]. Aromatic 
polyanhydrides were less soluble in organic solutions and have melting temperatures 
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significantly higher than aliphatic polymers. Aromatic homopolymers are rarely used due to 
their poor solubility in organics, lengthy degradation time, and their high melting 
temperatures [45]. The solubility of aromatic polyanhydrides can be improved by altering 
the ring substitution pattern from para to ortho [66-68], 
Aromatic diacids separated by branched aliphatic spacers were synthesized and 
copolymerized with SA [69], The new polymers fabricated were: poly(l,2-bis(4-
carboxyphenoxy)propane-co-SA), poly( 1,3-bis(4-carboxyphenoxy)~2-methyl propane-co-
SA), and poly(l,3-bis(4-carboxyphenoxy)-2,2-dimethly propane-co-SA). The polymers had a 
low solubility in organic solvents. A fluorinated aromatic polyanhydride was synthesized by 
melt condensation of 4,4'-(hexafluoroisopropylidene)bis benzoic acid [70]. The fluorinated 
polymer had a high solubility in organic solvents and had Mw in the range of 15,000-18,000. 
2.4.3 Unsaturated 
Fumaric acid (FA), acetylenedicarboxylic acid (ACDA), and 1, 4 ' -stilbendicarboxylic 
acid (STDA) were polymerized as unsaturated polyanhydrides by either melt or solution 
polymerization [29], The structure of the polymers produced was -[-(-CO-CH=CH-COO-)x-
(-CO-R-COO-)y-]n-. Infrared spectroscopy (IR) and NMR confirmed the existence of the 
double bond after the polymerization. The unsaturated homopolymers were insoluble in 
common organic solvents and water. The polymers were also highly crystalline. Copolymers 
of fumaric acid and aliphatic diacids resulted in less crystalline polymers that were soluble in 
chlorinated hydrocarbons. The Mw of all polymers studied ranged from 10,000 to 30,000 
[29]. 
2.4.4 Aliphatic-aromatic homopolymers 
Homopolymers based on aliphatic-aromatic diacids (5-(p-carboxyphenoxy)valeric 
acid (CPV), 8-(p-carboxyphenoxy)octanoic acid (CPO), and 2-(p-carboxyphenoxy)acetic 
acid (CPA)) were synthesized by melt and solution polymerization residue [18]. An aromatic 
head and an aliphatic tail characterized the diacids, as shown in Table 1. The maximum Mw 
obtained was 44,600 and the polymers had low melting temperatures. The stability of the 
polymers was studied both in solid state and in chloroform. The polymers did not undergo 
any molecular weight loss in solid state during a 6-month period, however, they did undergo 
molecular weight loss when stored in chloroform for the same amount of time. The 
degradation rate of the homopolymers was dependent on the length of the alkaloid acid. 
2.4.5 Amino acid-based 
Polyanhydrides have poor mechanical properties, preventing them from being used as 
sutures or as orthopedic devices. To overcome this shortcoming, amide and imide bonds 
were incorporated into the backbone of polyanhydrides. The first step in the polymerization 
of amino acid based polyanhydrides was to convert the amino acid (either naturally occurring 
or co-amino acids) into a diacid by condensation with trimellitic anhydride [32, 42]. The 
diacid was then polymerized forming mixed anhydrides and prepolymers, and was further 
polymerized by either solution or melt polycondensation reactions [22, 41,42,71, 72]. 
Poly(anhydride-co-imides) based on natural occurring amino acids, co-amino acids, 
sebacic acid, and 1,6-bis(p-carboxyphenoxy)hexane were studied [22, 32, 41,42], see Table 
2.1. By incorporating an imide into the backbone of either poly(CPH) or poly(SA), the 
mechanical properties of the polymer were enhanced. Poly(anhydride-co-imides) containing 
a high aromatic or imide content were only soluble in polar solvents, while polymers with a 
high aliphatic or low imide content were more soluble in common organic solvents. 
Increasing the molar percent of imide in a copolymer caused a decrease in the molecular 
weight of the polymer [22]. In polymers containing aliphatic anhydrides the incorporation of 
imides increased the polymer hydrophobicity, however, little to no change was seen when the 
imide was incorporated into an aromatic backbone. 
Glycine, ^-alanine, y-aminobutyric acid, L-leucine, and ^-tyrosine have all been 
incorporated into /V-trimellitylimido acid polymers [32]. The incorporation of an imide in the 
backbone of TV-trimellitylimido acid polymers produced brittle polymers with a Mw of less 
than 10,000. Incorporating an aliphatic spacer, sebacic acid, produced higher molecular 
weight polymers. As the content of the aliphatic spacer increased the polymer's solubility in 
common organic solvents increased, and the tensile strength of the polymer decreased. 
The in vivo degradation and biocompatibility of compression molded disks[TMA-
gly:CPH (10:90, 30:70, and 50:50) and PMA-ala:CPH (10:90 and 30:70)] implanted 
subcutaneously in rat tissues were examined [58, 73]. PMA-ala:CPH caused minimal 
inflammation and fibrosis. TMA-gly:CPH (10:90 and 30:70) caused mild inflammation 
while the 50:50 composition induced a moderate inflammatory response. The difference in 
the histological response was a result of the increased degradation rate of 50:50 (14 days) 
compared to 10:90 and 30:70 (60 days). The PMA-ala:CPH and TMA-gly:CPH (10:90 and 
30:70) disks maintained their shape throughout the two month study [73]. 
2.4.6 Fatty acid-based 
Fatty acids are naturally occurring hydrophobic materials that if incorporated into 
polyanhydrides would increase the hydrophobicity and degradation time of the polymers. 
Fatty acids have been incorporated into the backbone of polyanhydrides in two ways: 1) by 
converting the mono functional fatty acid into a diacid fat based monomer and 2) by using the 
monofunctional fatty acid as a chain terminator [50, 74-79], 
Using the first approach, two unsaturated fatty acids, oleic acid and erucic acid, were 
made into dimers [79]. The fatty acid dimers contained two carboxylic acids that were 
further polymerized by either melt of solution polymerization [78-81], The dimers 
themselves formed liquid oil, and homopolymers of the fatty acids are viscous liquids with a 
Mw of 133,000 [82], When copolymerized with sebacic acid, the Mw was increased to 
235,000 [77], 
Linear fatty acids (C8-C18) have been added to the terminal position of poly(SA) 
[50, 83], The resulting fatty acid terminated polymer had a waxy off-white appearance [50, 
83] with Mw in the range of 5,000 to 9,000 (for 30% and 10% w/w fatty acid respectively). 
The higher the fatty acid content in the polymer the lower the molecular weight, due to the 
shortening of the polymer chain. The addition of the fatty acid at the terminal position 
increased the hydrophobicity of the polymer and increased the storage stability of the 
polymer. Fatty acid terminated poly(SA) showed no molecular weight loss when stored at 
17°C or 4°C for over a year, as compared to non-terminated poly(SA) that showed significant 
molecular weight loss during the same period [83]. A comprehensive review of fatty acids 
and polyanhydrides by Kumar et al. [76] is available. 
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2.4.7 Poly (ester-anhydridesj and poly(ether-anhydrides) 
Both random and block copolymers of poly(SA-co-ethylene glycol) have been 
synthesized by melt polycondensation [25, 35, 84]. The Mw of both the block and random 
copolymers decreased as the molar percent of poly(ethylene glycol) (PEG) was increased. 
The presence of the PEG in the copolymer backbones increased the flexibility of the sebacic 
acid, which increased the crystallinity of the poly(SA) component. However, the presence of 
the poly(SA) in the backbone decreased the flexibility of the PEG, preventing the formation 
of PEG crystals. As the content of PEG in the backbone was increased from 0 to 30%, the 
density of the polymer decreased [84]. The mechanical strength of the random copolymer 
was superior to either of the homopolymers, supporting the idea that the random copolymer 
can prevent energy accumulation by absorbing external forces, which is particularly 
important for biomaterials that would be subjected to large impacts [30]. The degradation 
rate of the block copolymer was found to be faster than the degradation rate of poly(SA) 
[20]. In addition, PEG coated poly(SA) nanospheres were fabricated by the use of the 
diblock PEG-SA polymers [82]. 
Vogel and Mallapragada [85] first synthesized aromatic anhydride monomers 
containing ethylene glycol. Torres et al. [86] later modified the synthesis mechanism to 
obtain polymers that could more easily be fabricated into controlled delivery devices. These 
novel polymers l,8-bis(p-carboxyphenoxy)-,6-dioxaoctane (CPTEG) and 1,14-bis(p-
carboxyphenoxy)-3,6,9,12-tertaoxatetradecane (CPOEG-5) combined the hydrophobic 
surface eroding properties of polyanhydrides with the more hydrophilic bulk eroding 
properties of ethylene glycol. The aim of incorporating PEG into an aromatic polyanhydride 
was to maintain a controlled release for an extended time while improving protein-polymer 
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interactions. By copolymerizing CPTEG with CPH, the mechanism of polymer degradation 
could be varied from bulk to surface erosion. 
A salicylic acid-derived poly(ester-anhydride) was synthesized by a melt 
polycondensation reaction [28]. The backbone of the polymer was composed of alkyl chains 
connected to the aromatic salicylic acid groups by ester bonds (Figure 2.6). As the polymer 
underwent hydrolysis, the biologically active salicylic acid was released and induced new 
bone growth [87]. 
Scheme 2.6. The chemical structure of salicylic acid-derived poly(anhydride-esters). 
Reprinted with permission from ref. [6]. 
Triblock poly(lactic acid) (PLA) terminated poly(SA) chains have been synthesized 
by melt polycondensation [88]. The molecular weights of the polymers ranged from 3000 to 
9000 as the content of PLA increased the molecular weight decreased. The incorporation of 
the PLA into the polymer backbone increased the degradation time of the polymer as 
compared to poly(SA). Poly(SA) completely degraded in 10 days while the triblock 
copolymer took 3 weeks to completely degrade. 
A poly(ester anhydride) was formed by incorporating ricinoleic acid, a natural fatty 
acid, into the backbone of poly(SA) [89]. The hydroxyl group of ricinoleic acid reacted with 
the anhydride group of poly(S A) via a transesterification reaction. As the ricinoleic acid 
content was increased, the Tm and the crystallinity decreased. 
n 
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2.4.8 Cross linking 
The need for a high strength biodegradable material that can be used in orthopedic 
applications has lead researchers to study the mechanical properties and the degradation rates 
of crosslinked polyanhydrides. Crosslinking polyanhydrides resulted in high strength three-
dimensional networks. Crosslinked polyanhydrides were prepared by chemical and photo 
crosslinking [21, 29, 90, 91]. In the case of chemical crosslinking unsaturated monomers 
(e.g. divenyl benzene (DVB)), and a catalyst (e.g. benzoyl peroxide (BzP)) were added to 
unsaturated polymers (e.g. poly(FA:SA)) and allowed to react either in solution or in bulk. 
The resulting crosslinked polymer was insoluble in organic solutions and decomposed at 
temperatures over 200°C [29]. 
Photopolymerization is an attractive way of crosslinking polyanhydrides because the 
monomers can be injected into a fracture sight and then polymerized, allowing them to take 
the shape of a complicated fracture or break. The anhydride monomers of SA, CPP, CPH, 
tricarballylic acid (TCA), and PMA-ala have been capped with methacrylates (MSA, MCPP, 
MTCA, and MPMA-ala) and photopolymerized to form crosslinked polyanhydrides [90, 91]. 
The crosslinking of the homopolymer MSA showed a two fold decrease in the degradation 
time over the linear homopolymer poly(SA). By copolymerizing MSA and MCPH the 
degradation rate of the crosslinked copolymer was varied from 2 days to over one year. 
MSA was also copolymerized with linear CPP, CPH, poly(methyl methacrylate) (PMMA), 
and 50:50 (CPP:CPH) to study the degradation rate of semi-interpenetrating polymer 
networks (IPNs) [90, 92]. The copolymers resulted in crosslinked MSA that had chemically 
independent yet physically entangled the linear polymers. The degradation rate of the IPN 
was significantly reduced as compared to the crosslinked homopolymer MSA. Burkoth et al. 
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[92] copolymerized MSA with methacrylated steric acid (MStA) and methacrylated 
cholesterol (MC). The rate of mass loss of the copolymers MSA:MStA and MSA:MC was 
significantly slower than the homopolymer MSA. The mechanical properties of all 
photopolymerized polyanhydrides were greatly increased as compared to linear 
polyanhydrides. The tensile modulus of poly(MSA) and poly(MCPP) was 40 ± 120 MPa and 
640 ± 80 MPa respectively. These values were between the reported tensile modulus of the 
cortical and trabecular, 17-20 GPa and 50-100 Mpa, respectively [90]. 
Poshusta et al. [93] examined the histological effects of IPNs (MSA copolymerized 
with linear CPP and CPP:CPH) implanted subcutaneously in rats, and the in situ 
photopolymerization of MSA:MC in the rat tibia. The IPN formulation MSA: CPP invoked 
a heightened inflammatory response while MSA:CPP:CPH invoked a minimal response and 
encouraged a cellular response. The in situ photopolymerization of MSA:MC also 
encouraged a cellular response with no adverse effects from the reaction. 
2.4.9 Branched 
Random and graft branched poly(SA) were synthesized by polymerizing sebacic 
acid with 1,3,5 benzenetricarboxylic acid and poly(acrylic acid), as shown in Figure 2.7 [94]. 
The branched polymers had similar thermal and crystalline properties as linear poly(SA). 
The only morphological differences between the linear and branched polymers were that the 
branched polymers had a higher molecular weight and lower specific viscosity. The 
degradation rate of the two branched polymers were compared to the degradation rate of 
linear poly(SA), the two branched polymers degraded at relatively the same rate yet faster 
than the linear polymer [94]. 
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Scheme 2.7. An example of a branched polyanhydride, poly(SA) branched with 1,3,5 
benzenetricarboxylic acid. Reprinted with permission from ref. [6], 
2.4.10 Blends 
When two or more polymers are physically mixed the resulting blend may display 
microscopic or macroscopic heterogeneity depending if the blended polymers are miscible 
(totally or partially) or immiscible, respectively. If the mixed polymers are miscible the 
polymer blend will take on new properties distinct from the individual components of the 
blend. Domb [77] reported that aliphatic, aromatic, and copolymer polyanhydrides were 
miscible and the blends had lower Tm and crystallinity than the starting polymers. The 
polymers were miscible independent of the molecular weight of the initial polymers. 
Polyanhydrides are partially miscible with poly(orthoesters), poly(hydroxybutyric acids), and 
low molecular weight (< 2000) polyesters. These partially miscible polymers formed 
uniform mixtures with polyanhydrides, yet displayed two melting temperatures, one for each 
of the blended polymers. Domb et al. [75, 83] also reported that polyanhydrides are 
immiscible with polycaprolactone or lactide-glycolide copolymers. 
Blends of poly(trimethylene carbonate) poly(TMC) and poly(AA) have been studied 
both in vitro and in vivo as a potential biomaterial [31, 60]. The partially miscible blend was 
found to be biocompatible and contained two Tg's corresponding to the two starting 
polymers. By blending poly(TMC) and poly(AA), the new polymer blend had a more 
acceptable degradation rate than either of the starting polymers. The poly(AA) in the 
polymer blend degraded first leaving behind a porous polymer matrix, enhancing the 
degradation rate of the poly(TMC). 
The effects of blending poly[bis(glycine ethyl) phosphazene] (PGP) with poly(SA-co-
TMA-GLY)-block-PEG) poly(STP) (30:50:20) was investigated [95]. PGP was partially 
miscible with poly(STP) as a result of hydrogen bonding. The blend had two distinct Tg's. 
As the poly(STP) content was increased, the Tg associated with PGP increased, as the content 
of PGP was increased the Tg associated with poly(STP) decreased. The in vitro degradation 
of the blend was investigated, increasing the amount of poly(STP) in the blend increased the 
erosion rate of the blend. 
The effects of blending PEG and poly(SA) were studied using DSC and FTIR [96]. 
Blends with less than 10% PEG were miscible with poly(SA) while blends containing more 
than 10% PEG were not miscible. In miscible blends of poly(SA) and PEG, the crystallinity 
of poly(SA) was increased due to a decrease in the Tg of the poly(SA) component as a result 
of the PEG. 
2.5 Characterization of Polymer Erosion 
The distinction between the terms "erosion" and "degradation" is important. 
Degradation of a polymer is defined as the cleavage of polymer bonds either by hydrolysis or 
enzymatic reactions, leading to the formation of oligomers and monomers. Degradation is 
the most important step of the erosion process. As oligomers and monomers are formed by 
chain scission, they dissolve in the water and eventually diffuse away from the polymer 
system. Erosion is the sum of all of the above steps. To better understand and predict the 
erosion process for polyanhydrides, several models have been developed. Kipper et al. [97] 
developed a model to predict the release kinetics of drugs from the model systems 
poly(CPH:SA) and poly(CPP:SA). The model took into account the microphase separation 
of the copolymer and assumed that degradation was the controlling step of the erosion 
process. The model did not take into account the degree of crystallinity of the copolymer, the 
local pH, or the polymer molecular weight. Kipper and Narasimhan [47] later improved the 
model by including differences in degradation rates between micro-phase separated domains 
and by including the preferential partitioning of drugs into domains. The erosion process of 
polyanhydrides is complex, and no model has been developed that takes all variables into 
consideration. In the following sections, the complexity of the modeling problem will 
become more apparent as the different variables that affect polyanhydride degradation and 
erosion are discussed. There are several review articles available that discuss the complexity 
of polymer erosion and modeling of this phenomenon [92, 98-100], 
2.5.1 Polymer degradation 
There are certain factors that are known to influence the rate of degradation of 
polyanhydrides, even though the degradation mechanism of every polymer is unique. These 
factors include the pH of the system, the degree of crystallinity of the polymer, the mobility 
of the water in the polymer, and the type of bonds that are present between monomer units. 
The degradation rate of copolymers is determined by the most prevalent monomer. 
Polyanhydrides were found to degrade much faster under alkaline conditions than under 
neutral or acidic conditions [25, 36]. The amorphous regions of polyanhydrides degrade 
faster than crystalline regions [24]. However, the most influential determinant of how fast a 
polymer will degrade is the type of bonds that connects the monomers in the polymer 
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backbone. Polyanhydrides, poly(ortho esters), poly(esters), and poly(amides), four common 
polymers used in biomedical applications, have half lives of 0.1 h, 4 h, 3.3 yr, and 83,000 yr, 
respectively [101, 102]. The degradation rate for polyanhydrides is very fast in the presence 
of water, as compared to other biomaterials. 
2.5.2 Polymer erosion 
Polymers can be classified as either bulk (homogenous) or surface eroding 
(heterogeneous) materials, as shown in Figure 2.8. In the case of bulk eroding materials, the 
polymer allows water to penetrate the material. As this occurs, the polymer undergoes 
degradation and erosion throughout the device [92]. Bulk eroding devices maintain their 
initial shape until the entire matrix has been eroded. Poly(D,L-lactide-co-glycolide) (PLGA) 
is an example of a bulk-eroding polymer. In the case of surface eroding materials 
degradation occurs faster than the water can penetrate the system, limiting degradation and 
erosion to the surface of the device. Polyanhydrides are considered surface eroding 
materials even though eroding polyanhydrides have properties of both surface and bulk 
eroding polymers [92]. Gôpferich et al. [103] showed that the there are three different layers 
to an eroding polyanhydride: two outer layers where the buffer has eroded the polymer and 
an inner layer where erosion has not begun. The outer zones have a higher ratio of degraded 
carboxyl groups to undegraded anhydride bonds as compared to the inner regions of the 




Figure 2.8. Schematic of erosion mechanisms (a) bulk (b) surface. Reprinted with 
permission from ref. [6]. 
2.5.2.1 Morphology. The erosion of poly(CPP:SA) disks was studied by fabricating 
disks of various thickness, while preserving the total surface area [104]. Initially the erosion 
kinetics of the different disks with different thicknesses were identical, proving that the 
erosion of the polymer was occurring from the surface inward. As the erosion front reached 
the center of the thinner films, the erosion kinetics differed depending on the thickness of the 
film. As the erosion front moved towards the center of the disk, the polymer changed from a 
non-porous material to a highly porous material, and all of the poly(S A) in the "erosion 
zone" was depleted, leaving only a porous poly(CPP) shell. The resulting pores were 
classified as either micropores (diameter of 0.1 pm) or macropores (diameter of 100 jam). 
Micropores were the result of the faster erosion of the amorphous regions as compared to the 
crystalline regions, while macropores were a result of surface cracking that occurs soon after 
the polymer begins to erode [92, 99]. The disks maintained their original shape for a long 
time, even after the erosion front reached the center of the matrix. 
2.5.2.2 pH. The bioactivity of encapsulated proteins and drugs is dependent on the 
pH of the environment into which they are released. The rate of diffusion of oligomers and 
monomers that form as a result of hydrolysis is also dependent on the pH, thus studies have 
been conducted to determine the pH of the microclimate inside and surrounding degrading 
polyanhydrides. Scanning electron microscopy (SEM) was used to measure the pH profile 
surrounding the degrading polymer, 20:80 poly(CPP:SA), by relating the gray levels from 
channels 1 (540 nm) and 2 (600 nm) to the pH [103]. The pH surrounding the copolymer 
was plotted as a function of distance from the copolymer surface. From this data it was 
apparent that the pH directly surrounding the polymer matrix was lower than the pH of the 
bulk fluid. Using spectral spatial electron paramagnetic resonance imaging (e.p.r.i.) the 
internal pH of the degrading copolymer was determined [105]. During the early stages of 
degradation the copolymer disk had an internal pH of 4.7. As the copolymer eroded the pH 
slowly increased to the pH of the buffer. For comparison, the pH within eroding PLGA was 
reported to be as low as 1.5 [106]. 
2.5.2.3 Crystallinity. McCann et al. [24] studied the changes in crystallinity of 
copolymers of poly(CPP:SA) using liquid-state and solid-state *N NMR. Amorphous regions 
of copolymers were found to undergo erosion faster than crystalline regions. As the 
amorphous regions of the copolymer eroded there was an increase in crystallinity of the 
polymer. This finding contradicted the result reported by Gôpferich and Langer [103] that as 
the copolymer eroded there was a decrease in observed crystallinity by using DSC and X-ray 
diffraction. This discrepancy arises due to lack of accounting for the changes in 
experimental enthalpies due to changes in mass of the eroding polymer [24]. 
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2.6 Mechanisms of Protein Denaturation 
As recombinant DNA techniques become more routine, the number of 
commercially marketed pharmaceutical proteins continues to increase [107]. With this new 
wave of therapies come new challenges. Unlike conventional low molecular weight drugs, 
proteins are large globular molecules whose function is related to their structure. The 
amino acid sequence (the primary structure) that encodes each protein contains reactive 
moieties and chemically labile bonds. Any alteration in the amino acid sequence can be 
detrimental to the pharmaceutical potential of the protein. Amino acid sequences interact 
with themselves to form structures such as a-helixes and ^-sheets. These structures interact 
with each other to form a globular protein molecule. In many instances the globular 
structure that a protein exhibits is essential for it to carry out its biological function. For 
example, lipocalins are a family of proteins that are composed of eight anti-parallel (3-
sheets that form a |3-barrel [108]. The calyx of the barrel is where the protein binds low 
molecular weight ligands. If the structural hierarchy of the protein is altered and the 
protein no longer forms a ^-barrel, then the molecule may be inactive (denatured). Before 
a therapeutic protein can be used, it must be stabilized in order to prevent an immunogenic 
response. A protein's stability is defined by its resistance to changes in it molecular weight 
or biological function when exposed to dénaturants (e.g. heat or acidity). The FDA defines 
a stable pharmaceutical as one that deteriorates less than 10% in two years [109]. 
Pharmaceutical proteins typically have to be lyophilized to achieve this level of stability. 
However, lyophilization can induce unwanted stress on the protein [110, 111]. In order to 
stabilize a protein for therapeutic use, it is important to understand and prevent the 
mechanism of denaturation of the protein. The most common methods of protein 
denaturation are protein aggregation (e.g., the formation of inter-molecular disulfide 
bonds), deamidation, and oxidation [112]. Each will be discussed below in more detail. 
2.6.1 Disulfide formation & aggregation 
Disulfide bonds are covalent cross-links, responsible for maintaining the structural 
and biological integrity of many proteins. Disulfide bonds are the de novo bonds synthesized 
in globular proteins. The formation or breakage of a disulfide bond does not always result in 
loss of activity for the protein. a-Interferon has two disulfide bonds between residues land 
98 and then between residues 29 and 138. If the bond is broken between residues 1 and 98, 
the protein undergoes almost no activity loss, whereas, if the bond between 29 and 138 is 
broken, the protein loses most of its biological function [113]. 
Disulfide scrambling can also be a problem with proteins. Lyophilized insulin has 
three disulfide bonds and no free Cys residues. However, the protein is prone to disulfide 
scrambling which results in aggregates of the lyophilized protein [109]. 
Bovine serum albumin (BSA) also undergoes covalent aggregation as a result of 
either thiol-thiol group oxidation or thiol-disulfide interchanges [114-116], (Ovalbumin also 
forms covalent aggregates via thiol-disulfide interchanges but to a lesser extent than BSA 
[115].) A thiol-thiol group oxidation occurs when the sulfhydryl group of two BSA 
molecules react, eliminating free thiol groups. The thiol-thiol group oxidation produces a 
non-reactive aggregate. A propagation reaction occurs when a thiol of one BSA molecule 
attacks (nucleophilic) a disulfide bond of another BSA molecule. The result is an 
intermolecular disulfide interchange and the conservation of a free reactive thiol. 
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2.6.2 Deam idation 
Deamidation is a hydrolysis reaction, in which the amide group is removed from 
either asparagine (Asn) or glutamine (Gin) forming aspartic acid (Asp) or glutamic acid 
(Glu), respectively [112]. Deamidation can occur under basic or acidic conditions, and at 
high temperatures. The rate at which deamidation occurs is influenced by the local sequence 
and structure of the polypeptide. For instance polar residues attached to the N-terminus of 
Asn or Gin increase the rate of deamidation while large bulky hydrophobic groups attached 
to the C-terminus side decrease the rate of deamidation. 
Deamidation has varying effects on the biological activity of a protein. Deamidation 
does not affect interleukin-la, insulin, or aminotransferase, however, it does reduce the 
activity of cytochrome C, lysozyme, and calmodulin. One way in which deamidation can 
disrupt the activity of a protein is by increasing the net negative charge on the protein 
surface, which can lead to conformational changes [112]. 
2.6.3 Oxidation 
In order for a species to undergo oxidation, the oxidation state of the species must be 
altered. Trace amounts of metal ions, oxidants (e.g. singlet oxygen, hydrogen peroxide, 
ozone), and exposure to light are known catalysts for oxidation. The amino acids that are 
most susceptible to oxidation are methionine (Met), cysteine (Cys), tryptophan (Trp), 
tyrosine (Tyr), and histidine (His) [112]. 
Oxidation almost always results in some biological activity loss of a protein, but the 
extent is usually less than if the protein underwent deamidation or hydrolysis. One exception 
is human insulin-like growth factor 1 (hIGF-1) which has three possible routes of 
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degradation: oxidation at Met59, deamidation of Asn26 and Gin15, and the reduction of three 
different disulfide bridges (Cys6-Cys48, Cys47-Cys52, and Cys18-Cys48). The oxidation at the 
Met59 is the controlling route of degradation for insulin like growth factor 1 (IGF-1) [113]. 
2.6.4 Degradation by proteases 
Proteins are susceptible to biological degradation by proteases, natural occurring 
enzymatic proteins. Proteases are found in both extracellular and intracellular pathways. 
Trypsin and chymotrypsin are two examples of digestive proteases that break down ingested 
proteins into smaller fragments. These small peptide fragments can then be transferred to the 
bloodstream [117]. 
2.7 Microsphere Fabrication 
Due to the biological instability of proteins, they cannot be administered orally [113]. 
Instead, they need to be delivered via an injection. The in vivo half-life of therapeutic 
proteins is short and the therapeutic value of a single injection is limited. Therefore, the 
medical community is seeking a delivery device that is capable of encapsulating, stabilizing, 
and providing a controlled release of proteins. Polymer microspheres are small enough to be 
administered via injection and have demonstrated the ability to encapsulate, stabilize, and 
provide a controlled release of proteins [6], Thus, microsphere fabrication techniques have 
received much attention. Microspheres have been fabricated by hot-melt 
microencapsulation, solvent removal, and spray drying. Polyanhydride microspheres of 
varying diameters and polymer compositions have been studied. The results from these 
studies are discussed below. 
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2.7.1 Hot-melt microencapsulation 
Acid orange (AO), /7-nitroaniline (PNA), insulin, and myogloblin have been 
encapsulated in (21:79) poly(CPP:SA) microspheres by hot-melt encapsulation [118]. By 
heating the copolymer to 81°C, 5°C above the Tm of poly(SA), and suspending a fine powder 
of a low molecular weight drug or protein in the viscous polymer, encapsulation of the 
molecules was possible. The melted polymer/drug slurry was then added to either silicon or 
olive oil and stirred at 81°C until the emulsion was stabilized. Once the emulsion was 
stabilized the suspension was cooled, while being stirred. The microspheres were then 
washed with petroleum ether to obtain a free flowing powder. 
The size of the microspheres could be controlled by the rate of stirring. The newly 
formed microspheres had a smooth external surface with few pores as determined by SEM. 
SEM was also used to examine the microspheres after 15 h, 24 h, and 10 days of degradation. 
From this study it was shown that the microspheres underwent surface degradation. As long 
as the same molecular weight polymer was used reproducible yields, size, and loading 
distributions were obtained with an error of less than 5% [118]. 
The main drawback of this fabrication technique is the need to melt the polymer and 
expose the drug/protein to elevated temperatures. By using high temperatures drug/polymer 
interactions are more prevalent and loss of biological activity becomes a concern. 
2.7.2 Solvent removal microencapsulation 
Solvent removal techniques are used most frequently to fabricate polymeric 
microspheres. The general idea behind this fabrication method is that an emulsion is formed 
between a dissolved polymer and a non-solvent. The polymer solvent is then allowed to 
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evaporate leaving solid polymer microspheres that are suspended in a non-solvent. Different 
solvent removal techniques have been employed including: oil-in-oil (o/o), water-oil-oil 
(w/o/o), or water-in-oil-in-water (w/o/w) emulsions. Solvent extraction techniques are 
relatively straightforward and do not require any specialized equipment. Figure 2.9 outlines 
the steps required when fabricating microspheres using a solvent removal technique. 
H Aqueous protein solution D Aqueous solution (W/O/W) or organic (W/O/O) 
D Organic polymer solution 8 Aqueous protein solution 
D Organic polymer solution 
Figure 2.9. Schematic of the double emulsion technique used to fabricate polymer 
microspheres by the double emulsion technique, (a) An aqueous protein solution is added to 
a larger volume of dissolved polymer these phases are emulsified to form the primary 
emulsion, (b) The primary emulsion is then emulsified in a larger volume of an organic 
solvent (W/O/O) or aqueous solution (W/O/W) containing a surfactant forming 
microspheres. 
The oil/oil solvent removal technique has been employed to fabricate polyester (e.g. 
PLGA) and polyanhydride (e.g. SA, CPH, CPP) microspheres [119-122], Using an oil/oil 
emulsion the polymer and the drug/protein were co-dissolved or suspended in an organic 
solvent, typically methylene chloride. This solution/suspension was then added dropwise to 
a second organic phase, silicone oil, which contained a surfactant. The microspheres were 
stirred for an hour before petroleum ether was added to the suspension. The addition of 
petroleum ether and the continued stirring caused the microspheres to harden. The 
microspheres were collected by centrifugation, washed with petroleum ether, and dried 
overnight. The surface morphology of the resulting microspheres was dependent on the 
polymer/copolymer used to make the microsphere. In the case of poly(SA) microspheres the 
surface was covered with crevices. The surface roughness of poly(CPP:SA) and 
poly(CPH:SA) copolymers was dependent on the molar ratio of CPP or CPH, as the CPH or 
CPP ratio was increased the surface of the spheres became smoother. The difference in 
surface morphology was attributed to be a function of the degree of crystallinity of the 
polymer and the rate at which it precipitates [119]. 
Water-soluble molecules have also been encapsulated using the o/o method in 
solution (e.g., dissolved in water) by emulsifying the aqueous phase with the organic polymer 
phase forming an inner emulsion. This emulsion is then added to a larger organic solution, in 
which the polymer is not soluble and emulsified again. This method is called the w/o/o 
method [6]. 
An advantage of using the o/o technique to fabricate microspheres is that the 
polymers do not undergo degradation during the fabrication process. On the contrary the 
polymers are exposed to several organic solutions that need to be completely removed from 
the final product, due to their toxicity. Protein loading efficiencies greater than 90% have 
been reported for both polyesters and polyanhydride microspheres fabricated via o/o [120, 
123]. 
The second type of solvent encapsulation is the w/o/w technique. The w/o/w 
fabrication technique has been used the most to fabricate protein loaded polyanhydride and 
polyester microspheres, as shown in Figure 2.9. In this method proteins are dissolved in an 
aqueous phase, either with or without a surfactant [e.g. polyvinyl alcohol) (PVA)]. The 
protein solution is then added to a polymer solution and emulsified. The protein/polymer 
emulsion is then added to a larger water phase with a surfactant, typically PVA, and stirred 
for several hours. The microspheres are washed, collected by centrifugation, and freeze-
dried to obtain a free flowing powder. Yang et al. [124] used PVA as a surfactant in both the 
inner and outer water emulsions. A higher PVA content in the inner emulsion led to higher 
encapsulation efficiency, more even distribution of the protein, and a smaller initial burst. 
The concentration of PVA in the outer emulsion influenced the diameter of the microspheres; 
higher concentrations led to smaller diameter microspheres, as a result of preventing the 
polymer/protein droplets from coalescing during the second emulsion [124, 125]. The 
benefit of this method over o/o is that this method reduces the number of toxic organics that 
the microspheres are exposed to, making the procedure more suitable for in vivo applications. 
There are three drawbacks to the w/o/w method. The first is that the proteins are exposed to 
an organic/aqueous interface, which is known to alter the bioactivity of proteins [126, 127]. 
The second is that the polymer begins to undergo hydrolysis during the several hours it is 
suspended in water [128]. The third is that high protein loading efficiencies are rarely 
obtained [124, 125]. 
2.7.3 Spray drying microencapsulation 
An alternative to the hot melt or solvent removal microsphere fabrication methods is 
spray drying. Mathiowitz et al. [129] reported the fabrication of poly(SA), poly(CPP:SA), 
poly(CPH:SA), and poly(FA:SA) microspheres by spray drying. The drug/protein was first 
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co-dissolved or suspended in an organic solution with the polymer. The solution/suspension 
was then spray dried, as the particles fell from the bottom of the spray dryer they were dried 
by an upward flow of nitrogen. The microspheres fabricated with 50:50 poly(CPP:SA) and 
50:50 poly(CPH:SA) were prone to fusing together before they were dried, it was 
hypothesized that the low Tg of these polymers was responsible for this phenomenon. To 
prevent the microspheres from fusing together lower polymer concentrations were used. 
Using SEM it was revealed that poly(SA) microspheres had a surface that was covered with 
crevices. Copolymers made with SA and the aromatic monomers CPP and CPH displayed 
smoother surfaces as the molar ratio of the aromatic component was increased. Spray drying 
is an advantageous procedure for fabricating microspheres because it can be easily scaled up, 
it is highly reproducible, it can be done at or below room temperature, and it eliminates the 
creation of a water/oil interface. 
Berkland et al. [130] reported the fabrication of monodisperse PLC microspheres and 
later the fabrication of drug loaded polyanhydride microspheres [131] using a modified 
version of spray drying. The drug-loaded polyanhydride microspheres (poly(SA)) were 
fabricated by first dissolving the polymer (20% w/v) and drug (rhodamine B (RhBB) 3% 
w/w, PNA 10% w/w, or piroxicam 10% w/w) in methylene chloride. The solution was then 
pumped through a small-gauge hypodermic needle at various velocities. Uniform droplets of 
the polymer/drug solution were obtained by exciting the solution using an ultrasonic 
transducer controlled by a frequency generator. The diameter of the droplets was controlled 
by a carrier stream of 1% w/v PVA in deionized water that engulfed the polymer/drug 
stream. The particles were collected in a solution of 1% PVA and allowed to stir for 3 h. 
The resulting poly(SA) microspheres were monodisperse, and 90% of the microspheres had a 
diameter within 1.5 p,m of the average diameter. 
Cryogenic atomization has also been employed to fabricate protein-loaded PLGA 
microspheres [132-135]. When using this method the drug/protein was first dissolved in an 
appropriate solution and spray dried to obtain particles with diameters between 1-5 microns. 
The polymer was then dissolved in a solvent (e.g. methylene chloride) and the solid protein 
particles were suspended in the polymer solution by mechanical mixing (e.g. sonication). 
The suspension was then pumped to an ultrasonic atomizing nozzle. As the newly formed 
microspheres left the nozzle they fell into a layer of liquid nitrogen overlaying a frozen layer 
of ethanol, see Figure 2.10. The liquid nitrogen immediately froze the microspheres. The 
vessel was then stored at -80 °C for three days. During this time the ethanol slowly thawed 
and the solvent was slowly extracted from the polymer, leaving solid microspheres. The 
microspheres were then collected by filtration and lyophilized. Lam et al. [135] reported 
100% loading efficiency of IGF-I in PLGA microspheres using this method. 
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Figure 2.10. Schematic of atomizing technique used to fabricate polymer microspheres. The 
polymer/protein suspension leaves the atomizing nozzle as a fine mist that then falls into 
liquid nitrogen overlaying a layer of frozen ethanol. 
2.8 Protein-Loaded Microsphere Characterization 
When encapsulating proteins in polymer microspheres, the protein is exposed to 
conditions that are less than ideal (e.g. organic solvent, mechanical stresses, and hydrophobic 
interactions with the polymer) [37, 126, 136-138]. These conditions could lead to the 
deactivation of the protein. In previous work little attention has been given to studying the 
stability of proteins encapsulated in polymer microsphere. Once administered to a patient the 
protein-loaded microsphere begin to degrade. As it degrades the water content within the 
microsphere increases affecting the stability of the protein. It is therefore essential to test the 
stability of the encapsulated as well as the released protein. As mentioned previously in this 
chapter pharmaceutical proteins must have a stable shelf life (deteriorate less than 10% in 2 
years) in order for the FDA to approve their use. In the following section, methods of 
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determining the protein distribution within the microspheres as well as testing the structural 
stability of encapsulated and released proteins are discussed. 
2.8.1 Confocal laser scanning microscopy 
Confocal microscopy has been used to study protein distribution within polymeric 
microspheres [124, 125, 139]. Sun et al. [125] used confocal laser scanning microscopy to 
study the distribution of BSA-FITC in PLGA microspheres made using the W/O/W 
technique. As the amount of BSA-FITC initially used to fabricate the microspheres was 
increased the protein distribution changed from uniform distribution to pockets of protein 
aggregation. 
2.8.2 A nalysis of secondary structure 
By mixing protein-loaded microspheres with an excess of potassium bromide, 
transmission Fourier transform infrared spectroscopy (FTIR) has been used to study the 
secondary structure of proteins encapsulated in polyester microspheres [123, 127, 140-145], 
The absorbance spectrum of blank microspheres (microspheres containing no protein) was 
subtracted from the spectra of protein-loaded microspheres to obtain spectra of the protein. 
In order to quantify the structural components of the protein within the amide I region (1700-
1600 cm"1), Gaussian curves were fit to the corrected spectra. The corrected spectra were 
obtained by either performing a Fourier self-deconvolution or by taking the second derivative 
of the protein spectra. Fu et al. [144] encapsulated BSA in PLGA microspheres via the 
w/o/w fabrication technique and reported an a-helix content of 18% as compared to a 37% 
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and 27% a-helix content of the protein when in an aqueous solution or lyophilized, 
respectively. 
FTIR has also been used to study the secondary structure of proteins in aqueous 
solutions [ 146-152]. Aqueous protein solutions can be analyzed using either calcium 
fluoride windows (transmission) or by using a zinc selenide attenuated total reflectance 
(ATR) accessory. Unlike circular dichroism (CD) or fluorescence, studies that require high 
protein concentrations, concentrations as low as 10 nM provide adequate signal-to-noise 
ratios for structural analysis using FTIR [152]. 
CD and fluorescence have also been used to study the secondary and tertiary 
structures of proteins released from polymer microspheres into aqueous solutions [142, 153, 
154]. Carrasquillo et al. [142] used CD to report a decrease in a-helix content of BSA when 
encapsulated in PLGA microspheres via the o/o fabrication technique. Zhu et al. [153] used 
a combination of CD and fluorescence to confirm that BSA released from PLGA 
microspheres was still intact. 
2.8.3 Analysis of primary structure 
Size exclusion chromatography-high pressure liquid chromatography (SEC-HPLC) 
and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) have been used 
to determine the molecular weight of released proteins from polymer microspheres [141, 142, 
144, 153, 155-157]. Park et al. [157] used reducing and non-reducing SDS-PAGE to show 
that lysozyme extracted from PLGA microspheres was still intact, (e.g., no cleavage or 
aggregation). Castellanos et al. [141] used SEC-HPLC to determine if BSA released from 
PLGA microspheres had undergone aggregation via thiol-disulfide interchange. 
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2.9 In Vitro Release 
Prior to administering therapeutic protein-loaded microspheres to animals or human 
patients the release kinetics of the protein need to be understood in vitro. This includes 
establishing the initial conditions of the release (is there a burst) and the length of time it will 
take for the encapsulated protein to be released. 
2.9.1 In vitro release kinetics of protein-loaded microspheres 
Crotts et al. [155] reported that the release profile of BSA was dependent on the 
medium used for the experiment. BSA was released in 5 mM PBS/0.01% sodium azide and 
5 mM SDS/PBS/0.01% sodium azide solutions. Ten-20% more BSA was released from the 
polymer microspheres when released in the buffer containing surfactant (SDS), supporting 
the idea that BSA does absorb to the degrading polymer. 
Zhu et al. [153] reported that only 20% of the BSA loaded into PLGA microspheres 
via the w/o/w technique was released, and it was released as protein dimers, trimers, and as 
peptide fragments as a result of the acidic microclimate. The remaining 80% of the protein 
was never released from the polymer matrix due to the formation of insoluble aggregates. By 
co-encapsulating Mg(OH)2, a basic salt, over 80% of the encapsulated BSA was released as 
monomelic protein, hence eliminating aggregation due to the microclimate. 
Castellanos et al. [141] reported that the solvent and the use of excipient influenced 
morphology, initial burst, and length of protein release from PLGA microspheres made via 
the s/o/w technique. When BSA and trehalose were co-encapsulated the initial burst was 
reduced to only 16%, as compared to over 20% when BSA was encapsulated alone and 
acetate was used as the solvent. Castellanos et al. [141] reported a loading efficiency of 
85% for BSA when co-encapsulated with trehalose, and the protein was continuously 
released for a little over 600 h. 
Tabata et al. [137] encapsulated chicken egg lysozyme, bovine pancreatic trypsin, 
heparinase, chicken egg albumin, BSA, and bovine immunoglobin into copolymers of 
poly(FAD:SA). The enzymatic activity of the released enzymes and the release profile of all 
of the proteins encapsulated in microspheres made by w/o/w procedure were reported. The 
encapsulation efficiency, irrespective of the protein used, was 85% and more than 90% of the 
microspheres fabricated had diameters in the range of 50 to 125 jj.m. There was no initial 
burst and all of the proteins have similar release profiles. The activity of released trypsin and 
heparinase after 2 days was compared to the activity of the proteins left in solution for 2 
days. The activity of the encapsulated proteins was higher than that of the non-encapsulated 
proteins; trypsin in solution lost 80% of its activity while trypsin released from microspheres 
lost only 10% of its activity [137]. The release profiles were found to be independent of the 
initial molecular weight of the copolymer. Tabata et al. [137] used SEM to determine how 
the morphology of the degrading polymer microspheres changed. Initially the microspheres 
were smooth with no traces of BSA on the exterior surface. The microspheres were also 
sectioned prior to any degradation in order to view the interior of the microspheres. The 
interiors were dense, and after 44 h, only the surface of the spheres had undergone 
degradation. 
Chiba et al. [158] and Hanes et al. [159] used poly(anhydride-coimide) and 
poly[trimellitylimido-L-tyrosine-cosebacic acid-co-1,3-bis(carboxyphenoxy)propane] (poly 
(TMA-Try: S A: CPP)) microspheres to release BSA. The release of the BSA was independent 
of the initial molecular weight of the polymer and closely followed the erosion of the 
microspheres, which was dependent on the pH of the system [158]. The more acidic the 
release buffer, the slower the polymer degraded [158]. As the amount of CPP in the 
backbone increased, the hydrophobicity of the copolymer increased, and the release of BSA 
was significantly slowed. 
The effect of loading protein into poly(FA:SA) microspheres on the erosion profile 
was studied [160]. Blank poly(FA:SA) microspheres and raw polymer eroded slower than 
microspheres loaded with BSA. As the BSA on the surface of the microspheres was 
released, more surface area of the microsphere was exposed. This increase in surface area 
lead to an enhanced erosion profile. 
2.9.2 In vitro effect of polymer degradation products on protein stability 
Johansen et al. [161] incubated tetanus toxoid in the presence of lactic and glycolic 
acid to study the effect of the degradation products on the stability of the protein. This study 
was motivated by the need to understand how the degradation products of biodegradable 
polymers affect released proteins. It was reported that the temperature was more detrimental 
to the stability of the protein than the low pH. Xing et al. [154] performed a similar study 
using free tetanus toxoid to determine the effect that pH and temperature had on the stability 
of the protein. During the first few days of the experiment, tetanus toxoid began to unfold 
under the warm acidic conditions (37°C and pH 2.5). 
2.10 Summary 
In the last two decades polyanhydrides have emerged as a very promising 
biomaterial. Much effort has gone into synthesizing and characterizing polyanhydrides. 
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There is a plethora of literature discussing microsphere fabrication techniques and extensive 
studies have shown that polyanhydrides of varying compositions are biologically inert and 
have minimal interactions with many drugs/proteins studied. Yet the FDA has approved only 
one drug delivery device for human use, and this device requires surgical implantation in the 
brain [62]. In order for polyanhydrides to be used for routine delivery of proteins a more 
detailed understanding of how polyanhydrides and proteins interact is necessary. 
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CHAPTER 3 
RESEARCH OBJECTIVES AND ORGANIZATION 
3.1 Research Objective 
Chapter 1 demonstrated the importance of developing controlled delivery devices for 
proteins. The idea of delivering proteins via a controlled delivery device is not novel, and 
much attention has been given to this topic, as was discussed in Chapter 2. However, no two 
proteins behave exactly the same. Therefore, no one material is capable of stabilizing all of 
the recombinant proteins that are being marketed today. The majority of the current research 
in this field is done with poly(D,L-lactide-co-glycolide) (PLGA) and little of the available 
literature has focused on the importance of determining how proteins interact with the 
polymers in which they are encapsulated. The research described in the following chapters 
focuses on the polyanhydrides, poly(sebacic acid) (poly(SA) and copolymers of poly(SA) 
and poly[ 1,6-bis-/?(carboxyphenoxy)hexane] (poly(CPH)) with regards t their ability to 
provide a means of stabilizing proteins while providing an extended controlled release. The 
overall goal of this research is to demonstrate that polyanhydrides can be used to stabilize 
and to provide a controlled release of therapeutic proteins. The four specific goals of this 
work were: 
1. Demonstrate the feasibility of using polyanhydrides microspheres as protein 
carriers. 
2. Discern the compatibility of proteins with biodegradable polymer degradation 
products. 
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3. Study the role of microsphere fabrication methods on protein stability. 
4. Apply the insights gained from specific goals 1, 2, and 3 to design uterocalin-
loaded polyanhydride microspheres to expedite cell migration for applications 
in wound healing. 
Specific goal 1 will provide evidence to support the hypothesis that polyanhydrides 
can stabilize proteins and provide a controlled release profile. Bovine serum albumin (BSA) 
has been chosen as the model protein. The in vitro data obtained by encapsulating and 
releasing BSA from polyanhydride microspheres will lay the foundation for further studies 
with the therapeutic protein, uterocalin. After completing specific goal 1, a comprehensive 
understanding of the experimental techniques needed, including microsphere fabrication, and 
an in depth analysis of the encapsulated and released protein(s). 
It is important to understand how proteins released from degrading polymer devices 
interact with polymer degradation products. Specific goal 2 will demonstrate the importance 
of such interactions on the structural and enzymatic or antigenic activity of lysozyme, 
ovalbumin, and tetanus toxoid. These experiments will demonstrate rational methods for 
selecting compatible polymer/protein systems prior to protein encapsulation. The stability of 
three proteins (tetanus toxoid, lysozyme, ovalbumin, and uterocalin) in the presence of 
various polymer degradation products will be evaluated. The data will aid in expediting the 
development of protein-loaded drug delivery devices by establishing methods of discerning 
incompatible systems, reducing time and resources spent studying incompatible systems. 
The data collection upon successful completion of Specific goal 3 will provide 
information on how different microsphere fabrication processes affect protein stability and 
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release kinetics. These experiments will be designed to compare the stability of ovalbumin 
encapsulated in microspheres fabricated using four different fabrication techniques (water-
oil-water, water-oil-oil, solid-oil-oil, and a cryogenic atomization technique). By directly 
comparing the different fabrication methods used to encapsulate the same protein, the 
superior fabrication method will be identified and used for future studies. 
The knowledge gained by completing specific goals 1, 2, and 3 will be used to 
develop and test uterocalin-loaded microspheres. The stability of the encapsulated uterocalin 
will be assessed as will the bio-activity of the released protein by performing cell culture 
studies. 
3.2 Dissertation Organization 
Each of the following four chapters discusses the work that was performed to 
complete each specific goals of this project, starting with chapter 4 addressing specific goal 1 
and ending with chapter 7 addressing specific goal 4. 
The overall conclusions of this work are discussed in chapter 8 along with the future 
applications for using polyanhydrides as controlled delivery devices. 
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CHAPTER 4 
ENCAPSULATION, STABILIZATION, AND RELEASE OF FITC-BSA FROM 
POLYANHYDRIDE MICROSPHERES 
A paper published in Journal of Controlled Release 100 (1), 97-109, 2004 
Amy S. Determan1'2, Brian G. Trewyn3, Victor S.-Y. Lin3, Marit Nilsen-Hamilton4, Balaji 
Narasimhan2,5 
4.1 Abstract 
In order to determine the efficacy of using polyanhydrides as a carrier for therapeutic 
proteins, the model protein bovine serum albumin labeled with fluorescein isothiocyanate 
(FITC-BSA) was encapsulated in microspheres of poly sebacic anhydride (poly(SA)), and 
random copolymers of poly(SA) and poly( 1,6-bis-/?-carboxyphenoxy)hexane (poly(CPH)). 
The microspheres were fabricated via the double emulsion (water/oil/water) technique and 
were characterized using scanning electron microscopy, gel permeation chromatography, 
confocal microscopy, and particle size determination. The effect of protein loading, protein 
distribution, and change in polymer composition was examined in an in vitro release study. 
The secondary structure of the encapsulated FITC-BSA was determined with Fourier 
transform infrared spectroscopy. The primary structure of the released protein was analyzed 
using sodium dodecyl sulfate polyacrylamide gel electrophoresis. Poly(SA) and 20:80 
1 Graduate student; primary author and researcher 
2 Department of Chemical Engineering, Iowa State University 
3 Department of Chemistry, Iowa State University 
4 Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University 
5 Major professor; corresponding author 
(CPH:SA) microspheres were found to conserve both the primary structure of the released 
protein and the secondary structure of the encapsulated and released protein, and showed a 
sustained delivery for approximately 15 and 30 days, respectively. As the CPH content in 
the copolymer increased, the secondary structure of FITC-BSA was not conserved, as 
indicated by the steep decrease in the a-helix content. 
4.2 Introduction 
Between 1980 and 2001 the U.S. Food and Drug Administration (FDA) approved 554 
new therapeutic drugs [1], Small molecular mass drugs made up the majority of the new 
therapeutics approved (504), followed by recombinant proteins (40), and monoclonal 
antibodies (10). As recombinant DNA practices have become routine, the number of protein 
products entering the market has increased. With the increasing number of therapeutic 
proteins being marketed in the United States each year more research is being directed 
towards developing superior methods of delivering proteins. Unlike small molecular mass 
drugs, proteins are complex three-dimensional molecules, whose functionality depends on 
their higher-order structure [2], Proteins are prone to chemical (e.g., deamidation, oxidation) 
and physical (aggregation, precipitation, and adsorption) alterations [2-5]. The mechanisms 
by which proteins undergo structural alterations is protein specific, however, there are known 
factors that decrease the stability of proteins such as elevated temperature and moisture [3, 4, 
6, 7]. Parenteral administration remains the most common method of delivering proteins, 
however, it provides no stabilization of the shelf life of the protein or increase of the half-life 
of the protein in vivo [8]. 
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A vehicle capable of encapsulating proteins, minimizing the mechanisms of 
degradation, maximizing the in vivo activity, and providing controlled release that can be 
delivered via parental administration would be a valuable asset for the effective delivery of 
various drugs or vaccines. The polymer that has received the most attention as a protein 
delivery vehicle is poly(D,L-lactide-co-glycolide) (PLGA). PLGA has been used to 
encapsulate and release numerous model and recombinant proteins, such as bovine serum 
albumin (BSA) [9-16], lysozyme [15, 17, 18], recombinant human growth hormone (rhGH) 
[19-22], and recombinant human insulin like growth factor-1 (rhIGF-I) [23-25], Because 
PLGA is a bulk-eroding polymer in an aqueous environment, the encapsulated protein is 
quickly exposed to elevated moisture content. This increase in moisture has been shown 
cause aggregation of the encapsulated protein [6, 7], The addition of excipients (e.g. 
trehalose or dextran) was shown to prevent covalent aggregation of the encapsulated protein 
[12, 13, 26]. Another potential negative issue with PLGA is that, as it degrades, the pH 
within the polymeric device drops significantly [27], which can be detrimental to the protein. 
This problem can be overcome by the co-encapsulation of basic compounds, which have 
proven to help stabilize the encapsulated protein [9], 
Polyanhydrides are biodegradable polymers that have also been shown to stabilize 
and provide sustained release of proteins [28]. Unlike PLGA, polyanhydrides are surface 
eroding polymers, an advantage that minimizes the moisture level to which an encapsulated 
protein is exposed, thus reducing protein aggregation due to moisture [29-32]. Another 
benefit of polyanhydrides is that the pH of the degrading polymeric material does not drop as 
severely as PLGA, thus providing a more suitable (or less hostile) microclimate for 
encapsulated (and released) protein molecules [31]. 
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In parenteral formulations, microspheres are the most commonly used vehicle to 
encapsulate proteins or small molecular mass drugs. Microspheres can be fabricated by three 
different procedures: hot melt, solvent removal, or spray drying [33-40]. The hot melt 
procedure is not advantageous when encapsulating proteins because the elevated 
temperatures needed to melt the polymer can denature the protein. Solvent removal, either 
oil-in-oil (O/O) or water-in-oil-in-water (W/O/W) (also known as the double emulsion 
method), and spray drying can both be performed at room temperature. While spray drying 
requires the use of an atomizer, the solvent removal technique requires no special equipment; 
however, care must be taken when encapsulating proteins via the solvent removal technique 
because the presence of a water/oil interface can cause protein inactivation [41]. 
The polymers used in this study are poly(sebacic anhydride) (poly(SA)) and random 
copolymers of poly(SA) and poly(l,6-bis-p-carboxyphenoxy)hexane (poly(CPH)) (see 
Figure 4.1). These polymers are of interest because they have vastly different degradation 
rates. Poly(CPH) degrades on a time scale of years, while poly(SA) degrades on a time scale 
of weeks [42]. Random copolymers of SA and CPH have degradation times that fall in 
between the degradation time of the homopolymers [43]. By varying the polymer chemistry 
a suitable degradation time can be achieved to meet delivery needs. 
a. b. 
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Figure 4.1. Structure of repeating units of polymers (a) poly(CPH) (b) poly(SA). 
The release of /7-nitroaniline (PNA), a small molecular mass model drug, from 
microspheres of homopolymers and copolymers of poly(CPH) and poly(SA) has been 
previously studied [44]. It was shown that the release profile of PNA is a function of 
polymer erosion rate and the interaction of the drug with the polymer. The hypothesis of this 
research is that the release of proteins from polyanhydrides is also a function of polymer 
erosion rate and the interaction of the protein with the polymer. 
The focus of this work is to determine the effectiveness of polyanhydride carriers 
such as poly(SA) and copolymers of poly(CPH) and poly(SA) with respect to the 
stabilization and release of bovine serum albumin labeled with fluorescein isothiocyanate 
(FITC-BSA). The double emulsion technique was employed to fabricate the microspheres. 
The protein-loaded microspheres were then characterized by various techniques. Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to determine the 
primary structure of FITC-BSA after it was released from the eroding polyanhydride 
microspheres. The secondary structure of FITC-BSA encapsulated in the microspheres was 
assessed using Fourier transform infrared spectroscopy (FTIR). 
4.3 Materials and Methods 
4.3.1 Materials 
Sebacic acid (99%), /?-carboxy benzoic acid (99+%), and l-methyl-2-pyrrolidinone 
anhydrous (99+%), and KBr (FTIR grade) were purchased from Aldrich (Milwaukee, WI). 
1,6-dibromohexane (98+%) and poly(vinyl alcohol) (99+%) (PVA) were purchased from 
Acros (Fairlawn, NJ). Fluorescein isothiocyanate bovine serum albumin (FITC-BSA) was 
purchased from Sigma (St. Louis, MO). The BCA assay kit was purchased from Pierce 
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Chemicals (Rockford, IL). 40% polyacrylamide/bis 19:1, the SDS-PAGE silver staining kit, 
and molecular mass standards for SDS-PAGE were purchased from BioRad (Hercules, CA). 
Petroleum ether (hexane, 55% n-hexane) was purchased from Fisher Scientific (Pittsburgh, 
PA) and dried and distilled over sodium and benzophenone (Fisher) before use. All the other 
chemicals were of analytical grade and were purchased from Fisher Scientific (Pittsburgh, 
PA). 
4.3.2 Polymer synthesis 
The prepolymers of SA and CPH were synthesized by the methods described by Shen 
et al. [45], and for the CPH prepolymer, the method was similar to the one described by 
Conix [46] for 1,3-bis(p-carboxyphenoxy)propane. The polymers were synthesized by melt 
polycondensation as described by Kipper et al. [44]. 
4.3.3 Polymer characterization 
Neat polymers were characterized by the procedures described by Kipper et al. [44]. 
The chemical structure of the polymers was characterized with *H NMR. Samples were 
dissolved in deuterated chloroform (99.8% atom-d) and the chloroform peak was used to 
calibrate the chemical shift of the polymer. Polymer molecular mass was determined using 
gel permeation chromatography (GPC). A PL Gel column from Polymer Laboratories 
(Amherst, MA) and a Waters GPC system (Milford, MA) were used to separate the samples 
dissolved in chloroform. The elution times of the samples were compared to poly(methyl 
methacrylate) standards from Fluka (Milwaukee, WI). Using differential scanning 
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calorimetry (DSC) (DSC7, Perkin Elmer, Shelton, CT), the melting point of the 
semicrystalline polymers was compared to that reported by Shen et al. [45]. 
4.3.4 Microsphere fabrication 
A double emulsion technique was employed to encapsulate FITC-BSA in microspheres 
of varying polymer composition. The following polymers were used: poly(SA), 20:80 
(CPH:SA), 50:50 (CPH:SA), and 80:20 (CPH:SA), The fabrication technique used was 
similar to the method reported by Tabata and Langer [28]. Briefly, FITC-BSA (5 mg) was 
dissolved in de-ionized water (200 pJ) and was added to polymer (100 mg) dissolved in 
methylene chloride (2 ml). The two phases were emulsified with a homogenizer at 10,000 
rpm for 30 seconds (Tissue-Tearer™, Biospec Products, Inc., Bartlesville, OK) forming the 
inner emulsion. Four ml of 1% PVA saturated with methylene chloride (80 |il) was 
immediately added to the inner emulsion and homogenized for 30 sec at 10,000 rpm to form 
the double emulsion. The microspheres were then dispersed in 1% PVA (100 ml) and stirred 
for 2 h at 300 rpm using an overhead stirrer with a 3-in impeller (Wiarton, Ontario). The 
microspheres were collected by centrifugation for 10 min at 1500 g using an Eppendorf 
Centrifuge 5403 (Westbury, NY). After the first centrifugation the supernatant was collected 
and then replaced with de-ionized water to wash the microspheres. The microspheres were 
washed two additional times to ensure all of the free protein and PVA had been removed. 
The microspheres were then suspended in 4 ml of de-ionized water, flash frozen, and dried 
under vacuum overnight. 
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4.3.5 Microsphere characterization 
The mass of microspheres recovered divided by the initial mass of polymer and 
protein was used to calculate the yield. To determine the size distribution the microspheres 
were dispersed by sonication in Coulter® Balanced Electrolyte Solution prior to using a 
Beckman Model Multisizer™ Three Coulter Counter (Fullerton, CA). Scanning electron 
microscopy (SEM) (Hitachi S-2460N) was used to study the surface morphology of the 
microspheres. Confocal microscopy (Nikon Eclipse TE200 microscope and Chiu Technical 
Corporation 100W mercury source) was used to analyze the FITC-BSA distribution within 
the microspheres. The molecular mass loss during the fabrication process was determined 
using GPC by comparing the molecular mass of blank microspheres to that of neat polymer. 
4.3.6 Protein loading 
The amount of FITC-BSA encapsulated in the microspheres was indirectly 
determined using a procedure similar to the one described by Bouillot and co-workers [11]. 
During the fabrication process the microspheres were collected by centrifugation, and the 
supernatant was collected. The BCA protein assay was utilized to determine the 
concentration of FITC-BSA present in the supernatant, thus providing the mass of protein not 
encapsulated. A mass balance was performed to determine the amount of FITC-BSA that 
was loaded into the microspheres. The protein that was lost while washing the microspheres 
during the fabrication process was not accounted for when calculating the loading. Hence 
the loading and loading efficiency are slightly overestimated. The encapsulation efficiency 
of the protein was determined by dividing the mass of the loaded protein by the initial mass 
of protein. 
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4.3.7 In vitro protein release 
Fifteen mg of microspheres were suspended in 1 ml of water containing 3% (w/w) 
sodium dodecyl sulfate (SDS). The samples were placed in an incubator at 37°C and 
continuously agitated at 100 rpm. To determine the mass fraction of FITC-BSA released the 
supernatant from the samples was collected at predetermined times and fresh release media 
was added to maintain perfect sink conditions. The concentration of protein in each sample 
was determined using the BCA protein assay upon removal. The amount of protein released 
was normalized by the amount of protein initially loaded into the microspheres. The 
experiments were done in triplicate. The Bonferroni multiple comparison adjustment was 
used to determine that the p-values for all the multiple comparisons. 
4.3.8 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was used to determine the primary structure of the FITC-BSA released 
from microspheres in vitro. Microspheres were suspended in water containing 3% (w/w) 
SDS under the same conditions as the microspheres used for the in vitro release study. The 
microspheres were allowed to degrade until the concentration of released BSA reached at 
least 30 jag/ml in the aqueous phase. The samples were mixed with an equal volume of a 
SDS (1% w/v), Tris-HCl (pH 6.8,0.06 mM), glycerol (3 mM), bromophenol blue (0.01% 
w/v) solution with and without (3-mercaptoethanol (0.05% v/v) for staining with silver. [3-
mercaptoethanol is a reducing agent that breaks covalent disulfide bonds [47], thus by 
comparing the samples with and without (3-mercaptoethanol, it was possible to determine if 
the released FITC-BSA had formed inter-protein disulfide bonds. The samples were 
resolved through a 10% polyacrylamide gel with a 5% polyacrylamide stacker. 
Electrophoresis was performed using a BioRad Mini-Protean II electrophoresis setup at a 
constant voltage (120 volts) as described by the manufacturer. The resolved proteins were 
stained using a Silver Stain kit (BioRad). The apparent molecular mass of the detected bands 
was compared to standards. FITC-BSA samples were also run on the gel to. The silver 
stained gels were immediately photographed and dried overnight. 
4.3.9 Fourier transform infrared spectroscopy (FTIR) 
FTIR spectroscopy was performed using a Nicolet Nexus 470 (Madison, WI), 
equipped with a cooled MCT/A detector and an Ever-Glo source. Omnic 5.2 software was 
used to collect the data and to perform initial data analysis. Dry air was purged through the 
optical bench throughout data acquisition in order to reduce IR absorbance due to water. 
Samples were prepared by mixing microspheres (either BSA-loaded or blank) with KBr (4% 
w/w). In order to compare the native structure of the protein with that of the encapsulated 
protein, FITC-BSA samples were also mixed with KBr (4% w/w). Prior to collecting FTIR 
spectra all samples were stored at 50 °C under vacuum overnight to eliminate any residual 
moisture. The dry powder was then placed in a 7 mm dye and a pellet was formed with a 
hand press (Spectra-Tech Inc., Sheldon, CT). 
Each spectrum was collected by running a total of 256 scans at a resolution of 4 cm"1. 
The spectra of the encapsulated FITC-BSA were obtained by subtracting the spectra of the 
blank microspheres from the spectra of the FITC-BSA loaded microspheres. A subtraction 
was considered successful if the resulting spectra had a straight baseline in the region of 
1800-2500 cm"1 [48]. Fourier self-deconvolution was then performed on the amide I region 
of the subtracted spectra using the Omnic 5.2 software with an enhancement factor of 1.2 and 
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a bandwidth of 20 kHz [49]. Gaussian curves were fit to the Fourier self-deconvoluted 
spectra [15, 49]. The same procedure was also carried out on the spectra of the native 
protein. The assignment of secondary structure either: a-helix, (3-sheet, or unordered was 
done using the assignment of peaks for BSA listed by Fu et al. [15]. The area under each 
peak in the amide I region was calculated and used to determine the secondary structure of 
the protein using procedures described elsewhere [12-15, 22, 48-51]. A Student t-test was 
preformed to determine if the secondary structure of the encapsulated ovalbumin differed 
significantly from that of the native protein. Treatments that different significantly from the 
native BSA were noted. 
4.4 Results and Discussion 
4.4.1 Microsphere characterization 
The yield for the microspheres was 56-67%, with the centrifugation step being the 
most pivotal in the overall recovery of microspheres, see Table 4.1. The yield was calculated 
from no less than five batches of microspheres of all compositions. The size distribution of 
all compositions of microspheres was found to be uni-modal. As an example, the size 
distribution ofpoly(SA) is shown in Figure 4.2. The maximum volume percent of all the 
microspheres used in this study was found to occur at a particle diameter of ca. 20 |im. 
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Table 4.1. Characteristics of microsphere yields and loading efficiency of FITC-BSA. 
Polymer Yield % 
Loading 
Efficiency (%)a 
SA 68  ±11  54 ± 14 
20:80 56 ± 9 68 ± 13 
50:50 67  ±8  48 ± 16 
80:20 57  ±10  54  ±8  
a ± values are standard deviation values calculated from a minimum of five batches 
The anhydride bond is labile in an aqueous environment and the fabrication of the 
polyanhydride microspheres was done in the presence of water, therefore, the amount of 
degradation that the polymers underwent during the fabrication process was quantified by 
GPC (Table 4.2). Poly(SA) showed the greatest Mn loss while 80:20 CPH:SA showed the 
least. With increasing amounts of CPH in the copolymers, the number of CPH:CPH bonds 
increases. It is known that CPH:CPH bonds are not as labile as CPH:SA or SA:SA bonds 
[52, 53], therefore, these chemical properties control the decrease in the Mn associated 
withcopolymers containing increasing amounts of CPH. These results are similar to those 
reported by Kipper et al. [44]. Figure 4.3 shows the surface morphology of the microspheres 
obtained by using SEM. The surface morphology of the microspheres varies with the 
polymer composition such that the more hydrophobic the polymer (e.g., the higher the CPH 
content), the smoother the surface of the microspheres. As the content of SA increases, the 
surface appears to get rougher and dark circles below the surface become apparent. The 
rough surface morphology of the SA-rich compositions is a consequence of the fast 
degradation of SA:SA bonds [54-57]. The dark circles that are present in microspheres 
containing higher contents of SA are attributed to the inner emulsion breaking near the 
surface. Figure 4.4 shows the distribution of FITC-BSA within the microspheres obtained by 
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confocal microscopy. The protein is uniformly distributed in the poly(SA) microspheres. As 
the CPH content increases, the BSA-FTIC is distributed less evenly throughout the 
microspheres, as is apparent by both the protein rich (identified by the intense fluorescence) 
and protein void regions (identified by the lack of fluorescence). The uneven distribution of 
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Figure 4.2. Size distribution of the polyanhydride microspheres based on volume percent of 
microspheres as a function of particle diameter for poly(sebacic acid). 
Table 4.2. Molecular mass characteristics of polymer microspheres as determined by GPC. 






Poly(SA) 74000/15000 37000/11000 25 
CPH:SA (20:80) 21000/10000 18000/9000 11 
CPH: SA (50:50) 15000/7000 14000/7000 0 
CPH: SA (80:20) 20000/10000 20000/10000 0 
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Figure 4.3. Scanning electron micrographs of polyanhydride microsphere surface 
morphologies (a) poly(SA) (b) 20:80 (CPH:SA) (c) 50:50 (CPH:SA) (d) 80:20 (CPH:SA). 
d. 
Figure 4.4. Fluorescence photomicrographs depicting the cross-sectional distribution of 
FITC-BSA in polyanhydride microspheres (a) poly(SA) (b) 20:80 (CPH:SA) (c) 50:50 
(CPH:SA) (d) 80:20 (CPH:SA). 
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4.4.2 Protein loading 
The encapsulation efficiency of FITC-BSA was approximately 50%, and is similar to 
previous reports that use the W/OAV method, see Table 4.1 [58, 59]. Because of the 
variation in loading efficiency from batch to batch, the protein content of each batch of 
microspheres was determined a priori in order to perform the normalization. 
4.4.3 In vitro protein release 
The in vitro release was conducted in an aqueous solution containing 3% SDS. The 
SDS acted as a surfactant to ensure that the (sticky) protein did not bind to the reaction 
vessel, the sampling equipment, or the degrading microspheres [10]. Because SDS denatures 
proteins, the secondary structure of the released protein could not be assessed. The addition 
of SDS to the release media did slightly increase the amount of FITC-BSA released (data not 
shown) and aided in more accurate BCA readings and resulted in protein concentrations 
detectable by SDS-PAGE. 
The release profile of FITC-BSA loaded microspheres was a function of the polymer 
chemistry as shown in Figure 4.5. The Bonferroni multiple comparison adjustment was used 
to determine that the p-values for all the multiple comparisons were less than 0.001 
indicating that release profiles of each polymer composition are statistically different [60]. 
The release of FITC-BSA from poly(SA) and 20:80 (CPH:SA) shows a small initial burst 
followed by a period of zero order release. The initial burst seen from the SA-rich 
microspheres was due to the accelerated surface degradation that occurred during the 
fabrication. The release of FITC-BSA from 50:50 (CPH: SA) and 80:20 (CPH: SA) did not 
show an initial burst. The lack of an initial burst was attributed to the fact that each 
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microsphere had a slightly different distribution of FITC-BSA as seen with the confocal 
microscopy studies. It is hypothesized that the varying distribution of FITC-BSA within the 
microspheres counteracted any fluctuations that may have resulted from the protein rich 
regions or protein void spaces near the surface, as seen in Figure 4.4. As the hydrophobicity 
of the polymer increased, the duration of release increased. After 10 and 20 days, 
respectively, the majority of the protein encapsulated in poly(SA) and 20:80 (CPH: SA) was 
released. After 50 days, only 50% of the encapsulated protein was released from 50:50 
(CPH:SA) and only 10% was released from 80:20 (CPH:SA). This data suggested that by 
altering the copolymer composition both the release rate of FITC-BSA as well as the shape 
of the release profile. It is possible that some of the FITC-BSA was released as insoluble 
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Figure 4.5. In vitro release of FITC-BSA from polyanhydride microspheres incubated in 1 ml 
of a 3% SDS solution at 37°C. Aliquots of 0.75 ml were collected and 0.75 ml of fresh 
solution was added to the sample to maintain perfect sink conditions. Results are 
representative of three replicates. Errors bars represent the standard deviation of the samples. 
4.4.4 SDS-PAGE analysis 
Figure 4.6 shows the SDS-PAGE analysis of the released FITC-BSA and native 
FITC-BSA under reducing and non-reducing conditions. Any protein aggregates present in 
the FITC-BSA would be conserved when analyzed without (3-mercaptoethanol. Because 
BSA was known to form inter-protein multimers via disulfide bonds [61], [3-mercaptoethanol 
was used in order to break any disulfide bondsproviding insight on the possible formation of 
protein multimers. Samples with and without [3-mercaptoethanol were compared. A small 
percentage of the commercially available FITC-BSA contained multimers, as indicated by 
the higher molecular mass bands seen in lane 2 of Figure 4.6a. These same bands were seen 
in lanes 3-6 of Figure 4.6a, the protein released from the polyanhydride microspheres. In the 
absence of (3-mercaptoethanol the released BSA showed no additional indications of inter-
protein multimers as compared to the unencapsulated protein, which would have been 
represented by a larger percentage of higher molecular mass bands. With the addition of (3-
mercaptoethanol, the disulfide bonds that were present in the unencapsulated BSA were 
eliminated as were the higher molecular mass bands seen in the BSA released from the 
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Figure 4.6. SDS-PAGE of FITC-BSA released from polyanhydride microspheres in a 3% 
SDS solutions (a) Electrophoresis run under non-reducing conditions. Lane 1 : FITC-BSA, 
Lane 2: molecular mass ladder, Lane 3: poly(SA), Lane 4: 20:80 (CPH:SA), Lane 5: 50:50 
(CPH:SA), Lane 6: 80:20 (CPH:SA) (b) Electrophoresis run under reducing conditions. 
Lane 1: FITC-BSA, Lane 2: molecular mass ladder, Lane 3: poly(SA), Lane 4: 20:80 
(CPH:SA), Lane 5: 50:50 (CPH:SA), Lane 6: 80:20 (CPH:SA). 
Native bovine serum albumin has a molecular mass of 66,400 Da [61] and was 
represented in lane one of Figure 4.6. If the released protein was still intact, it should have a 
band corresponding to 66,400 Da. As shown in Figure 4.6, bands corresponding to 66,400 
Da were present in all the lanes. However, faint low molecular mass bands were also 
observed. These low molecular mass bands indicated that a small portion of the protein 
underwent hydrolysis due to the experimental conditions. The pH of the release medium 
drops slightly as the polyanhydride microspheres degrade especially in the absence of a 
buffering solution. Because protein concentrations high enough to be detected by silver 
staining can only be obtained by allowing the microspheres to degrade for several days, the 
released protein was exposed for a long time to a high temperature and mildly acidic 
conditions which lead to hydrolysis [62]. This observation was consistent with the data 
88 
reported by Igartua et al. [16] indicating that BSA incubated at 37°C for one day remained 
intact, BSA incubated for several days was hydrolyzed [16]. To verify this, the native 
protein was incubated with 15 mg of polymer in a 3% SDS solution. After several days the 
media was sampled and run on a gel. The protein did undergo cleavage as a result of the 
acidic conditions and the incubating temperature (data not shown). Because the darkest 
bands (indicating the highest protein content) correspond to 66,400 Da for all polymer 
compositions, it was concluded that the primary structure of FITC-BSA encapsulated within 
polyanhydride microspheres was generally conserved. 
4.4.5 FTIR analysis 
The secondary structure of FITC-BSA encapsulated within polyanhydride 
microspheres was determined to assess what effects the microsphere fabrication process and 
the presence of the polymer had on the storage stability of the protein. The two typical 
signatures of protein secondary structure are a-helices and (3-sheets [63]. Lyophilized 
proteins have a higher content of (3-sheets than proteins in aqueous solutions due to 
intermolecular interactions [49]. Because the P-sheet content of lyophilized powder was not 
always indicative of the integrity of protein structure, only the a-helix content was used to 
determine the secondary structure of FITC-BSA [49]. Three sets of spectra were collected: 
blank microspheres, FITC-BSA loaded microspheres, and the native protein. The spectra of 
the encapsulated protein were obtained by subtracting the spectra of the blank microspheres 
from that of the BSA-loaded microspheres. This spectrum was then compared to the spectra 
of the native protein. 
The a-helix content of the lyophilized FITC-BSA was 45% (Figure 4.7), which was 
comparable to the values reported previously for unlabeled BSA [12,13,15, 49, 50]. To 
determine if the fabrication process or the presence of the polymer altered secondary 
structure of FITC-BSA, the spectrum of the encapsulated protein was compared to the native 
protein. The FITC-BSA encapsulated in poly(SA) and 20:80 CPH:SA microspheres showed 
little or no deviation in the a-helix content when compared to the native protein (see Figure 
4.7). This indicated that neither the polymer nor the microsphere fabrication process had an 
effect on the protein secondary structure. Thus, FITC-BSA can be stabilized in poly(SA) and 
20:80 CPH:SA and released continuously for three weeks. However, as the CPH content in 
the microspheres was increased to 50% and beyond, the % a-helix content decreased 
steadily, to a point at which no a-helices were detected for the protein encapsulated in 80:20 
(CPH:SA). This decrease in the a-helix content was attributed to the polymer 
hydrophobicity, and not to the microsphere fabrication process, since no change in a-helix 
content was observed in the poly(SA) microspheres, which were fabricated by the same 
process. To further verify this contention, lyophilized protein was physically mixed with 
each polymer (poly(SA), 20:80 (CPH:SA), 50:50 (CPH:SA), and 80:20 (CPH:SA)) and 
analyzed as before. The spectrum of the protein was obtained by subtracting the spectrum of 
the polymer from the spectrum of the polymer/protein blend. Fourier self-deconvolution was 
then performed on the amide I region and Gaussian curves were fit to the spectra. The 
secondary structure of protein mixed with polymer was found to match the secondary 
structure of the encapsulated protein (data not shown). To verify that this phenomenon was 
not an artifact of the polymer peaks interfering with the subtraction process, protein was 
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added to a polymer pellet without physically mixing the two and analyzed as before. The 
subtracted spectra of the polymer from the protein/polymer spectra (when not physically 
mixed) showed a-helices, indicating that the polymer was not interfering with the data 
analysis. Hence, the change in protein secondary structure due to increased polymer 
hydrophobicity was a result of the polymer-protein interactions. 
Figure 4.7 also shows the (3-sheet content of the encapsulated FITC-BSA in each of 
the polymer microspheres. Native FITC-BSA had a (3-sheet content of 23%. Once 
encapsulated, the (3-sheet content increased, indicating that the encapsulated protein 
aggregated and forms pockets of protein-rich regions in the microspheres, trying to minimize 
exposure to the polymer. These observations were consistent with the confocal microscopy 
images in Figure 4.4. 
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Figure 4.7. Histogram showing the secondary structure (as determined by FTIR) of native 
FITC-BSA vs. FITC-BSA encapsulated in polyanhydride microspheres. The results are 
representative of a minimum of three experiments (± indicates the standard deviation). * 
Represents p-value < 0.05 and ** represents p-value < 0.001 as determined by a Student t 
test. 
4.5 Conclusions 
It has been shown that polyanhydrides are capable of releasing FITC-BSA for an 
extended time period, and by varying the copolymer composition the release profile of the 
protein can be altered. Polyanhydride microspheres rich in SA fabricated by the double 
emulsion technique were successful in preserving the primary structure of the encapsulated 
FITC-BSA without the addition of excipients or lyoprotectants. The hydrophobic 
polyanhydride microspheres also prevented the FITC-BSA from undergoing covalent inter-
protein multimers via the formation of disulfide bonds. The primary structure of the released 
protein was intact and underwent hydrolysis only after it was allowed to incubate at 37 °C in 
mildly acidic media for several days. Though the protein has been shown to be stable while 
encapsulated and capable of being released at its native molecular mass, the secondary 
structure of the protein could be altered upon encapsulation into or release from the 
microspheres. Because BSA has no measurable biological activity and the secondary 
structure could not be determined in these studies, further work needs to be performed to 
further support the conclusion that poly(SA) and 20:80 (CPH:SA) microspheres can delivery 
biologically active therapeutic proteins. 
Though polyanhydride microspheres offer a sanctuary against the formation of 
covalent disulfide bonds and provide a method of prolonged delivery, not all polyanhydrides 
are suitable vehicles for protein stabilization. From this study, it was evident that the 
increased hydrophobicity of CPH provided a harsh climate for the FITC-BSA. The 
secondary structure of the protein, quantified by the a-helix content, underwent significant 
perturbations. The increased degradation time (-few months) of the CPH-rich copolymers 
also limits the usefulness of such copolymers for medical applications. The data indicates 
that polyanhydrides such as poly(SA) and 20:80 (CPH:SA) are well suited for protein 
stabilization and delivery. 
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CHAPTER 5 
PROTEIN STABILITY IN THE PRESENCE OF POLYMER DEGRADATION 
PRODUCTS: CONSEQUENCES FOR CONTROLLED RELEASE 
FORMULATIONS 
A paper submitted to Biomaterials 
Amy S. Determan x'2, Jennifer H. Wilson 3, Matt J. Kipper2, Michael J. Wannemuehler3, 
Balaji Narasimhan2'4 
5.1 Abstract 
When encapsulating proteins in polymer microspheres for sustained drug delivery 
there are three stages during which the stability of the protein must be maintained: (1) the 
fabrication of the microspheres, (2) the storage of the microspheres, and (3) the release of the 
encapsulated protein. This study focuses on how proteins would be affected by the polymer 
degradation products during the release of a protein from degrading microspheres. Tetanus 
toxoid, ovalbumin, and lysozyme were incubated for 0 or 20 days in the presence of ester 
(lactic acid and glycolic acid) and anhydride (sebacic acid and 1,6-bis(p-
carboxyphenoxy)hexane) monomers. The structure and antigenicity or enzymatic activity of 
each protein in the presence of each monomer was quantified. Sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, circular dichroism, and fluorescence spectroscopy were 
used to assess/evaluate the primary, secondary, and tertiary structures of the proteins, 
1 Graduate student; primary author and researcher 
2 Department of Chemical and Biological Engineering, Iowa State University 
3 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University 
4 Major professor; corresponding author 
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respectively. Enzyme-linked-immunosorbent-assay was used to measure changes in the 
antigenicity of tetanus toxoid and ovalbumin, and a fluorescence-based assay was used to 
determine the enzymatic activity of lysozyme. Tetanus toxoid was found to be the most 
stable in the presence of anhydride monomers, while ovalbumin was most stable in the 
presence of sebacic acid, and lysozyme was stable when incubated in the presence of all of 
the monomers studied. 
5.2 Introduction 
As the number of therapeutic proteins being marketed in the U.S. each year continues 
to increase, new challenges are arising [1], Proteins have shorter half-lives and are more 
prone to chemical and physical mechanisms of deactivation in vivo in comparison to small 
molecular weight drugs [2-7]. The delicate nature of proteins limits the feasibility of oral 
administration of protein-based therapeutics. Traditional delivery techniques often require 
high doses and multiple administrations of vaccines or pharmacological mediators, placing a 
high burden upon patient compliance (e.g., self administration of the next dose, repeat office 
visit) for the treatment regimen to be effective [2], Thus, an injectable biodegradable 
controlled delivery device that is capable of encapsulating and providing a sustained release 
of biologically active proteins is desirable. 
Encapsulating proteins into polymer microspheres is the most common method of 
fabricating an injectable controlled delivery device. Numerous biodegradable polymers have 
received attention as protein carriers, including polyesters and polyanhydrides [8-11]. 
Polyesters and polyanhydrides have different erosion mechanisms. Polyesters are bulk-
eroding materials with elevated moisture levels within the degrading device, that results in 
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moisture-induced aggregation of some proteins [12, 13]. In contrast, polyanhydrides are 
surface-eroding materials that significantly reduce the moisture level within the degrading 
device [12,14]. Another difference between polyanhydrides and polyesters is the strength of 
acidity generated by the degradation products. As polyesters erode, their degradation 
products are more soluble in water than anhydride monomers and create a microenvironment 
with a pH that is lower than that created by eroding polyanhydrides [15-17], The acidic 
environment produced by either degrading polymer could denature some proteins, with those 
induced by polyesters likely to be more destructive to protein integrity. Polyesters are used 
as drug delivery vehicles more frequently than polyanhydrides, though both are approved by 
the U.S. Food and Drug Administration (FDA) for human use. One reason that polyesters 
are used more frequently is because they are less hydrophobic than polyanhydrides reducing 
the risk of non-covalent interactions with the encapsulated and released protein [18]. 
Before a protein can be encapsulated in a polymeric microsphere, care must be taken 
to select a polymer that can stabilize the protein of interest. The FDA defines a stable 
pharmaceutical as one that deteriorates less than 10% in two years [2], Every protein has 
varying levels of stability and each has a different mechanism of denaturation [2-7, 19]. 
Thus, it is important to understand the conditions that can be detrimental for a protein and try 
to prevent the exposure of the protein to those conditions. When encapsulating proteins in 
polymeric microspheres, there are three stages in which the protein must maintain its 
stability: microsphere fabrication, storage, and the release of the protein from the eroding 
microsphere. The work presented here investigates the changes in structure and activity of 
three proteins (tetanus toxoid, ovalbumin, and lysozyme) after being incubated with the 
degradation products (monomers) of both polyesters and polyanhydrides. The goal of this 
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work was to study the effect of ester or anhydride monomers on the stability of different 
proteins. These experiments simulated the conditions that the protein would be exposed to as 
it is released from a degrading microsphere. The esters (in the form of polymer degradation 
products) used for this study were lactic acid (LA) and glycolic acid (GA). The anhydrides 
(in the form of polymer degradation products) used for this study were sebacic acid (SA) and 
1,6-bis(/>carboxyphenoxy)hexane (CPH). The primary, secondary, and tertiary structures, 
and the antigenicity or enzymatic activity of each protein were determined after incubating at 
37°C for 0 and 20 days with each of the monomers. For these studies, tetanus toxoid, 
ovalbumin, and lysozyme were chosen as model therapeutic proteins to give a broad 
perspective on how different polymer degradation products affected the stability of different 
proteins. 
5.3 Materials and Methods 
5.3.1 Materials 
Sebacic acid (99%), ^ -carboxy benzoic acid (99+%), 1 -methyl-2-pyrrolidinone 
anhydrous (99+%), DL-lactic acid (85% solution in water), and glycolic acid (99%) were 
purchased from Aldrich (Milwaukee, WI). 1,6-dibromohexane (98+%) was purchased from 
Acros (Fairlawn, NJ). Chicken egg white ovalbumin, hen egg white lysozyme, monoclonal 
anti-chicken egg albumin (clone ova-14 mouse ascites fluid), anti-chicken egg albumin 
developed in rabbit, anti-rabbit IgG alkaline phosphatase conjugate developed in goat, fetal 
calf serum (FCS), Coomassie R-250, Sigma 104 phosphatase substrate, and /?-nitrophenyl 
phosphatase (pNPP) liquid substrate system were purchased from Sigma (St. Louis, MO). 
Mini gradient gels (4-20%, Tris-Glycine) were purchased from Gradipore (Australia). 
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Protein molecular mass standards were purchased from BioRad (Hercules, CA). The 
fluorescent-based assay, EnzCheck®, used to determine the enzymatic activity of lysozyme, 
was purchased from Molecular Probes (Eugene, OR). Tetanus toxoid (TT) was purchased 
from University of Massachusetts Biologic Laboratories (Jamaica Plain, MA) at a purity of 
1.5 mg/ml and 490 Lf7ml. Tetanus antitoxin was purchased from Fort Dodge Laboratories, 
Inc (Fort Dodge, LA). The IgG fraction was purified from tetanus antitoxin using the T-gel 
purification kit with immobilized protein A from Pierce (Rockford, IL) following the 
manufacturer's instructions. Biotin-conjugated goat anti-horse IgG (H&L) was purchased 
from KPL, (Gaithersburg, MD). Alkaline phosphatase-conjugated streptavidin was 
purchased from Southern Biotechnology Associates (Birmingham, AL). All the other 
chemicals were of analytical grade and were used as purchased from Fisher Scientific 
(Pittsburgh, PA). 
5.3.2 In vitro incubation 
The stability of tetanus toxoid (TT), ovalbumin, and lysozyme when incubated for 0 
and 20 days with different ester monomers, anhydride monomers, or phosphate buffered 
saline (PBS) pH 7.4, was examined. The 20-day samples were incubated at 37°C and 
agitated at 100 rpm. The LA and GA solutions were prepared by dissolving the acids in de-
ionized water (5 mM) and filtering (0.22 jam). CPH diacid was synthesized as described 
previously [20]. The CPH and SA diacid solutions were obtained by incubating an excess of 
each diacid in de-ionized water at 37°C (100 rpm) overnight. The diacid solutions were then 
centrifuged and filtered (0.22 gm). The final concentration of the CPH and SA diacid 
solutions were 1 mM and 5 mM, respectively. Mixtures of LA/GA and CPH/SA were 
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obtained by mixing equal volumes of each solution (prepared separately) together. Table 5.1 
shows the pH and the concentration of each of the solutions used. Stock solutions of tetanus 
toxoid, ovalbumin, and lysozyme (1.5 mg/ml) were made in a saline/thimerosal solution (8.5 
g/L NaCl, 0.003% thimerosal). The protein solution was added to the monomer solution at a 
volume ratio of 20%. The final protein concentration of all samples was 300 |xg/ml, unless 
otherwise stated. Experiments were repeated a minimum of three times. 
Table 5.1 : Polymer degradation products used, and the pH of the solutions. 
Solution Concentration Type of Polymer pH 
CPH 1 mM (saturated) Polyanhydride 5.5 
SA 5 mM Polyanhydride 4.2 
CPH/SA 0.5/2.5 mM Polyanhydride 5.0 
LA 5 mM Polyester 3.5 
GA 5 mM Polyester 3.6 
LA/GA 2.5/2.5 mM Polyester 3.5 
5.3.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
assess changes in the primary structure of the proteins after being incubated with the polymer 
degradation products for 0 and 20 days. All the gels were run under reducing conditions. 
Each sample was mixed with an equal volume of a solution containing SDS (1% w/v), Tris-
HC1 (pH 6.8, 0.06 mM), glycerol (3 mM), bromophenol blue (0.01% w/v), and [3-
mercaptoethanol (0.05% v/v). The samples were boiled for 10 min and allowed to cool to 
room temperature before loading onto the gel. The samples (7.5 (xg/lane of ovalbumin and 
lysozyme and 18.75 pg/lane of TT) were then resolved though 4-20% precast gradient 
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polyacrylamide gels (Gradipore). Electrophoresis was performed using a BioRad Mini-
Protean 13 electrophoresis setup at a constant voltage (100 V) as described by the 
manufacturer. Prestained BioRad low-range standards were used to estimate the molecular 
mass of each protein sample. The gels were stained either with GelCode Blue (Pierce) 
following manufacturer directions or with Coomassie Blue (methanol 10% v/v, acetic acid 
10% v/v, and Coomassie Blue R-250 0.1% w/v) overnight and then destained with a 
methanol (30% v/v) solution. The gels were then photographed and dried. The molecular 
weight of the detected bands was compared to that of standards. 
The TT samples used for the SDS-PAGE experiments were incubated at a 
concentration of 150 pg/ml. To increase the visibility of the TT bands on the gel, the 
samples were concentrated prior to loading onto the gel. The TT samples were concentrated 
using Vivaspin centrifugation (Vivascience, Hannover, Germany) (3000 MW cutoff) 
following the manufacturer's instructions. Samples were diluted in PBS and concentrated to 
remove the monomers. Equal quantities of each TT sample were loaded per lane (18.75 jxg 
protein based on original concentrations). 
5.3.4 Circular dichroism (CD) 
Far UV circular dichroism (CD) (190-250 nm) was used to monitor changes in the 
secondary structure of the proteins after 0 and 20 days of incubation with the polymer 
degradation products. Due to the high absorbance of the PBS solution (without any protein) 
water was used as a control for all CD experiments. To ensure that the ellipticity of TT and 
lysozyme was within a workable range for these experiments, the protein concentration was 
reduced from 300 (xg/ml to 150 jj.g/ml. All CD spectra were collected on a Jasco J-710 
104 
(Eastern, MD) instrument with a 1 cm quartz cell. Using the Jasco software, the background 
solution (polymer degradation product in de-ionized water with saline/thimerosal solution 
added) was subtracted from each protein spectrum. A minimum of three protein spectra were 
collected per sample and averaged. 
5.3.5 Fluorescence spectroscopy 
To determine if the protein underwent any changes in tertiary structure while in the 
presence of the polymer degradation products, fluorimetry was performed (Varian Gary 
Eclipse Fluorescence Spectrometer, Australia). The emission spectrum (300-500 nm) of 
each sample was collected at an excitation wavelength of 280 nm. When excited at 280 nm, 
the emission spectrum is a result of contributions from both tryptophan and tyrosine residues 
in the protein [21]. Each protein spectrum was corrected by subtracting the spectrum of the 
appropriate blank solution (no protein) to eliminate spectral features from the solvent. 
5.3.6 TT-specific enzyme-linked-immunosorbent-assay (ELISA) 
Ninety-six well microtiter plates (Costar high protein binding) were coated overnight 
at room temperature with 100 gl PBS (pH 7.4) containing different dilutions of the incubated 
TT samples, in duplicate. By measuring different dilutions of TT, the concentration at which 
the antigenicity of TT was no longer detectable was determined. To remove unbound TT, 
plates were washed with PBS containing 0.05% Tween 20 (PBST) and then blocked for 2 h 
at room temperature with PBST containing 2% gelatin. Anti-TT antibodies (100 pl/well) 
(IgG fraction purified from Tetanus Antitoxin, 1 mg/ml diluted 1:20,000) were diluted in 
PBST supplemented with 1% FCS (PBST-FCS). Following an overnight incubation (18 h at 
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4°C) the plates were washed three times with PBST. A volume of 100 pi of PBST-FCS 
containing biotin-conjugated goat anti-horse IgG (H&L) (0.5 mg/ml diluted 1:2000) was then 
added to each well. After a 4 h incubation, the plates were washed three times with PBST 
and 100 ml alkaline phosphatase-conj ugated Streptavidin (diluted 1:1000) was added. After a 
2 h incubation, the plates were washed three times with PBST and 100 pi of sodium 
carbonate buffer (pH 9.3) containing phosphatase substrate (1 mg/ml) was added and allowed 
to react for 1 h at room temperature. The optical density (OD) of the reaction was measured 
at 405 nm using a Spectramax 190 Plate Reader (Molecular Devices, Sunnyvale, CA). 
5.3.7 Ovalbumin-specijic enzyme-linked-immunosorbent-assay (ELISA) 
High binding Costar ninety-six well plates were coated overnight at 4°C with 100 pi 
of mouse monoclonal anti-chicken egg albumin diluted 1:2000 in PBST. The plates were 
then washed three times with PBST and blocked for 2 h at room temperature with a 2% BSA 
solution in PBST. The blocking solution was removed and the plates were washed three 
times with PBST. One ovalbumin sample incubated with each monomer or PBS was then 
diluted in PBST to a final concentration of 150 pg/ml and 100 pi was added to each well (in 
triplicate). Following an overnight incubation (18 h at 4°C), the plates were washed three 
times with PBST. A volume of 100 pi of anti-ova developed in rabbit (2 pg/ml) was then 
added to each well and allowed to incubate at room temperature for 2 h. The plates were 
then washed three times with PBST. After washing, 100 pi of anti-rabbit IgG alkaline 
phosphatase developed in goat diluted in PBST (1:30,000) was added to each well. After 
incubating for 2 h at room temperature the plates were washed three times with PBST. A 
volume of 100 pi of pNPP liquid substrate was then added to each well and allowed to react 
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for 1 to 2 h. The OD of the reaction was measured using a Bio-TEK EL 340 microtiter plate 
reader (Winooski, VT) at 405 nm. All the values were normalized by the initial protein and 
reported as relative epitope availability. A Student t test was used to determine the statistical 
differences between the ovalbumin incubated in PBS and each of the monomers investigated. 
Treatments showing a statistical difference were noted. 
5.3.8 Lysozyme activity test 
The activity of lysozyme was quantified using the fluorescent-based kit EnzChek® as 
described by the manufacturer. Briefly, one sample recovered from each monomer or PBS 
incubation was diluted with IX reaction buffer (0.1 M sodium phosphate, 0.1 M NaCl, 2 mM 
sodium azide, pH 7.5) and 50 (il per well was added to a 96 well plate. Fifty p.1 of lysozyme 
substrate {Micrococcus lysodeikitcus labeled with fluorescein diluted in IX reaction buffer) 
was added to each sample. The samples were then allowed to react in the dark for 30 min at 
37°C. The fluorescence intensity was then measured using a Varian Gary Eclipse 
Fluorescence Spectrometer by exciting the samples at 494 nm and measuring the emission at 
518 nm. All samples were compared to standards of known activity. A Student t test was 
used to determine the statistical differences between the ovalbumin incubated in PBS and 
each of the monomers investigated. Treatments showing a statistical difference were noted. 
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5.4 Results 
5.4.1 Stability of tetanus toxoid 
5.4.1.1 SDS-PAGE analysis. Tetanus toxoid (TT) is a 150 kDa heterodimer known 
to lose its immunogenicity when exposed to high moisture environments [22]. TT was 
included in the study because both polyesters and polyanhydrides have been used to 
encapsulate TT with the intent to develop a single dose vaccine [9, 23, 24]. Mature TT is 
composed of 1,351 amino acid residues comprising two polypeptide chains (N-terminal light 
chain, 52 kDa and the C-terminal heavy chain, 98 kDa) that are linked by a disulfide bridge 
[25]. In order to address changes in the primary structure of TT, changes in the molecular 
mass were investigated using SDS-PAGE after 0 and 20 days of incubation in the presence of 
ester and anhydride monomers (Figure 5.1). Three bands were visible by SDS-PAGE 
analysis when the TT was suspended in PBS and incubated for 0 days. The highest intensity 
band corresponded to intact TT (i.e 150 kDa) and the two smaller bands corresponded to the 
heavy and light chains of TT, respectively. Because TT is prepared as a formalin-fixed 
solution, the majority of the TT supplied by the manufacturer was present as a heterodimer 
with a molecular size of 150 kDa; however, a smaller fraction of the TT preparation was 
present as separate light and heavy chains. The TT that was dissolved in solutions containing 
polyester or polyanhydride degradation products and immediately analyzed by SDS-PAGE 
showed similar banding patterns, indicating that the primary structure of TT was not affected 
by these solutions. After 20 days of incubation in solutions containing the different 
monomers (Table 1), changes in the primary structure of TT were investigated. Following 
incubation in the indicated solution, an equal amount of total TT was loaded into individual 
lanes of the gel. The staining intensity of the bands corresponding to 150, 98, and 52 kDa for 
108 
TT samples incubated in the presence of the polyester monomers was much lower than that 
of the protein incubated with PBS or the polyanhydride monomers. The disappearance of the 
TT bands is a consequence of protein aggregation. Because TT is a large protein (150 kDa) 
its aggregated form is difficult to resolve on a gel. Johansen et al. [26] also observed that 
TT became undetectable by SDS-PAGE after the samples had been incubated in 100 mM of 
either LA or GA as a consequence of aggregation. The results of this experiment 
demonstrated that incubation of TT in the presence of polyester degradation products lead to 
protein aggregation, while the primary structure of TT incubated with anhydride monomers 
was unaffected. 
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Figure 5.1. SDS-PAGE analysis of tetanus toxoid samples (18.75 gg/lane) incubated in the 
presence of the indicated ester and anhydride monomers for (a) 0 days or (b) 20 days. Lane 
1: molecular mass ladder; lane 2: 1 mM 1,6-bis(p-carboxyphenoxy)hexane (CPH); lane 3: 5 
mM sebacic acid (SA); lane 4: 0.1/2.5 mM CPH/SA; lane 5: 5 mM lactic acid (LA); lane 6: 5 
mM glycolic acid (GA); lane 7: 2.5/2.5 mM LA/GA; lane 8: phosphate buffer saline (PBS). 
5.4.1.2 Circular dichroism analysis. The secondary structure of TT incubated with 
polyester and polyanhydride degradation products was monitored using far UV CD (190-250 







TT spectrum had two minima at 208 and 222 nm, in agreement with previous work, as shown 
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in Figure 5.2 [27]. The two minima at 208 and 222 nm are signatures of a-helices and a-
helices + (3-sheets [28, 29]. After 0 days of incubation with either the ester or anhydride 
monomers, there was no change in the spectra of TT. After the TT was incubated for 20 days 
with LA, GA, and LA/GA, the minimum at 222 nm shifted to 217 nm indicating an increase 
in the p-sheet content of the protein [28]. The spectra of TT incubated with the 
polyanhydride degradation products for 20 days showed no deviation from those of TT 
incubated in water for the same length of time. This experiment showed that TT underwent 
conformational alterations in the presence of polyester degradation products, but not in the 
presence of polyanhydride degradation products. 
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Figure 5.2. Circular dichroism spectral analysis of tetanus toxoid (150 |ig/ml) after 20 days 
of incubation in the presence of water (closed circle), 5 mM sebacic acid (SA)(open square), 
or 5 mM glycolic acid (GA) (open triangle). Results are representative of three replicate 
experiments. 
5.4.1.3.1 Fluorescence spectroscopy. The fluorescence spectra of TT incubated 
with each of the polymer degradation products for 0 and 20 days are shown in Figure 5.3. 
The TT samples dissolved in PBS and analyzed immediately generated one large peak with a 
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maximum absorbance (Xmax) at 330 nm and a much smaller peak with a )vmax at 445 nm. 
Similar results were observed by Xing et al. [30]. The smaller peak at 445 nm corresponded 
to a tryptophan oxidation product [30]. The fluorescence spectra obtained immediately after 
solubilizing TT in solutions containing the ester or anhydride monomers were similar to the 
spectrum obtained when TT was solubilized in water. After a 20-day incubation in solutions 
containing the polymer degradation products, the intensity of the 330 nm peak decreased 
while the intensity of the 445 nm peak increased, as shown in Figure 5.3b. Following 
incubation of TT in solutions containing the polyester degradation products, the fluorescence 
spectra displayed the highest intensity at the 445 nm peak at day 0 and 20, indicating an 
alteration of the tryptophan residues [30]. 
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Figure 5.3. Fluorescence spectral analysis of tetanus toxoid (300 gg/ml) incubated with ester 
and anhydride monomers for (a) 0 days or (b) 20 days. Results are representative of three 
replicate experiments. 
5.4.1.4 Antigenicity. Tetanus toxoid has multiple immunologic epitopes to which 
serum antibodies specific of TT can bind. The overall antigenicity of a protein will be 
defined by the total sum of the antibody molecules bound to the individual epitopes. If 
protein denaturation destroys an antibody-binding site (e.g., epitope), the overall antigenicity 
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of the resultant peptide mixture would be reduced. However, if a protein was degraded and 
the epitopes remain intact, the overall antigenicity of the peptide mixture would remain 
unchanged. In order to assess the effects of the polyester and polyanhydride degradation 
products on the antigenicity of TT, an ELIS A was preformed using polyclonal equine 
antiserum to detect the antigenic integrity of TT. The ELIS A results analyzing TT samples 
incubated in the indicated solutions for either 0 or 20 days are shown in Figure 5.4. The 
antigenic reactivity of TT samples was unchanged when analyzed immediately after 
preparation of the TT-containing ester or anhydride solutions. After 20 days of incubation, 
the antigenicity of TT was unaffected for samples incubated in the presence of PBS or the 
anhydride monomers. However, incubation of TT for 20 days in solutions of the ester 
monomers resulted in a significant decrease in the antigenicity of the protein. The loss of 
antigenicity was most evident when the lowest detectable concentration of total protein was 
determined. TT incubated in the presence of SA or SA/CPH monomers lost about 50% of its 
antigenicity while TT incubated with the ester monomers was four times less antigenic than 
TT incubated in PBS. Similar to previous results reported by Xing et al. [32], these results 
suggested that the loss of antigenicity was due to protein degradation associated with the 
more acidic environment created by the ester monomers in comparison to the solutions 
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Figure 5.4. The antigenicity of tetanus toxoid measured by ELIS A using a standard dilution 
of equine anti-tetanus toxoid. The antigenic stability of tetanus toxoid was evaluated as 
described in Materials and Methods after being incubated with ester and anhydride 
monomers for (a) 0 days or (b) 20 days and was compared to tetanus toxoid incubated in 
phosphate buffered saline for the same time periods. Results are representative of three 
replicate experiments. 
5.4.2 Stability of ovalbumin 
5.4.2.1 SDS-PAGE analysis. Ovalbumin (48 kDa) is an abundant protein that has 
previously been used as a model antigen for microencapsulation [31-34], SDS-PAGE was 
used to monitor changes in the primary structure of ovalbumin after being incubated in the 
presence of polyanhydride and polyester degradation products for 0 or 20 days. The SDS-
PAGE profiles for ovalbumin incubated in the presence of the ester or anhydride monomers 
for 0 or 20 days were identical, hence only the gel depicting the samples incubated for 20 
days is shown in Figure 5.5. Under these experimental conditions, the primary structure of 
ovalbumin was not altered by any of the monomer-containing solutions. There was no 
evidence that ovalbumin underwent aggregation or hydrolysis in these solutions. Because 
ovalbumin is known to form covalent aggregates via disulfide bonding [35], the samples 
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were also run under non-reducing conditions to verify the absence of aggregates. The results 
(not shown) confirmed that ovalbumin did not form covalent aggregates in any of the 
treatment solutions. This experiment demonstrated that ovalbumin resisted changes in its 









Figure 5.5. SDS-PAGE analysis of ovalbumin samples (7.5 |xg/per lane) after being 
incubated for 20 days. Lane 1 : molecular mass ladder; lane 2: native ovalbumin; lane 3: 1 
mM 1,6-bis(p-carboxyphenoxy)hexane (CPH); lane 4: 5 mM sebacic acid (SA); lane 5: .5/2.5 
mM CPH/SA; lane 6: 5 mM lactic acid (LA); lane 7: 5 mM glycolic acid (GA); lane 8: 
2.5/2.5 mM LA/GA; lane 9: phosphate buffer saline (PBS). 
5.4.2.2 Circular dichroism. Far UV CD (190-250 nm) was used to monitor the 
secondary structure of ovalbumin incubated with polyester and polyanhydride degradation 
products and water. Koseki et al. [36] reported that incubating ovalbumin in an acidic 
environment alone does not denature the protein, instead the protein takes on a molten 
globular form in which the flexibility of the side chains is increased, decreasing the stability 
of ovalbumin. The spectra of ovalbumin incubated for 0 and 20 days in water were identical, 
indicating that ovalbumin did not undergo any conformational changes. Each spectrum had 
two minima at 208 and 222 nm (Figure 5.6), consistent with previous studies [36]. The 
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ovalbumin incubated with the ester and anhydride monomers for 0 days also had two minima 
at 208 and 222 nm. After a 20-day incubation with LA, the spectrum of ovalbumin was 
unchanged. When incubated with GA and LA/GA for 20 days, the spectrum of ovalbumin 
was altered, and the minimum at 222 nm shifted to 218 nm indicating an increase in the 13-
sheet content of the protein. The spectra of ovalbumin incubated with the polyanhydride 
degradation products for 0 days was identical to the spectrum of ovalbumin in water. After 
20 days of incubation, the ovalbumin incubated with the CPH and the SA showed no 
changes, while the spectrum of ovalbumin incubated for 20 days with CPH/SA showed 
deviation. The spectrum of ovalbumin after incubation in CPH/SA for 20 days still 
contained minima at 208 and 222 nm; however, the ratio of [0]222/[0]208 changed from 1.32 
(water) to 0.85 (CPH/SA) indicating an increase in the a-helical content [21]. Zemser et al. 
[21] and Takeda and Moriyama [37] reported similar findings when SDS was added to 
ovalbumin. The anionic detergent, SDS, interacts with the hydrophobic side chains of 
ovalbumin disrupting the hydrophobic bonds within the protein. The disruption of the 
hydrophobic bonds favors the formation of a-helices. Because the CPH monomer contains 
hydrophobic regions, it is anticipated that the monomer interacts with the hydrophobic side 
chains of the ovalbumin in the same way that SDS does. 
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Figure 5.6. Circular dichroism spectral analysis of ovalbumin (300 |xg/ml) after 20 days of 
incubation in the presence of water (closed circle), 5 mM sebacic acid (SA) (open square), or 
5 mM glycolic acid (GA) (open triangle). Results are representative of three replicate 
experiments. 
5.4.2.3 Fluorescence spectroscopy. When ovalbumin was excited at 280 nm, the 
resulting fluorescence spectrum had a single peak with a Xmax between 331 and 342 nm, 
corresponding to the intense emission of tryptophan [21]. Ovalbumin contains three 
tryptophan residues that are located in the interior of the molecule. As the protein unfolds, or 
undergoes changes in its tertiary structure, the location of the internal tryptophan residues 
change and the resulting fluorescence spectrum is altered [21]. 
The fluorescence spectra of ovalbumin incubated for 0 and 20 days are compared in 
Table 5.2. The lma% of all protein spectra at day 0 were within the range of 331 to 342 nm. 
Following a 20-day incubation, the ovalbumin incubated with PBS, the anhydride monomers, 
and LA had a Xmax within the normal range of 331-342 nm. Though the Imax of the 
ovalbumin incubated with CPH and CPH/SA was within the acceptable range, there was a 
shift in the Xmax to longer wavelengths. A similar shift of the Xmax was seen when 0.1 M and 
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0.01 M SDS was added to ovalbumin indicating an increase in a-helix formation [21]. This 
is consistent with the CD results of ovalbumin incubated with CPH/SA for 20 days. 
When ovalbumin was incubated with GA and LA/GA for 20 days, the Xmax of the 
resulting spectra fell outside of the expected range of 331 to 342 nm (see Table 5.2 for l^ax 
values at days 0 and 20), indicating that the protein was unfolding [21]. This finding is 
consistent with the work of Koseki et al. [36] where the side chains of ovalbumin were found 
to be more flexible and susceptible to denaturation when kept at acidic pH for an extended 
period of time. This change in the tertiary structure is also consistent with the changes in the 
secondary structure of ovalbumin incubated with GA and LA/GA as observed with CD. The 
change in the tertiary structure of ovalbumin is attributed to the glycolic acid interfering with 
the hydrogen-bonding pattern within the polar regions of the protein as seen when ovalbumin 
is incubated with guanidine [21]. 
Table 5.2. Wavelength maxima (Imax) of ovalbumin incubated in the indicated monomers for 
0 and 20 days. 
Polymer Degradation Products Xmax Day 0 (nm) Xmax Day 20 (nm) 
CPH 339 332 
SA 336 339 
CPH/SA 337 335 
. LA 340 340 
GA 336 344 
LA/GA 340 346 
PBS 339 337 
Data were obtained by fluorescence spectroscopy. Italicized values represent Xmax values that 
fall outside of the 331-342 nm range. 
5.4.2.3 Antigenicity. A capture ELIS A was used to monitor the changes in the 
antigenicity of ovalbumin incubated in the presence of polyester or polyanhydride 
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degradation products for 0 or 20 days. The results are shown in Figure 5.7. The ELISA 
values represent a relative epitope availability of ovalbumin after the values had been 
normalized by the epitope availability of native ovalbumin (e.g., incubated in PBS). If no 
structural alterations occurred, the ratio of the relative epitope availability would be 1, as 
observed for the ovalbumin solubilized in PBS or anhydride monomers and assayed 
immediately. These results are consistent with previous reports that the antigenicity of 
ovalbumin was retained when the pH was >3.0 [38]. The increase in the relative epitope 
availability exhibited by ovalbumin solubilized in the polyester monomers was a result of 
protein unfolding and exposing more epitopes that were being recognized by the polyclonal 
antibody used in the assay. Because the solutions containing the ester monomers were more 
acidic (Table 1), the flexibility of the side chains was increased. 
Figure 5.7. The antigenicity of ovalbumin (150 pg/ml) measured using ELISA, after being 
incubated with ester and anhydride monomers for (a) 0 days or (b) 20 days (± indicates 
standard deviation). * represents p-value < 0.05 and ** represents p-value < 0.001 as 
determined by a Student t test. 
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Ovalbumin incubated for 20 days in PBS, CPH, or CPH/SA containing solutions 
showed no change in ovalbumin antigenicity. Ovalbumin incubated in solutions containing 
SA, LA, GA, or LA/GA showed a large increase in the fractional antigenicity of ovalbumin. 
The mechanism underlying this increase in antigenicity was likely associated with the 
unfolding of this protein that resulted in exposing more linear epitopes that are being 
recognized by the polyclonal antibody used in these studies. On a weight comparison, the 
apparent increase in antigenicity of ovalbumin incubated in the presence of select monomers 
is likely attributable to the excessive unfolding of ovalbumin as a consequence of the higher 
acidity of these monomers. Though no previous experiment in this work provided evidence 
of ovalbumin undergoing conformational changes in the presence of SA, this solution was 
still more acidic than the PBS, CPH, or CPH/SA solutions due to the higher water solubility 
of SA [15]. The data suggested that this increase in acidity affected the overall stability or 
conformation of the protein. 
5.4.3 Stability of lysozyme 
5.4.3.1 SDS-PAGE analysis. Lysozyme (14 kDa) is a model protein that is widely 
available and has been used for microsphere encapsulation. SDS-PAGE was used to monitor 
changes in the primary structure of lysozyme after being incubated with polymer degradation 
products. The results from days 0 and 20 were identical. The 20-day incubation data are 
shown in Figure 5.8 and indicate that the protein did not undergo any changes in its primary 
structure after being incubated with either ester or anhydride monomers. These results 
indicate that all of the degradation products provided a suitable environment for maintaining 
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the primary structure of lysozyme. These results are consistent with previous observations 
that lysozyme is stable under acidic conditions [39]. 
1 2 3 4 5 6 7 8 9 
Figure 5.8. SDS-PAGE analysis of lysozyme samples (7.5 p.g/per lane) after being incubated 
for 20 days in the presence of the indicated monomers. Lane 1: 1 mM 1,6-bis(/> 
carboxyphenoxy)hexane (CPH); lane 2: 5 mM sebacic acid (SA); lane 3: .05/2.5 mM 
CPH/SA; lane 4: 5 mM lactic acid (LA); lane 5: 5 mM glycolic acid (GA); lane 6: 2.5/2.5 
mM LA/GA; lane 7: phosphate buffer saline (PBS); lane 8: native lysozyme; lane 9: 
molecular mass ladder. 
5.4.3.2 Circular dichroism. Far UV CD was used to monitor the stability of lysozyme 
in the presence of water, polyester, and polyanhydride degradation products. There was no 
change in the spectra of lysozyme incubated in water for 0 and 20 days. The spectra of 
lysozyme dissolved in water displayed two minima at 208 and 222 nm, as previously 
reported [40]. The spectra of lysozyme incubated in either polyester or polyanhydride 
degradation products for 0 days were identical to that of lysozyme incubated with water. 
Incubation with LA or LA/GA for 20 days were the only treatments that were found to alter 
the secondary structure of lysozyme. Instead of having two minima, the lysozyme incubated 
with either LA or LA/GA had a single minimum at 208 nm, and representative examples are 
shown in Figure 5.9. This corresponds to an increase in the a-helix content, and is consistent 
with a previous study in which lysozyme was incubated in methanol [41]. 
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Figure 5.9. Circular dichroism spectral analysis of lysozyme (150 (ig/ml) after 20 days of 
incubation in presence of water (closed circle), 5 mM sebacic acid (SA) (open square), or 5 
mM lactic acid (GA) (open triangle). Results are representative of three replicate 
experiments. 
5.4.3.3 Fluorescence spectroscopy. The fluorescence spectrum of lysozyme, like 
ovalbumin, had one peak with a A^axbetween 330-345 nm [30]. Unlike ovalbumin, 
lysozyme is more stable under acidic conditions, and thus more resistant to unfolding. To 
determine if lysozyme unfolded in the presence of any of the polymer degradation products 
after 20 days, fluorescence spectroscopy was used to monitor the tertiary structure of the 
protein. The Xmax of all of the lysozyme samples from days 0 and 20 fell within the 330-345 
nm range, indicating the tertiary structure of the protein had not been detectably altered, as 
shown in Figure 5.10. These results suggest that lysozyme would be stable when released 
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Figure 5.10. Fluorescence spectral analysis of lysozyme (300 pg/ml) incubated with ester 
and anhydride monomers for (a) 0 days (b) 20 days. Results are representative of three 
replicate experiments. 
5.4.3.4 Activity. In order to denature lysozyme, dénaturants are needed (e.g., to 
denature 50% of native lysozyme 1.1 M of guanidinium thiocyanate, 2.8 M guanidinium 
hydrochloride, or 7.4 M urea are required) [39]. Thus, it was anticipated that lysozyme 
would lose little of its activity after being incubated with polyanhydride and polyester 
degradation products. Figure 5.11 shows the measured activity of lysozyme after being 
incubated with polyanhydride and polyester degradation products for 0 and 20 days. The 
enzymatic activity of lysozyme incubated with the CPH and CPH/SA monomers for 20 days 
was statistically reduced from lysozyme incubated in PBS for 20 days (-20% activity loss). 
This loss in activity was attributed to hydrophobic interactions between the protein and the 
CPH monomer. There was little enzymatic activity lost by lysozyme after being incubated 
with SA or polyester monomers for as long as 20 days. This indicates that any of the 
polymers (studied in the form of monomers) would provide a suitable environment for 
lysozyme and could be chosen as a delivery vehicle for similar acid-stabilized enzymes. 
122 
i 1 1 r 
• Day 0 
H Day 20 
CPH SA CPH/SA LA GA LA/GA PBS 
Figure 5.11. The enzymatic activity of lysozyme (300 p.g/ml) was measured using a 
fluorescence-based assay, after being incubated with ester and anhydride monomers for (a) 0 
days or (b) 20 days (± indicates standard deviation). Results are representative of two/three 
replicate experiments. ** represents p-value < 0.001 as determined by a student t test. 
5.5 Conclusions 
To effectively administer drugs or vaccines in fabricated delivery vehicles, it will be 
essential that the released compounds be functionally active or retain immunogenicity. 
Recently, Kipper et al. [9] described the use of polyanhydride microspheres as vaccine 
delivery vehicles. The current studies complement those studies by evaluating protein 
stability following exposure of test proteins to solutions containing anhydride or ester 
monomers. The experiments described above were performed using the same concentration 
of both ester and anhydride monomers. Yet, the concentrations represent a best and worse 
case scenario for the polyesters and polyanhydrides, respectively. Poly(LA) and poly(GA) 
are bulk-eroding polymers, thus the entire bulk of the microsphere degrades simultaneously. 
Under these conditions, a protein encapsulated in a polyester microsphere would be exposed 
to concentrations of LA or GA near saturation with an even lower pH than the solutions used 
in these experiments. Poly(CPH) and poly(SA) are surface-eroding materials. As they 
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degrade, the polymer degradation products would be at the surface of the microsphere and 
would quickly diffuse away. It is unlikely that proteins released from polyanhydride 
microspheres would be exposed to a saturated solution of CPH or SA diacids for a prolonged 
period [15]; therefore, these experiments represented a worse case scenario for the anhydride 
monomers. 
This work has demonstrated that TT, ovalbumin, and lysozyme behaved differently 
when incubated for extended periods of time with different polymer degradation products. In 
the presence of polyester degradation products, TT showed evidence of aggregation and 
structural unfolding resulting in a larger decrease in antigenicity, which is consistent with 
previous work [26]. The structural and antigenic changes that occurred in the presence of the 
ester monomers could result in the induction of poor to undetectable immune responses if the 
polyesters were used as the delivery vehicle for TT. The results of this study have shown 
that the structure and antigenicity of TT would be better maintained following encapsulation 
into polyanhydrides in comparison to polyesters. Thus, polyanhydrides are viable candidates 
for use as a drug delivery vehicle for proteins that are susceptible moisture induced 
aggregation. 
The consequences of encapsulating a protein known to take on a molten globular 
structure in an acidic environment (e.g., ovalbumin) such as that formed in polyester 
microspheres could also lead to the induction of suboptimal immune responses as a result of 
a denatured protein being released from the microspheres. Ovalbumin in the presence of the 
ester monomers showed a decrease in stability as evidenced by the CD, fluorimetry, and 
ELISA experiments. CPH should be used with caution to encapsulate and release proteins 
similar to ovalbumin. Though no change was exhibited in the antigenicity of the protein 
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when incubated in the presence of the CPH, the secondary and tertiary structure of the 
protein was altered indicating a hydrophobic interaction between the protein and CPH. 
Sebacic acid provided the most stabilizing environment for ovalbumin and these results 
indicated that polymers containing SA should be further investigated as a delivery vehicle for 
proteins that take on a molten globular structure under acidic conditions. 
Minimal changes in structural integrity and enzymatic activity were detected 
following the incubation of lysozyme in solutions containing either polyester or 
polyanhydride degradation products. These experiments demonstrated that there was good 
potential for polymers based on either esters or anhydrides to successfully deliver acid-
stabilized proteins. 
These experiments have demonstrated for the first time how anhydride and ester 
monomers affected the stability of tetanus toxoid, lysozyme, and ovalbumin. These studies 
demonstrated that proteins behave differently in the presence of the anhydride or ester 
monomers and provided a "blueprint" for the analyses that should be performed prior to 
encapsulating proteins in microspheres that are intended for in vivo use. Finally, these 
studies demonstrated that a rational approach can be employed for selecting compatible 
polymer/protein systems prior to encapsulation of the protein. 
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CHAPTER 6 
THE ROLE OF MICROSPHERE FABRICATION METHODS ON THE STABILITY 
AND RELEASE KINETICS OF OVALBUMIN ENCAPSULATED IN 
POLYANHYDRIDE MICROSPHERES 
A paper submitted to the Journal of Microencapsulation 
Amy S. Determan1,3, Jennifer R. Graham2'3, Katherine A. Pfeiffer2'3, Balaji Narasimhan3'4 
6.1 Abstract 
The effect of microsphere fabrication methods on the stability and release kinetics of 
ovalbumin encapsulated and released from polyanhydride microspheres was investigated. 
The polyanhydrides used were poly(sebacic anhydride) (poly(SA)) and a 20:80 random 
copolymer of poly[(l,6-bis-/>-carboxyphenoxy)hexane] (poly(CPH)) and poly(SA). 
Microspheres were fabricated using three double emulsion methods (water/oil/water (w/o/w), 
water/oil/oil (w/o/wo), and solid/oil/oil (s/o/o)) and a cryogenic atomization technique. The 
encapsulation efficiency was the highest for the cryogenic atomization technique and lowest 
when the w/o/w technique was used. Microspheres fabricated by the s/o/o method had the 
largest initial burst of released protein. All the fabrication methods resulted in zero-order 
release of the protein after the burst. The release of ovalbumin from poly(SA) and 20:80 
(CPH:SA) microspheres was complete at ~3 and ~6 weeks, respectively. For all fabrication 
methods the primary structure of released ovalbumin was conserved as determined by gel 
'Graduate student; primary author and researcher 
Undergraduate student; 
department of Chemical and Biological Engineering, Iowa State University 
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electrophoresis. The secondary structure of ovalbumin encapsulated in 20:80 (CPH: SA) 
w/o/w microspheres was not conserved. 
6.2 Introduction 
The use of biodegradable microspheres is among the most commonly used parenteral 
delivery regimens [1,2]. Advances in microencapsulation technology have produced 
numerous successful microsphere-based controlled release devices [3]. Pharmaceutical^ 
acceptable encapsulation technologies for proteins using biodegradable polymers include 
spray drying and solvent extraction (e.g. double emulsion) techniques. However, major 
challenges remain in the area of encapsulation and release of biologically active proteins. 
While the complex physicochemical nature and the three-dimensional structural intricacies of 
proteins enhances their value as therapeutic drugs, it also makes them fragile under 
pharmaceutical^ relevant processing conditions. When a protein is encapsulated within a 
polymer microsphere, the diverse functional groups of the protein are prone to a plethora of 
deleterious processes under conditions relevant to their formulation, storage, and delivery [4], 
In addition to conserving the hierarchical structure of the protein and its activity, it is also 
important to sustain the release of the protein over the desired time interval to maintain 
optimal drug concentration in serum and to improve patient compliance by reducing the 
frequency of administration. 
Surface-erodible polyanhydrides have been studied as potential drug delivery carriers 
for about two decades [5]. Studies have focused on the synthesis and characterization of 
random copolymers, their physicochemical properties, and biocompatibility [6]. This class of 
water-insoluble polymers degrades (by backbone chain scission across the anhydride bond) 
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into water-soluble monomers that can be absorbed by the body. The microstructural 
characterization and phase behavior of random copolymer polyanhydrides has been carried 
out using differential scanning calorimetry (DSC), small angle X-ray scattering (SAXS), 
wide angle X-ray diffraction (WAXD), and atomic force microscopy (AFM) [7-10]. The 
"block-like" microstructure of some random copolymer polyanhydrides has been confirmed 
by liquid state *H NMR spectroscopy, solid state NMR, and SAXS [11]. It has also been 
shown that drug release profiles do not match polymer erosion profiles over the entire 
duration of release [8, 12]. In fact, drug release profiles match individual monomer release 
profiles depending on their "affinity" to the monomer phase, pointing to the existence of 
microphase separation. The use of polyanhydride microspheres as carriers for proteins has 
been demonstrated [13]. In these experiments, fluorescein isothiocyanate labeled bovine 
serum albumin (BSA-FITC) was encapsulated in polyanhydride copolymer microspheres. It 
was found that increasing the hydrophobicity of the copolymer led to a decrease in the 
stability of the protein (via loss of secondary structure). These results are consistent with 
studies by Langer and co-workers [2, 14] on the release of polypeptides from polyanhydrides 
indicating that the water penetration into the core of the polyanhydride was reduced, thus, 
helping prevent covalent aggregation. 
The most commonly used methods for microsphere fabrication include solvent 
extraction (e.g. double emulsion) methods such as water-in-oil-in-water (w/o/w), water-in-
oil-in-oil (w/o/o), solid-in-oil-in-oil (s/o/o), and a cryogenic atomization procedure. 
Microspheres are most commonly fabricated using double emulsion techniques such as 
w/o/w and w/o/o [15]. These methods are attractive because they do not require any special 
equipment and are relatively straightforward. However, these methods have drawbacks since 
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they result in variable loading efficiencies and the creation of a water/oil interface [16-22], 
This interface causes proteins to migrate and act as surfactants. Once at the interface, the 
protein may begin to unfold. Ovalbumin is one of many proteins vulnerable to unfolding at 
the water/oil interface. It is known that after a 0.5 mg/ml solution of ovalbumin is emulsified 
with methylene chloride only 37.8% of the initial protein is recovered from the aqueous-
phase when no surfactant is added [21]. 
The s/o/o technique and the cryogenic atomization method offer viable alternatives to 
the aqueous double emulsion techniques by eliminating the water/oil interface and by 
increasing the loading efficiency [23, 24]. In order to encapsulate a protein using either of 
these methods, the protein must first be lyophilized. The lyophilized protein is then 
suspended in the organic polymer phase. Achieving a uniform distribution of a protein 
within microspheres fabricated with these methods is challenging. Large bursts (14 - 70% 
burst) of initial release are typically seen when lyophilized protein is encapsulated in 
microspheres [23-27]. Ultimately, the fabrication method needs to be capable of achieving 
the highest loading efficiency, providing reproducible and desired release kinetics, and 
stabilizing the encapsulated protein and releasing a functional protein. 
The objectives of this study are to evaluate the role of the fabrication method on the 
stability and the release kinetics of proteins encapsulated in polymer microspheres. The 
polyanhydrides used in this work are poly(sebacic anhydride) (poly(SA)) and a copolymer of 
poly(SA) and poly[ 1,6-bis-p-carboxyphenoxy)hexane] (poly(CPH)), 20:80 (CPH:SA). These 
polymers are of interest because they are biodegradable and varying the composition of SA 
and CPH monomers can control the rate of degradation of the copolymer. Poly(CPH) is 
more hydrophobic than poly(SA), hence the copolymer 20:80 (CPH:SA) is more 
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hydrophobic than poly(SA) and will take longer to degrade [28]. These two polymers are 
also of interest because previous work has shown that BSA-FITC can be stabilized within 
and released from microspheres based on these two polyanhydrides [13]. 
6.3 Material and Methods 
6.3.1 Materials 
Sebacic acid (99%), 4-hydroxybenzoic acid, l-methyl-2-pyrrolidinone anhydrous 
99.5%, 1,6-dibromohexane, potassium bromide (FTIR grade), Hanks' balanced salt solution 
(without phenol red), poly(vinyl alcohol) (PVA), and ovalbumin from chicken egg white 
(grade V minimum 98% gel electrophoresis) were purchased from Sigma-Aldrich 
(Milwaukee, WI). The BCA kit used to quantify the release of ovalbumin was purchased 
from Pierce Biotechnology Inc. (Rockford, IL). 40% acrylamide, low molecular 
massstandards, and the silver stain plus kit were purchased from BioRad (Hercules, CA). 
Dow coming fluid 550 and 200 proof ethanol were purchased from in-house bulk supplies. 
All other chemicals were purchased from Fischer Scientific (Pittsburgh, PA) and used as 
received. 
6.3.2 Polymer synthesis & characterization 
The synthesis of SA and CPH prepolymers used has been previously described [7, 
12]. The synthesis of CPH prepolymer was performed by modifying the synthesis of 1,3-
bis(p-carboxyphenoxy)propane as described by Conix [29]. The SA and CPH prepolymers 
were polymerized via a melt polycondensation reaction under vacuum (3 x 10"1 torr) for 90 
min at 180 °C [7, 12]. The polymers were characterized using gel permeation 
133 
chromatography (GPC), proton nuclear magnetic resonance ('H NMR), and Fourier 
transform infrared spectroscopy (FTIR). 
6.3.3 Ovalbumin lyophilization 
To obtain solid ovalbumin with a small particle size (<1 |im) the ovalbumin was 
constituted in a 50 mM ammonia bicarbonate solution. The protein solution (5 mg/ml) was 
then placed in a gas tight syringe and pumped (3 ml/min) to an 8700-1200 MS ultrasonic 
atomizing nozzle (Sono Tek Corporation, Milton, NY). The protein solution was atomized at 
an output of 2.5 W into 400 ml of liquid nitrogen. The liquid nitrogen was allowed to boil 
off and the frozen atomized protein was dried under vacuum overnight. To characterize the 
lyophilized protein some of the ovalbumin particles were coated with 200 Â of gold and 
viewed with JOEL 840A scanning electron microscope (SEM). 
6.3.4 W/O/W microsphere fabrication method 
The w/o/w solvent removal technique employed to fabricated ova-loaded 
microspheres has been previously described [13]. Briefly, an ovalbumin solution (5 mg of 
ovalbumin dissolved in 200 jj.1 of de-ionized water) was added to a polymer solution (100 mg 
polymer dissolved in 2 ml methylene chloride). The two solutions were emulsified, forming 
the inner emulsion, with a Tissue-Tearor™ (Biospec Products, Bartlesville, OK) at 30 000 
rpm for 30 sec. A 1% PVA (4 ml) solution saturated with methylene chloride (80 ja.1) was 
then added to the polymer/protein emulsion and further emulsified at 10 000 rpm for 30 sec 
to form the double emulsion. The newly formed microspheres were added to a stirring 1% 
PVA (100 ml) solution. The dispersion was stirred (300 rpm) with an overhead stirrer with a 
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3 in impeller (Wiarton, Ontario) on ice for 2 h. The dispersion was then centrifuged for 10 
min at 1500 g (Eppendorf Centrifuge 5403, Westbury, NY) to collect the microspheres. To 
remove any unencapsulated protein and PVA from the surface of the microspheres the 
supernatant was removed and replaced by fresh de-ionized water. The microspheres were 
centrifuged and washed a total of three times. The washed microspheres were then 
suspended in 4 ml of de-ionized water and flash frozen and dried overnight under vacuum. 
6.3.5 W/O/O microsphere fabrication method 
The w/o/o procedure used for this study was similar to previously reported methods 
[30, 31], An ovalbumin solution (5 mg dissolved in 200 |ol of de-ionized water) was 
emulsified with a polymer solution (100 mg polymer dissolved in 2 ml methylene chloride) 
using a Tissue-Tearor™ at 30 000 rpm for 30 sec, forming an inner emulsion. Dow Coming 
oil 550 (3 ml) saturated with methylene chloride (4 ml) was added to the protein/polymer 
emulsion and homogenized at 30 000 rpm for 30 sec forming a double emulsion. To extract 
the solvents the newly formed microspheres were stirred (300 rpm) in 200 ml of heptane on 
ice for 2 h. The hardened microspheres were then collected by filtration and dried under 
vacuum overnight. 
6.3.6 S/O/O m icrosphere fabrication method 
The s/o/o fabrication technique used was modified from the procedure described by 
Carrasquillo et al. [27]. Microspheres were constructed by adding atomized ovalbumin (5 
mg) to polymer (100 mg) dissolved in methylene chloride (2 ml). The protein was suspended 
in the organic phase by mechanically mixing using a Tissue-Tearor™ at 30 000 rpm for 1 
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min. Dow Corning oil 550 (3 ml) saturated with methylene chloride (4 ml) was then added 
to the polymer/protein suspension and emulsified at 20 000 rpm for 1 min. The resulting 
microspheres were added to 200 ml of heptane stirring at 300 rpm (overhead stirrer) on ice. 
After stirring for 2 h the microspheres were filtered and dried under vacuum overnight. 
6.3.7 Cryogenic atomization method for microsphere fabrication 
The cryogenic atomization method used in this work has been previously described 
[24, 32]. Atomized ovalbumin (5 mg) was suspended in a polymer solution (100 mg of 
poly(SA) in 3 ml of methylene chloride or 100 mg of 20:80 (CPH: SA) in 1 ml of methylene 
chloride) using a Tissue-Tearor™ at 10 000 rpm for 30 sec. The suspension was transferred 
to a gas tight syringe and pumped (3 ml/min) to an ultrasonic nozzle operating at 2.5 W or 
1.5 W for SA and 20:80, respectively. The suspension was atomized into 200 ml of liquid 
nitrogen overlaying 300 ml of frozen ethanol. The frozen microspheres and ethanol were 
stored at -80°C for three days, during which time the ethanol thawed and the methylene 
chloride was extracted from the polymer, leaving behind solid microspheres. The 
microspheres were then collected by filtration and dried overnight under vacuum. 
6.3.8 Microsphere characterization 
The yield of each batch of microspheres was calculated by dividing the mass of 
microspheres recovered by the initial mass of polymer and protein used. The surface 
morphology of the microspheres was examined by coating the samples with 200 Â of gold 
and examining them using SEM. To determine the molecular massloss that occurred during 
the fabrication process, the molecular massof blank microspheres was compared to the 
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molecular massof neat polymer using GPC. The GPC columns were purchased from 
Polymer Laboratories (Amherst, MA) and polystyrene standards were used for calibration. 
6.3.9 Encapsulation efficiency 
The amount of protein loaded into of each batch of microspheres was determined by 
extraction as previously reported by Lam et al. [24]. Ovalbumin-loaded microspheres (-10 
mg) were suspended by sonication (Sonics & Materials Inc., Newton, CT) in 1 ml of 17 mM 
NaOH. The suspension was then loaded into a syringe. To ensure all microspheres were 
recovered, the test tube was rinsed twice with 1 ml of 17 mM NaOH. All 3 ml were then 
loaded into 3 ml Slide-A-Lyzer® (Pierce Biotechnology Inc., Rockford, IL) and suspended in 
600 ml of 17 mM NaOH. After 4 days at room temperature under constant agitation (100 
rpm), the NaOH solution was removed from the dialysis cassette and analyzed using the 
BCA assay to determine the amount of ovalbumin that had been loaded into the 
microspheres. The encapsulation efficiency was calculated by dividing the amount of 
ovalbumin obtained from the extraction study by the amount of ovalbumin used at the start of 
the microsphere fabrication process. 
6.3.10 In vitro release studies 
Microspheres made by each of the fabrication methods described above were 
suspended (15 mg) separately in 1.0 ml Hanks' balanced salt solution. Sodium azide (0.01% 
w/w) was added to the salt solution to prevent microbial contamination. The microsphere 
suspensions were incubated at 37°C under constant agitation at 100 rpm. At predetermined 
times the supernatant was sampled (750 p.1) and then replaced with fresh buffer (750 p.1) to 
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maintain sink conditions. The sampled supernatant was stored at 4°C until the protein 
concentration was quantified using the BCA assay. Prior to using the BCA assay the 
supematants were centrifuged (10 000 rpm, 10 min, at 4°C). The in vitro release data was 
normalized by the cumulative amount of ovalbumin released. Release studies were done in 
triplicate for each microsphere fabrication method and for both polymer compositions. 
6.3.11 Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) 
The conservation of primary structure of the protein following its encapsulation and in 
vitro release was verified by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). The microspheres were incubated in Hanks' balanced salt solution under the 
conditions described above. After 2 h of incubation, the supernatant was removed and 
replaced with an equal volume of fresh salt solution. After 46 h of additional incubation the 
supernatant was removed and analyzed using SDS-PAGE. This ensured that any un-
encapsulated protein was removed prior to the release of the encapsulated protein, and that 
any bands on the developed gels were a result of ovalbumin released from the microspheres. 
An equal volume of the sampled supernatant from each experiment was mixed with SDS-
loading dye (SDS 1% w/v, 0.06 mM Tris-HCl pH 6.8, 3.0 mM glycerol, bromophenol blue 
0.01% w/v, and p-mercaptoethanol) and loaded (10.0 jj.1) into polyacrylamide gels for 
electrophoresis (10% acrylamide running gel and 5% acrylamide stacking gel). 
Electrophoresis was also performed on ovalbumin samples (0.125 mg/ml) in Hank's balanced 
salt solution for comparison with the released samples. All the samples were compared to 
standards. 
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The BioRad Mini-Protean II electrophoresis setup was used to perform these 
experiments, with a constant voltage of 120V for 70 min. The gels were silver stained using 
the BioRad silver stain kit. The gels were photographed and dried. 
6.3.12 Fourier transform infrared spectroscopy (FTIR) 
Preservation of secondary structure of encapsulated ovalbumin was examined using 
Fourier transform infrared (FTIR) spectroscopy. Samples were prepared by mixing protein-
loaded microspheres, protein-free microspheres, or native ovalbumin with 99+% FT-IR (5% 
w/w) grade potassium bromide. Pellets were pressed under vacuum using a Carver press 
(Wabash, IN) at 2000 lb. 
Spectroscopy was performed with a Nicolet Nexus 470 (Madison, WI) utilizing a 
cooled MCT/A detector and an Ever-Glo source beam. The data collection software used 
was Omnic 7.2. Each spectrum consisted of 256 scans at a resolution of 4 cm"1. Background 
spectra were collected every 100 minutes. Following spectra collection, the spectra of the 
encapsulated protein were obtained by subtracting the spectra of the blank microspheres from 
the spectra of protein-loaded microspheres. The resulting spectrum was used only if a flat 
baseline in the region of 1800-2500 cm"1 was obtained from the subtraction [33]. Fourier 
self-deconvolution was preformed on the amide I region of the encapsulated protein spectra 
using a bandwidth of-20 and an enhancement factor of 1.5 [34]. Gaussian curves were fit to 
the deconvoluted spectra and the area of each deconvoluted peak was used to calculate the 
secondary structure of the encapsulated ovalbumin [35]. Each peak represented a secondary 
structure: a-helix, P-sheet, P-turn, or random coil and was assigned according to the 
designation made by Dong et al. [36]. A Student t-test was preformed to determine if the 
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secondary structure of the encapsulated ovalbumin differed significantly from that of the 
native protein. Treatments showing a statistical difference were noted. 
6.4 Results and Discussion 
6.4.1 Ovalbumin atomization 
Ammonium bicarbonate is a volatile salt when dried under vacuum. Hence, it was 
chosen as the salt for the solution in the cryogenic atomization of ovalbumin. Using this 
volatile salt ensured that only ovalbumin (and not salts) was loaded into microspheres (e.g., 
s/o/o and cryogenic atomization methods). After the ovalbumin was atomized and dried, the 
size of the resulting protein particles was inspected visually using SEM. The atomized 
particles were smaller than the initial ovalbumin (data not shown) flakes. The small protein 
particles took on a fibrous form with <1 pm diameter and lengths ranging from <1 |im to 5 
|o,m. Upon mechanical mixing (or further scraping of the protein on the SEM stub), the size 
of the proteins was further reduced, enabling encapsulation in microspheres. 
6.4.2 Microsphere characterization 
A minimum of three batches were used to calculate the yield of poly(SA) and 20:80 
(CPH: SA) microspheres made by each of the four fabrication methods studied. As expected, 
the percent yield was independent of the type of polymer used as demonstrated by the little 
variation between poly(SA) and 20:80 (CPH:SA) microspheres fabricated by the same 
method. The results for poly(SA) microspheres are shown in Table 6.1. Microspheres 
fabricated using the w/o/w, w/o/o, or s/o/o methods resulted in yields of-75%. When 
microspheres were fabricated using the cryogenic atomization procedure, the percent yield 
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was lower (~ 60%). This lower yield was a result of some of the atomized microspheres not 
falling into the liquid nitrogen overlaying the frozen ethanol. As the polymer/protein 
suspension is atomized a fine mist falls from the nozzle into the liquid nitrogen. As this 
occurs, the liquid nitrogen begins to boil making it difficult to ensure a higher of the 
atomized microspheres. 
Table 6.1. Yields and loading efficiencies for poly(SA) microspheres. 
Po y(SA) 
Microsphere Yield Encapsulation 
Fabrication Method (%) Efficiency 
(%)" 
W/O/W 72 ± 14 60 ±23 
w/o/o 78  ±9  85  ±20  
s/o/o 73  ±6  85  ±20  
Cryogenic 51  ±9  100  ±2  
Atomization 
a ± values are standard deviation values calculated from a minimum of three batches 
To address the question of how much polymer degradation occurred during the 
microsphere fabrication process, the molecular massof neat polymer was compared to the 
molecular massof protein-free microspheres fabricated by each of the four methods using 
GPC. The results are shown in Table 6.2. The amount of molecular massloss was 
proportional to the amount of water used in the fabrication process. Neither the s/o/o nor the 
cryogenic atomization methods required any water. However, in the case of poly(SA) 
microspheres fabricated via the s/o/o method the polymer did undergo a 13% reduction in 
Mn. This reduction in molecular mass may be due to the water from the atmosphere 
degrading the polymer during the handling of the microspheres and by the water in the 
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atmosphere dissolved in the non-solvent (heptane) during the solvent extraction process. For 
all fabrication methods where molecular mass loss was detected, the largest molecular mass 
loss occurred in the poly(SA) microspheres. This result is expected because poly(SA) is 
more hydrolytically labile than 20:80 (CPH:SA). 
The surface morphology of the microspheres was analyzed using SEM. The 
photomicrographs of poly(SA) and 20:80 (CPH:SA) microspheres are shown in Figures 6.1 
and 6.2, respectively. The amount of polymer degradation that occurs during the fabrication 
process and the rate of solvent extraction influence the surface morphology of the 
microspheres. The rate of solvent extraction is influenced by temperature, the type of 
polymer, the non-solvent, and the stability of the inner emulsion present in the newly formed 
microspheres. As the volume of water used to fabricate the poly(SA) microspheres and the 
number of emulsions used to create the microspheres decreased, the surface of the 
microspheres got smoother. The surface of the poly(SA) microspheres fabricated using the 
w/o/w method was the roughest because this technique required the largest volume of water 
(leading to more polymer degradation). This method also required an inner emulsion that 
increased the rate of solvent extraction, leading to a rough surface morphology. The surface 
morphology of the poly(SA) microspheres fabricated using the w/o/o and s/o/o processes 
looked similar as a result of using the same non-solvent (e.g., heptane) in the outer emulsion 
and the inner aqueous phase (w/o/o method), thus having little effect on the rate of solvent 
extraction. The surface morphology of poly(SA) microspheres fabricated using the 
cryogenic atomization technique had the slowest rate of solvent extraction leading to the 
smoothest surface. The cryogenic atomization technique required the solvent extraction to 
occur at -80°C and ethanol was used as the non-solvent. 
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Table 6.2. Molecular mass of poly(SA) and 20:80 (CPH:SA) microspheres compared to neat 




M„ Loss (%) 
20:80 (CPH:SA) 
Mn Loss (%) 
W/O/W 25 8 
w/o/o 19 Not detected 
s/o/o 13 Not detected 
Cryogenic Not detected Not detected 
Atomization 
Figure 6.1. SEM photomicrographs depicting the surface morphology of ovalbumin-loaded 
poly(SA) microspheres fabricated via (a) w/o/w; (b) w/o/o; (c) s/o/o; (d) cryogenic 
atomization 
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Figure 6.2. SEM photomicrographs depicting the surface morphology of ovalbumin-loaded 
20:80 (CPH:SA) microspheres fabricated via (a) w/o/w; (b) w/o/o; (c) s/o/o; (d) cryogenic 
atomization 
The surface morphology of 20:80 (CPH:SA) microspheres was independent of the 
microsphere fabrication process used. This was a result of the solvent being extracted from 
the 20:80 (CPH:SA) polymer at similar rates even when different non-solvents were used. 
Because the cryogenic atomization method produced extremely smooth poly(SA) 
microspheres, 20:80 (CPH:SA) was atomized into different non-solvents to try to obtain 
similar results. The surface roughness of ovalbumin-loaded 20:80 (CPH:SA) atomized 
microspheres remained the same when either isopropanol or heptane were used as non-
solvents. However, when protein-free 20:80 (CPH:SA) microspheres were atomized into 
isopropanol, the surface morphology was smooth and similar to that of the poly(SA) 
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atomized microspheres (data not shown) indicating that ovalbumin increased the rate of 
solvent extraction, leading to microspheres with a rougher surface topography. 
6.4.3 Encapsulation efficiency 
The degradation for polyanhydrides is base catalyzed [5, 37, 38]. Thus, a 17 mM 
NaOH solution was used to accelerate the degradation of ovalbumin-loaded microspheres in 
order to quantify the encapsulation efficiency of ovalbumin. The molarity of the NaOH used 
was chosen by determining the highest NaOH concentration in which ovalbumin was 
soluble. By placing the microsphere suspension in a dialysis cassette, the released ovalbumin 
was retained in the cassette while the soluble polymer degradation products were removed. 
Table 6.1 shows the encapsulation efficiencies of ovalbumin-loaded poly(SA) 
microspheres made by the various fabrication methods. The results for the 20:80 (CPH:SA) 
microspheres were similar. The highest encapsulation efficiency was obtained when 
microspheres were fabricated using the cryogenic atomization method; almost 100% of the 
protein was loaded into the microspheres. Microspheres fabricated using the w/o/o and s/o/o 
techniques had similar loadings, as a result of using the same non-solvent. The lowest 
encapsulation efficiency was observed when using the w/o/w method. This method not only 
contains a poorly stabilized inner emulsion but also an exterior aqueous phase, which 
increases the probability that the protein within the forming microsphere would partition to 
the exterior aqueous phase reducing the encapsulation efficiency. If a surfactant had been 
used to stabilize the inner emulsion of either the w/o/w or w/o/o methods, it would have been 
co-encapsulated in the microspheres with the ovalbumin. No surfactant was used to prevent 
alterations of the release profiles and to allow comparison of the protein interacted with the 
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polymer after being fabricated by each of the four methods. However, by not using a 
surfactant in the inner emulsion, the emulsions were less stable and the variability of the 
encapsulation efficiency increased. 
6.4.4 In vitro release of ovalbumin 
The in vitro release studies were conducted in Hanks' balanced salt solution to mimic 
the physiological conditions. Sodium azide was added to the medium to inhibit microbial 
contamination. 
The in vitro release of ovalbumin from poly(SA) and 20:80 (CPH:SA) microspheres 
is shown in Figure 6.3. The largest bursts occurred when the s/o/o method was used to 
fabricate either the poly(SA) or 20:80 (CPH:SA) microspheres. For the poly(SA) 
microspheres, the second largest burst (-24%) was seen by microspheres fabricated by the 
cryogenic atomization technique. The 20:80 (CPH:SA) microspheres fabricated by this 
technique had a similar burst of -30%. In general, the larger bursts were associated with the 
protein being encapsulated as a solid. In these methods, it was difficult to maintain a uniform 
distribution of a solid protein during the microsphere fabrication process. This was 
consistent with previously reported data [23-27]. The w/o/o fabrication technique had 
varying effects on the release kinetics depending on the polymer used to fabricate the 
microspheres. The poly(SA) microspheres fabricated using the w/o/o technique had a 14% 
burst while the 20:80 (CPH:SA) microspheres had a 32% burst. This difference was 
attributed to the 20:80 (CPH:SA) polymer being more hydrophobic and decreasing the 
protein compatibility with the more hydrophobic polymer. The microspheres fabricated by 
the w/o/w techniques (both poly(SA) and 20:80 (CPH:SA)) showed the smallest initial 
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bursts. This was attributed to the protein maintaining a uniform distribution within the 
microspheres throughout the fabrication process. Similar results were observed when BSA-
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Figure 6.3. In vitro release of ovalbumin from (a) poly(SA) microspheres (b) 20:80 
(CPH:SA) fabricated by various methods. Studies were performed using Hanks' balanced 
salt solution with 0.01% sodium azide. Results are representative of three replicates. 
After the initial burst the release of ovalbumin from the microspheres, a period of 
zero order release followed for all the polymers and the fabrication methods studied. After 
10 days, all of the protein was released from poly(SA) microspheres fabricated by the s/o/o 
and w/o/o methods, providing the shortest release profile. The ovalbumin encapsulated in 
poly(SA) microspheres fabricated by the w/o/w and cryogenic atomization methods showed 
a more prolonged release lasting ~3 weeks. Thus, depending on the release kinetics desired, 
the appropriate fabrication method could be selected. If a large burst followed by a release of 
protein for ~1 week is needed, the s/o/o fabrication method could be employed. If a smaller 
burst was needed over a seven day period, the w/o/o method could be employed. For longer 
release times, either the w/o/w or cryogenic atomization method could be employed 
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depending on the desired initial burst. The release of ovalbumin from 20:80 (CPH:SA) 
microspheres continued for ~6 weeks and was independent of the fabrication method used. 
6.4.5 SDS-PA GE analysis 
The molecular massof the ovalbumin released from poly(SA) and 20:80 (CPH:SA) 
microspheres fabricated using the w/o/w, w/o/o, s/o/o, and cryogenic atomization was 
investigated using SDS-PAGE. The results are shown in Figure 6.4. The ovalbumin 
released from all of the microsphere formulations showed only one band corresponding to a 
molecular massof 45 KDa. No additional bands were present, indicating the released protein 
was neither aggregated nor fragmented. Similar findings for ovalbumin encapsulated and 
released from PLGA microspheres fabricated via w/o/w and w/o/o methods have been 
previously reported [39]. These results also agree with the previous work in which BSA-
FITC was released from poly(SA) and 20:80 (CPH:SA) microspheres [13]. Similar to BSA-
FITC, ovalbumin was known to form moisture-induced covalent aggregates [40]. Because 
there are no additional bands of higher molecular weight, it can be concluded that 
polyanhydrides microspheres prevented the covalent aggregation of ovalbumin. 
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Figure 6.4. SDS-PAGE of ovalbumin released from poly(SA) and 20:80 (CPH:SA) 
microspheres. Lane 1: ovalbumin; lane 2: atomized poly(SA); lane 3: w/o/o poly(SA); lane 
4: s/o/o poly(SA); lane 5: w/o/w poly(SA); lane 6: atomized 20:80 (CPE:SA); lane 7: w/o/o 
20:80 (CPH:SA); lane 8: s/o/o 20:80 (CPH:SA); lane 9: w/o/w 20:80 (CPH:SA). 
6.4.6 FTIR analysis 
FTIR was used to determine what effect, if any, the different microsphere fabrication 
methods had on the secondary structure of the encapsulated ovalbumin. Typical signatures 
of the secondary structure of ovalbumin are a-helices, P-sheets, (3-tums, and random coils 
[36]. It is known that the (3-sheet and random coil content of a protein vary as a protein is 
transferred between a solid and liquid state [34]. A lyophilized protein will have a higher 13-
sheet content than when dissolved in an aqueous solution. Hence, only the a-helical content 
of the encapsulated ovalbumin was used to determine if the fabrication processes altered the 
secondary structure. 
The a-helical content of native lyophilized ovalbumin was determined to be 24% 
(Figure 6.5a) and was consistent with the value determined by crystallography [41]. The 
spectrum of the encapsulated protein was compared to that of the native protein to determine 
if the fabrication process affected the secondary structure of the ovalbumin. The results of 
the spectral analysis are shown in Figure 6.5. Ovalbumin encapsulated in poly(SA) 
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microspheres showed no statistical difference in a-helical content when compared to the 
native protein. 
The secondary structure of the ovalbumin encapsulated in 20:80 (CPH:SA) 
microspheres was maintained when the microspheres were fabricated using the w/o/o, s/o/o, 
or cryogenic atomization techniques. Ovalbumin encapsulated in 20:80 (CPH:SA) 
microspheres fabricated using the w/o/w technique showed a small, but statistically 
significant loss in a-helical content indicating that the fabrication process lead to the 
déstabilisation of the protein. When fabricating microspheres using the w/o/w method, two 
water/oil interfaces were created increasing the possibility of protein destabilization. This 
loss in stability was not observed when poly(SA) was used to fabricate w/o/w microspheres. 
This difference in stability of encapsulated ovalbumin is attributed to the different 
interactions that occur between the protein and the polymers. As the hydrophobicity of the 
encapsulating polymer was increased, the stability of the protein was jeopardized [13]. 
Ovalbumin W/O/W W/Q.'O S/O/O Atomization Ovalbumin W/O/W W/O/O S/O/O Atomization 
Figure 6.5. The secondary structure of native ovalbumin vs. ovalbumin encapsulated in (a) 
poly(SA) microspheres (b) 20:80 (CPH:SA) microspheres. The * indicates statistical 
differences (p-value < 0.1) when compared to the secondary structure of native protein as 
determined by a Student t-test. 
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6.5 Conclusions 
This study has shown how microsphere fabrication processes affect the stability and 
release kinetics of ovalbumin from polyanhydride microspheres. Proteins encapsulated in an 
aqueous form (w/o/w and w/o/o) typically result in lower initial bursts and lower 
encapsulation efficiencies. As the hydrophobicity of the polymer increases, caution should 
be used when encapsulating a protein in an aqueous form due to the increased possibility of 
the protein being destabilized. This was observed by the reduction of a-helixes in ovalbumin 
encapsulated in 20:80 (CPH:SA) microspheres fabricated by w/o/w method. By 
encapsulating a protein as a solid, the likelihood of the protein undergoing conformational 
alterations was reduced. The drawback to using solid phase proteins was that it was difficult 
to obtain uniform distribution within a polymer solution when fabricating microspheres 
resulting in larger bursts of protein release. 
The poly(SA) microspheres fabricated using the s/o/o and w/o/o methods had the 
least desirable release kinetics due to the extremely fast release of ovalbumin (completely 
released in 10 days). The release of ovalbumin from the 20:80 (CPH:SA) from all the batches 
of microspheres lasted ~6 weeks, and no significant differences were observed in the size of 
the initial burst. 
From these studies, the cryogenic atomization method maintained the stability of the 
encapsulated protein and provided reasonable bursts for all the polymers used. The highest 
encapsulation efficiency was obtained when microspheres were fabricated using the 
cryogenic atomization method, which is an important consideration when working with 
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CHAPTER 7 
UTEROCALIN-LOADED POLYANHYDRIDE MICROSPHERES EXPEDITE CELL 
MIGRATION FOR WOUND HEALING APPLICATIONS 
A paper to be submitted to the Journal Biomedical Materials Research 
Amy S. Determan1'2, Marit Nilsen-Hamilton3, Balaji Narasimhan2,4 
7.1 Abstract 
A cryogenic atomization method was used to fabricate uterocalin (24p3, SIP24, 
Lcn2)-loaded polyanhydride microspheres. The polymers used for this work were 
poly(sebacic anhydride) (poly(SA)) and a 20:80 copolymer composed of l,6-bis(p-
carboxyphenoxy)hexane] (CPH) and SA. The in vitro release kinetics of uterocalin from the 
polyanhydride microspheres was zero order after an initial burst of 22% of the encapsulated 
protein. Uterocalin released from the polyanhydride microspheres maintained its primary 
structure as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis. The 
in vitro biological activity of uterocalin released from polyanhydride microspheres was 
investigated using a cell migration assay based on human colon epithelial cells (HT29). 
Uterocalin released from either poly(SA) or 20:80 (CPH:SA) microspheres maintained its 
biological activity as demonstrated by the increased the rate of HT29 cell migration. This 
work demonstrates the therapeutic use of polyanhydride microspheres as protein carriers. 
1 Graduate student; primary author and researcher 
2 Department of Chemical and Biological Engineering, Iowa State University 
3 Department of Biochemistry, Biophysics, and Molecular Biology, Iowa State University 
4 Major professor; corresponding author 
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7.2 Introduction 
For chronic diseases such as diabetes or rheumatoid arthritis, traditional therapeutic 
strategies require patients to undergo frequent drug administration. In the last two decades, 
the concept of using biodegradable polymers for sustained drug delivery, which reduces the 
frequency of drug administrations, has received much attention. In particular, polymeric 
microspheres have been extensively studied for use in sustained drug delivery because they 
are injectable and do not require surgical removal [1], 
Poly(D,L-lactide-co-glycolide) (PLGA) is one of the most commonly investigated 
polymers for use in sustained drug and protein delivery [1], Research has demonstrated that 
proteins can be stably encapsulated and released from PLGA microspheres. Nutropin Depot 
®, which encapsulates recombinant human growth hormone, is one example of a sustained 
drug delivery system approved for use in humans by the U.S. Food and Drug Administration 
(FDA) [2]. However, PLGA microspheres are not suitable delivery vehicles for many 
therapeutic proteins. Proteins are complex three-dimensional molecules that are usually 
biologically inactive or can cause adverse reactions if administered in a denatured form. One 
reason PLGA is not a suitable carrier for many proteins is because PLGA is a bulk-eroding 
polymer, and allows water to penetrate the entire volume of the degrading polymer 
microsphere. This increases the possibility of moisture-induced protein aggregation [3-5]. A 
second concern when using PLGA to encapsulate proteins is that the microenvironment in 
and around a degrading PLGA microsphere can become very acidic, with the pH reaching as 
low as 1.5 [6], This acidic microenvironment denatures many proteins [7]. 
Polyanhydrides have been investigated as an alternative to using PLGA as a vehicle 
for therapeutic proteins [8-11]. Unlike PLGA, polyanhydrides are surface-eroding polymers, 
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and, as such, they reduce the risks of moisture-induced aggregation of proteins [3, 4, 12]. 
Additionally, the degradation products of polyanhydrides are less soluble in water than the 
degradation products of PLGA. As a result, the microenvironment surrounding a degrading 
polyanhydride device is not as acidic as that produced by PLGA reducing any unwanted 
stress on an encapsulated protein [13]. 
Previous work has shown that the polyanhydrides microspheres based on 
poly(sebacic anhydride) (poly(SA)) and the 20:80 copolymer of l,6-bis(p-
carboxyphenoxy)hexane (CPH) and SA are capable of stabilizing the structure of 
encapsulated proteins [10, 11]. Little work to date has examined the ability of proteins 
encapsulated and released from microspheres made of either poly(SA) or 20:80 (CPH:SA) to 
maintain their biological activity [14]. The goal of this work is to determine that 
polyanhydrides based on SA and CPH can not only stabilize the structure of an encapsulated 
protein but also remain biologically active upon release. To this end, uterocalin (SIP24, 
24p3, Lcn2) was encapsulated and released from poly(SA) and 20:80 (CPH:SA) 
microspheres. Uterocalin was encapsulated in the polyanhydride microspheres using a 
cryogenic atomization technique [10, 15, 16]. This technique was used because it has been 
shown to minimize protein loss during the fabrication process, it eliminates water/oil 
interfaces, and reduces protein denaturation [17]. 
Uterocalin is an acute phase protein encoded in the mouse genomeby the gene Lcn2, 
and it is a member of the lipocalin protein family [18]. The human homolog of uterocalin is 
neutrophil gelatinase-associated lipocalin (NGAL). Uterocalin is a 24 kDa protein composed 
of a P-barrel [19]. It is hypothesized that uterocalin binds ligands in the calyx of the protein. 
It is also hypothesized that uterocalin would no longer be biologically active if the structure 
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of the protein was altered [20]. Though the in vivo function of uterocalin is still being 
investigated, two examples of in vitro functions of uterocalin have been identified. These 
include siderophore binding by uterocalin and the ability of uterocalin to increase cell 
migration of wounded epithelial cells [21, 22]. In this paper, we are interested in the wound 
healing application. 
One of the first responses the body has after being wounded is the secretion of acute 
phase proteins into the blood stream [23]. This is followed by the migration of epithelial 
cells. Because uterocalin is an acute phase protein that can increase the rate of epithelial cell 
migration in vitro, it is hypothesized that it plays a role in the wounding healing process in 
vivo. This work examines the ability of uterocalin to increase the rate of human colon 
epithelial (HT29) cell migration after being released from polyanhydride microspheres. 
It is the hypothesis of this work that uterocalin encapsulated in either poly(SA) or 
20:80 (CPH:SA) microspheres will be stabilized and will be released as a biologically active 
protein, capable of stimulating and sustaining epithelial cell migration in vitro. This work 
lays the groundwork for future therapeutic applications of uterocalin and NGAL while 
demonstrating the usefulness of polyanhydrides as vehicles for protein delivery. 
7.3 Materials and Methods 
7.3.1 Materials 
The following chemicals were purchased from Sigma-Aldrich (Milwaukee, WI): 
sebacic acid (99%), 4-hydroxybenzoic acid, 1 -methyl-2-pyrrolidinone anhydrous 99.5%, 1,6-
dibromohexane, bovine serum albumin (BSA), and Hanks' balanced salt solution (without 
phenol red). The BCA kit, dialysis cassettes (3500 MW cutoff), and mini dialysis cassettes 
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(3500 MWCO) were purchased from Pierce Biotechnology Inc. (Rockford, IL). Precast 12% 
polyacrylamide gels (Tris-HCl), low molecular mass standards, 2-mercaptoethanol, and a 
silver stain plus kit were purchased from BioRad (Hercules, CA). Bacto™ yeast extract, 
tryptone, and agarose were purchased from Becton, Dickinson, and Company (Sparks, MD). 
Ampicillin (sodium salt) and isopropyl-(3-D-thiogalactopyranoside (IPTG, dioxane free) were 
purchased from Research Products International Corporation (Mt. Prospect, IL). Ni-NTA 
was purchased from Qiagen (Valencia, CA). Human epithelial growth factor (EOF) was 
purchased from R&D Systems (Minneapolis, MN) and reconstituted in 10 mM acetic acid 
and 0.1% BSA. Ethanol (200 proof) was purchased from in-house bulk supplies. All other 
chemicals were purchased from Fischer Scientific (Pittsburgh, PA) and used as received. 
7.3.2 Polymer synthesis & characterization 
Sebacic acid (SA) and 1,6-bis(p-carboxyphenoxy)hexane (CPH) prepolymers were 
used to synthesize poly(SA) and the copolymer 20:80 (CPH:SA) by a melt polycondensation 
reaction. The synthesis of the SA and CPH prepolymers has been reported previously by 
Shen et al. [24]. The synthesis of poly(SA) and the copolymer (20:80 CPH:SA) has been 
previously described [25]. The newly synthesized polymers were characterized by Fourier 
transform infrared spectroscopy (FTIR) and gel permeation chromatography (GPC). 
7.3.3 Protein purification 
The plasmid pTrcHisUtc2, previously constructed by Ryon et al. [26], containing the 
full-length uterocalin cDNA and a 6X histidine tag, was amplified in XL1 Blue E. coli. The 
cells were first inoculated in a 10 ml culture (100 g/L tryptone, 5 g/L yeast extract, 5 mM 
159 
NaCl, 143 mM ampicillin) and grown at 37°C, 200 rpm for 16 h. The culture was then added 
to 2 L of superbroth (32 g/L tryptone, 5 g/L yeast extract, 170 mM NaCl, 5 mM NaOH, 143 
mM ampicillin) and allowed to grow under the same conditions until the optical density (OD) 
was between 0.7 and 0.9. Isopropyl-P-D-thiogalactopyranoside (IPTG) was then added to the 
culture to induce the production of the uterocalin. The cells were allowed to grow an 
additional 5 h before harvesting by centrifugation. The harvested cells were lysed (lysis 
solution 50 mM NaPi, 300 mM NaCl, pH 8.0), flash frozen (using liquid nitrogen), and 
stored at -80°C until purification. 
Ni-NTA resin was equilibrated with the lysed cells for 1 h at 4°C. The resin and cell 
solution was then loaded into a narrow bore column (Bio-Rad, Hercules, CA). The resin was 
allowed to settle and the solution was passed through the column. After all of the lysed cell 
solution had run through the column, the resin was washed with additional lysis solution until 
the effluent had an OD < 0.01 at 280 nm. The next step of the purification process was to 
wash the resin with a more acidic wash buffer (50 mM NaPi, 300 mM NaCl, pH 6.0). The 
resin was washed with the wash buffer until the effluent had an OD < 0.01 at 280 nm. The 
uterocalin was then eluted from the Ni-NTA resin in the column using an elution buffer (50 
mM NaPi, 300 mM NaCl, pH 4.5). Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western blotting were used to verify that the purified 
protein was uterocalin. The purified uterocalin was then dialyzed at 4°C against a 5 mM 
ammonia bicarbonate solution for a minimum of 4 h. The dialysate was exchanged a 
minimum of two times before the uterocalin sample was removed for further use. 
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7.3.4 Protein lyophilization 
The purified uterocalin, dissolved in 5 mM ammonia bicarbonate solution was 
atomized, as previously reported, to obtain a fine lyophilized powder [10]. The dissolved 
protein was transferred to a 10 ml gas tight syringe from where it was pumped at 3 ml/min to 
an 8700-1200 MS ultrasonic atomizing nozzle (Sono Tek Corporation, Milton, NY) 
operating at 2.5 W. The atomized protein was collected in 400 ml of liquid nitrogen. The 
liquid nitrogen was allowed to boil off at room temperature and the frozen protein particles 
were dried under vacuum overnight. A JOEL scanning electron microscope (SEM) was used 
to determine the size of the solid protein particles. 
7.3.5 Microsphere fabrication 
Blank and uterocalin-loaded microspheres were fabricated using a cryogenic 
atomization technique [10, 15, 16]. The polymers (100 mg) were first dissolved in methylene 
chloride (3 ml for poly(SA) or 1 ml for 20:80 (CPH:SA)). To fabricate uterocalin-loaded 
microspheres, the atomized uterocalin was suspended by mechanical mixing (Tissue-
Tearor™, Biospec Products, Bartlesville, OK) at 10,000 rpm for 30 s in the polymer solution. 
The protein/polymer suspension (uterocalin-loaded microspheres) or polymer solution (blank 
microspheres) was then transferred to a 10 ml gas tight syringe and pumped at 3 ml/min 
through an ultrasonic atomizing nozzle operating at 1.5 W. From the atomizing nozzle, the 
newly formed microspheres were collected in a layer of liquid nitrogen (200 ml) overlaying a 
frozen layer of ethanol (300 ml). The frozen microspheres and ethanol were stored at -80°C 
for three days to allow the ethanol to slowly thaw, extracting the methylene chloride from the 
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microspheres. The microspheres were collected by filtration and dried under vacuum 
overnight. 
7.3.6 Microsphere characterization 
The percent yield of each batch of uterocalin-loaded microspheres was quantified by 
dividing the mass of recovered microspheres by the initial mass of polymer and protein. 
Scanning electron microscopy (SEM) was used to study the external morphology of the 
uterocalin-loaded microspheres. The samples were coated with 200 Â of gold and then 
examined using a JOEL SEM. 
The loading efficiency of uterocalin (the percent of initial uterocalin loaded into the 
microspheres) was quantified by measuring the amount of protein extracted from the 
uterocalin-loaded microspheres. Polyanhydrides degrade faster under alkaline conditions; 
hence, sodium hydroxide was used to expedite the polymer degradation, as previously 
reported [10,16]. Briefly, the protein-loaded microspheres (15 mg) were suspended by 
sonication (Sonics & Materials Inc., Newton, CT) in 1 ml of 17 mM NaOH and loaded into a 
syringe. The test tube was then rinsed with 2 ml of 17 mM NaOH to ensure all microspheres 
were collected. The 3 ml microsphere suspension was then injected into a 3500 molecular 
weight cut off (MWCO) dialysis cassette (Pierce). The cassette was suspended in 600 ml of 
17 mM NaOH for 4 days at room temperature. The 3500 MWCO dialysis cassette was used 
to retain the released uterocalin while allowing the polymer degradation products (monomers 
and oligomers) to be removed from the cassette. The concentration of the uterocalin in the 
dialysis cassette after 4 days in the alkaline solution was determined using the BCA assay. 
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7.3.7 Sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) 
Uterocalin-loaded microspheres (15 mg) were suspended in 1 ml of Hanks' balanced 
salt solution, 0.01% sodium azide and incubated at 37°C and mixed at 100 rpm. After 2 h of 
incubation, the supernatant was removed and replaced with fresh solution. The microspheres 
were incubated an additional 46 h at which time the supernatant was again sampled and the 
molecular mass of the released protein was analyzed using SDS-PAGE. Each protein sample 
was mixed (1:2) with a loading buffer (1% w/v SDS, 0.006 mM Tris-HCL pH 6.8, 3 mM 
glyercol, 0.01% w/v bromophenal blue, and 0.05% v/v P-mercaptoethanol) and heated to 
96°C for 10 min. The samples were then resolved through a 12% polyacrylamide precast gel 
(Tris-HCl; Bio-Rad) using a constant voltage (100 V). The gels were silver stained, 
photographed, and dried. 
7.3.8 In vitro release 
To ascertain the rate of uterocalin release from the poly(SA) and 20:80 (CPH: SA) 
microspheres in vitro release experiments were conducted. The uterocalin-loaded 
microspheres (15 mg) were suspended in 1 ml of Hanks' balanced salt solution containing 
0.01% sodium azide. The microsphere suspension was incubated at 37°C and 100 rpm for 
the entire duration of the experiment. At predetermined times, 0.75 ml of the supernatant 
was removed and fresh solution was added to maintain constant sink conditions. The 
concentration of uterocalin in the sampled supernatant was quantified using the BCA assay. 
All experiments were performed in triplicate. The cumulative amount of uterocalin released 
at each time point was normalized by the total amount of uterocalin released from the 
microspheres to obtain the mass fraction of uterocalin released as a function of time. 
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7.3.9 Incubation of microspheres for cell migration assay 
Playford et al. [22] reported that uterocalin increased that rate of cell migration of 
HT29 cells in a dose dependent manner up to a concentration 15 (xg/ml, and that above this 
concentration there was no increase in the rate of cell migration. The results from this work 
demonstrate that uterocalin administered at a concentration of 5 ng/ml increases the rate of 
cell migration. After the formation of a wound (i.e., scraping away part of the cell monolayer 
in vitro), the cells migrate for -24 h before proliferation begins. In the first 24 h, only 35% 
and 24% of the encapsulated uterocalin was released from the poly(SA) and 20:80 (CPH: SA) 
microspheres, respectively (see results of in vitro release experiment below). When using 2 
mg of microspheres this small percentage of released uterocalin would not be enough to raise 
the concentration of uterocalin in the medium to 5 jj,g/ml. To ensure that enough uterocalin 
was released from the polyanhydride microspheres to reach a concentration of 5 pg/ml, the 
microspheres were incubated in phosphate buffer saline (PBS) prior to being added to the 
wounded cells. Approximately 2 mg of microspheres (either blank or uterocalin-loaded) 
were suspended in 100 ja.1 of PBS and allowed to degrade at room temperature for 5 days. 
After five days, the microspheres were then removed by sterile filtration using a Spin-X 0.22 
jj.m centrifuge tube filter (Costar, Cambridge, MA) and the sterilized solution was then used 
in the cell migration assay. To test the affect blank microspheres and free uterocalin had on 
the rate of cell migration the blank microspheres were allowed to degrade for 5 days and 
were then mixed with the free uterocalin (15 ng/ml) and then the suspension was sterile 
filtered. 
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7.3.10 Cell migration assay 
HT29 (human colonic epithelial cells) cells were provided by Dr. Diane Birt at Iowa 
State University. The cells were grown at 37°C in 10% CO2 until confluent in McCoy's 5 A 
medium (Gibco-Life Technologies, Grand Island, N.Y.) containing 10% calf serum and 10 
units/ml of penicillin and streptomycin. The cells were grown on 35 x 10 mm polystyrene 
culture dishes with an external 2 mm grid on the bottom of the dish. Once the cells were 
confluent, the medium was removed and replaced with McCoy's 5 A media (0.2% calf serum, 
10 units/ml of penicillin and streptomycin). The cells were then incubated for 24 h in the 
reduced serum medium before wounding the cells. The cells were wounded by removing % 
of the cells on the plate (leaving the cells in the middle of the plate) using a cell lifter 
(Coming Incorporated, Coming, N.Y.). The culture dishes were then washed three times 
with Tris-HCl buffer saline (TBS) to remove non-adherent cells. A volume of 2 ml of fresh 
McCoy's 5 A media (0.2% calf serum, 10 units/ml of penicillin and streptomycin) was then 
added to the cells. At this time, the treatments were added to the culture dishes. The 
following treatments were tested: epidermal growth factor (EGF) (used as positive control), 
buffer, free uterocalin (15 pg/ml and 5 jag/ml), the sterilized release medium in which blank 
poly(SA) microspheres were degraded in (5 days), uterocalin released from poly(SA) 
microspheres (final uterocalin concentration 5 jj.g/ml), the sterilized release medium in which 
blank poly(SA) microspheres were degraded in (5 days) plus free uterocalin (15 jj.g/ml), the 
sterilized release medium in which blank 20:80 (CPH:SA) microspheres were degraded in (5 
days), uterocalin released from 20:80 (CPH: S A) microspheres (final uterocalin concentration 
5 jig/ml), the sterilized release medium in which blank 20:80 (CPH:SA) microspheres were 
degraded in (5 days) and free uterocalin (p.g/ml). The final concentration of EGF used was 
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10 nM, a concentration previously shown to increase the rate of cell migration [27]. Table 
7.1 shows the concentrations and volumes used in each treatment. 
The wounded cells were imaged immediately after the treatments were added and the 
same region of the wound (determined by the exterior grid on the bottom of the petri dish) 
was imaged 24 h later. The rate of cell migration was determined by quantifying how far 
from the initial wound edge the cells had migrated after 24 h. The cells were magnified 10-
fold with a Nikon Eclipse TE200 microscope and imaged with a Hamamatsu digital camera. 
During the imaging period, the cells were incubated at 37°C in 10% CO2. A minimum of 
five images was taken of each wound at day 0 and day 1. 
Table 7.1. Experimental treatments tested for their ability to increase the rate of HT29 cell 
migration after being wounded. 
Treatment Uterocalin3 Microspheres'5 EGF0 
Buffer - - -
EGF - - 10 nM 
Uterocalin 15 & 5 ng/ml - -
Poly(SA) blank microspheres - 2 mg -
Uterocalin-loaded poly(SA) - 2 mg -
microspheres 
Poly(SA) blank microsphere 15 |-ig/ml 2 mg -
and free uterocalin 
20:80 (CPH: SA) blank - 2 mg -
microspheres 
Uterocalin-loaded 20:80 - 2 mg -
(CPH:SA) microspheres 
20:80 (CPH:SA) blank 15 ng/ml 2 mg -
microspheres & free uterocalin 
"47.5 (il of sterile PBS was added to all cells, either with or without uterocalin. b100 |il of 
PBS was added to all cells with or without suspended microspheres. e6 (4.1 of 10 mM acetic 
acid and 0.1% BSA with or without EGF was added to all cells. 
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7.3.11 Data analysis 
Adobe Photoshop 9.0 was used to label the wound edge on the cell images from day 
0. The images from day 1 were superimposed and aligned on the day 0 images. The original 
wound edge from day 0 was applied to the day 1 image. The distance that the cells had 
moved from the initial wound edge in 24 h was measured in ten different locations on each 
picture using the Image J software (NIH). 
The average distance of cell migration for each individual plate was calculated from 
the five pictures per wound (10 points per picture). All treatments were then compared to the 
negative control (buffer) using a linear multiple regression model that accounted for the 
unequal variance between treatments by taking the log of the response. The treatments that 
were significantly different from the negative control were noted. The differences in 
treatment responses were not correlated when the experiment was performed, and hence the 
variance due to different days was not included in the statistical model. The variances 
between treatments were found to be unequal, hence the log of the responses were used in the 
linear multiple regression statistical model. 
7.4 Results 
7.4.1 Uterocalin lyophilization 
In order to obtain salt-free lyophilized uterocalin, ammonium bicarbonate (a volatile 
solution under vacuum) was used as the solvent for the lyophilization process. After the 
uterocalin solution had been atomized into liquid nitrogen and dried under vacuum, SEM was 
used to verify that the solid protein particles had diameters < 1 p.m. It was essential that the 
protein particles be smaller than the polymer microspheres (average diameter ~ 18 |im) in 
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order to ensure that the protein could be encapsulated in the polymer microspheres and to 
increase the encapsulation efficiency. In all cases, the uterocalin lyophilized by the above 
procedure fit this criterion. 
7.4.2 Microsphere characterization 
The average yield of seven batches of either the poly(SA) or 20:80 (CPH:SA) 
uterocalin-loaded microspheres was 69%, as shown in Table 7.2. 
Table 7.2. Yields and loading efficiencies of uterocalin-loaded poly(SA) and 20:80 
(CPH:SA) microspheres. 
Polymer Yield Encapsulation Efficiency 
(%) (%) 
Poly(SA) 69  ±7  51  ±16  
20:80 (CPH:SA) 69  ±9  77 ± 19 
All numbers are calculated from a minimum of seven different microsphere batches. The ± 
values represent a 95% confidence interval. 
The surface morphology of the uterocalin-loaded microspheres was analyzed using 
SEM. The microspheres were first viewed at low magnifications to ensure that the particles 
were spherical. Higher magnifications were then used to view in more detail the surface 
morphology of individual microspheres. Figure 7.1 shows two magnifications of uterocalin-
loaded poly(SA) and 20:80 (CPH:SA) microspheres. The poly(SA) microspheres had a 
smoother surface than the 20:80 (CPH:SA) microspheres as previously reported [10]. The 
difference in the surface morphology of the poly(SA) and 20:80 (CPH:SA) microspheres is 
attributed to the two polymers having different rates of precipitation in the non-solvent, 
ethanol. Poly(SA) had a smoother external morphology because it precipitated slower, while 
20:80 (CPH:SA) precipitated more rapidly resulting in a rougher external surface. 
168 
Figure 7.1. Scanning electron photomicrographs showing the surface morphology of 
poly(SA) (panels a and b) and 20:80 (CPH:SA) (panels c and d). 
The encapsulation efficiency of uterocalin loaded into the poly(SA) and 20:80 
(CPH:SA) microspheres was 51% and 77%, respectively, as shown in Table 7.2. These 
values were in agreement with the total mass fraction of uterocalin released from the 
poly(SA) and 20:80 (CPH:SA) microspheres in the in vitro release experiment as discussed 
below. These encapsulation efficiencies were lower than previously reported encapsulation 
efficiencies using the same fabrication method [10, 16]. The lower encapsulation efficiencies 
may be a result of the N-terminal poly-histidine tag of the protein interacting with the 
polymer degradation products (being more reactive with the SA degradation products) and 
interfering with the detection assay. 
7.4.3 SDS-PAGE analysis 
The release of uterocalin from the polyanhydride microspheres for the SDS-PAGE 
experiments was performed using Hanks' balance salt solution with 0.01% sodium azide. 
Hanks' balanced salt solution was used to mimic physiological conditions and sodium azide 
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was added to the solution to inhibit bacterial contamination. In order to determine the 
primary structure of the encapsulated and released uterocalin, the supernatant was sampled 
after 2 h of incubation to remove any uterocalin that may not have been encapsulated or that 
was loaded onto the surface of the microspheres. This ensured that only uterocalin that had 
been encapsulated and released from the microspheres was studied by electrophoresis. 
The uterocalin released from poly(SA) and 20:80 (CPH:SA) microspheres detected 
on the resolving gel appeared at 24 kDa consistent with its native primary structure, see 
Figure 7.2. This result indicated that the released uterocalin was intact and no alterations in 
its primary structure (cleavage or aggregation) occurred during the encapsulation or release 




Figure 7.2. SDS-PAGE analysis of uterocalin released from polyanhydride microspheres. 
Lane 1 : molecular mass standards, lane 2: uterocalin released from poly(SA) microspheres, 
Lane 2: uterocalin released from 20:80 (GPU:SA) microspheres. 
Uterocalin 
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7.4.4 In vitro release kinetics 
The in vitro release profile of uterocalin from poly(SA) and 20:80 (CPH:SA) 
microsphere is shown in Figure 7.3. To obtain the mass fraction of uterocalin released, the 
total amount of uterocalin released was used to normalize the concentration of uterocalin at 
each time point in the experiment. 
The concentration of released uterocalin was measured 2 h after the start of the 
experiment to determine the initial burst. The initial burst accounted for -22% of the total 
uterocalin released from the microspheres. This is comparable to previous work in which a 
30% burst was observed when ovalbumin was encapsulated in poly(SA) microspheres 
fabricated using the cryogenic atomization method [10]. When solid proteins are 
encapsulated in polymeric microspheres, larger bursts are typically seen due to the difficulty 
of evenly distributing the protein throughout the polymer [28]. The release of the uterocalin 
from either poly(SA) or 20:80 (CPH:SA) microspheres followed a zero-order release after 
the initial burst. All of the uterocalin was released from the poly(SA) microspheres within 15 
days while it took 30 days for all of the uterocalin to be released from the 20:80 (CPH:SA) 
microspheres. Because 20:80 (CPH:SA) is more hydrophobic than poly(SA), it was 
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Figure 7.3. In vitro release of uterocalin from (filled circles) poly(SA) and (open squares) 
20:80 (CPH:SA) microspheres. Release of uterocalin from the microspheres was performed 
in triplicate as described in Materials and Methods. 
7.4.5 Cell migration assay 
Twenty-four hours prior to wounding, the cell monolayer the culture medium was 
changed from 10% calf serum to 0.2% calf serum. The cell migration assay was then 
performed under the serum-limiting conditions. The reduced serum concentration was used 
to lower the concentration of proteins and growth factors present in the serum and secreted 
by the growing cell population. These proteins and growth factors could influence the rate of 
cell migration minimizing the observable differences between the treatments. 
The results of the cell migration assay are shown in Figure 7.4. All treatments were 
compared to the negative control (buffer) and any statistical differences between a given 
treatment and the negative control are noted on the histogram. Differences between 
treatments were also compared and are noted by brackets on the histogram. EOF (10 nM), 
used as a positive control, showed the largest increase in the rate of cell migration over a 24 h 
period. This increase in cell migration due to EGF is well documented in the literature [27]. 
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Playford et al. [22] have previously reported that uterocalin affects the rate of HT29 cells 
migration in a dose dependent manner up to a concentration of 15 )ig/ml. To verify these 
experimental results, two concentrations (15 pg/ml and 5 jig/ml) of free uterocalin were 
added to wounded HT29 cells and tested for their ability to increase the rate of cell 
migration. No difference was found between the rates of cell migration when 15 |j,g/ml or 5 
p.g/ml of uterocalin was added to the cells, though both treatments increased the rate of cell 
migration over the negative control. 
5 i i i i i i i i i 
Figure 7.4. Histogram showing the average distance (arbitrary units) that wounded HT29 
cells migrated in 24 hours after being exposed to each treatment: (1) buffer, (2) EGF (10 
nM), (3) uterocalin (15 pg/ml), (4) uterocalin (5 jag/ml), (5) blank poly(SA) microspheres (2 
mg), (6) uterocalin-loaded poly(SA) microspheres (2 mg), (7) blank poly(SA) microspheres 
(2 mg) and free uterocalin (15 pg/ml), (8) blank 20:80 (CPH:SA) microspheres (2 mg), (9) 
uterocalin-loaded 20:80 (CPH:SA) microspheres (2 mg), (10) blank 20:80 (CPH:SA) 
microspheres (2 mg) and free uterocalin (15 j-ig/ml). Error bars represent 95% confidence 
intervals of treatments. ** represents p-value of < 0.01, * represents p-value of < 0.05 when 
compared to the negative control (buffer), brackets show statistical difference between 
treatments. 
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To assess if blank poly(SA) or 20:80 (CPH:SA) microspheres stimulated or inhibited 
cell migration, the supernatant in which ~2 mg of blank microspheres had been incubated for 
5 days was administered to the 2 ml culture of wounded HT29 cells. The rate of cell 
migration for the cells treated with buffer and the blank microspheres were identical 
indicating that the blank microspheres had no effect on the migration of the cells. 
When uterocalin released from either poly(SA) or 20:80 (CPH:SA) microspheres 
(previously incubated for 5 days) was added to the wounded monolayers, a statistically 
significant increase in the rate of cell migration was observed as compared to the negative 
control (buffer) and to the blank microspheres added to the wounded cells. There was no 
statistical difference between the cells treated with the uterocalin-loaded microspheres and 
cells treated with free uterocalin. This indicated that the uterocalin released from the 
polyanhydride microspheres was released as a biologically active protein. 
Uterocalin mixed with blank microspheres (that had been allowed to degrade for 5 
days in PBS) of either poly(SA) or 20:80 (CPH:SA) and added to the wounded cells failed to 
increase the rate of cell migration. This is attributed to the adsorption of the free protein to 
the surface of the microspheres prior to the sterile filtration. 
7.5 Conclusions 
Uterocalin was successfully encapsulated in poly(SA) and 20:80 (CPH:SA) 
microspheres using the cryogenic atomization fabrication technique. The encapsulation 
efficiency of uterocalin in polyanhydride microspheres was lower than that reported in 
previous work using the same polymers and the same microsphere fabrication technique [10]. 
This result is attributed to the interaction of the N-terminal poly-histidine tag of the protein 
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with the degradation products of the polymers (primarily of poly(SA)), thus interfering with 
the detection assay. Uterocalin is known to bind low molecular weight ligands, though the 
monomers of CPH would be more hydrophobic than SA monomers there would be more SA 
monomers present in the supernatant. The strength of the bonds between monomer units is 
as follows CPH-CPH > CPH-SA and SA-SA, thus it would take less time for a SA-SA bond 
to be broken than it would for a CPH-CPH bond in the copolymer [29]. 
This work has demonstrated that polyanhydride microspheres can conserve the 
structural integrity of an encapsulated protein and that the released protein is biologically 
active. The uterocalin released from the poly(SA) and 20:80 (CPH:SA) microspheres was 
released as an intact protein, as demonstrated by SDS-PAGE analysis. The uterocalin 
released from the polyanhydride microspheres was found to increase the rate of cell 
migration of HT29 cells supporting previous reports [22] and indicating that the biological 
activity of the protein was maintained after being encapsulated in poly(SA) and 20:80 
(CPH: SA) microspheres. 
When blank microspheres (previously incubated for 5 days) were added to the 
wounded cells that were treated with 15 ng/ml of free uterocalin, no difference in the rate of 
cell migration was observed. The blank microspheres used in this work were semi-
crystalline and their erosion rates are slower than that of the uterocalin-loaded microspheres 
[30]. This is attributed to the decreased degree of crystallinity of polyanhydrides when they 
are mixed with small amounts of compatible drugs. As a result, the increased hydrophobic 
surface area of the blank microspheres causes more of the free uterocalin to adsorb to the 
polymer microspheres and prevents it from interacting with the cells. Thus, no difference in 
the rate of cell migration is observed. Uterocalin mixed with poly(SA) microspheres 
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deviated statistically from the samples treated with uterocalin-loaded poly(SA) microspheres. 
However, there was only weak evidence of a statistical difference between the cells treated 
with free uterocalin mixed with 20:80 (CPH:SA) microspheres and cells treated with 
uterocalin-loaded 20:80 (CPH:SA) microspheres (p-value < 0.1). Because poly(SA) is more 
crystalline than 20:80 (CPH:SA) [24] there is a larger difference in the rate of degradation 
between a blank poly(SA) microsphere and a uterocalin-loaded poly(SA) microspheres than 
there is between a blank 20:80 (CPH:SA) microsphere and a uterocalin-loaded 20:80 
(CPH:SA) microsphere. 
The potential for using polyanhydride microspheres as protein carriers is enormous. 
They can stabilize proteins while providing a controlled release that can be altered by varying 
the polymer chemistry. 
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CHAPTER 8 
CONCLUSIONS AND FUTURE DIRECTIONS 
The goal of this research was to demonstrate that polyanhydrides, specifically 
poly(sebacic anhydride) (poly(SA)) and copolymers of [ 1,6-bis-p(carboxyphenoxy)hexane] 
(CPH) and SA, can be used to stabilize and provide controlled release of proteins. This 
project was broken up into four specific goals: 
1. Demonstrate the feasibility of using polyanhydrides microspheres as protein 
carriers. 
2. Discern the compatibility of proteins with biodegradable polymer degradation 
products. 
3. Study the role of microsphere fabrication methods on protein stability. 
4. Apply the insights gained from specific goals 1, 2, and 3 to design uterocalin-
loaded polyanhydride microspheres to expedite cell migration for applications 
in wound healing. 
Specific goal 1 was discussed in Chapter 4. Bovine serum albumin (BSA) was 
encapsulated and released from poly(SA), 20:80 (CPH:SA), 50:50 (CPH:SA), and 80:20 
(CPH:SA) microspheres. The microspheres were fabricated using the standard water-oil-
water fabrication technique. The BSA released from the polyanhydride microspheres was not 
aggregated; it was released as an intact polypeptide chain. Each of the polymer compositions 
used to encapsulate BSA prevented the formation of inter-protein multimers via disulfide 
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bonds. Cleavage of the protein only occurred when the protein was allowed to incubate for 
extended periods of time with the acidic polymer degradation products. As the 
hydrophobicity of the polymer increased (increasing amounts of CPH) the a-helix content of 
the encapsulated protein decreased steadily to a point were no a-helices were detected in the 
protein encapsulated within 80:20 (CPH:SA). These results demonstrated that poly(SA) and 
20:80 (CPH:SA) were capable of stabilizing BSA. This work also showed for the first time 
that the increased hydrophobicity of the copolymers 50:50 (CPH: SA) and 80:20 (CPH: SA) 
was not conducive for stabilizing encapsulated proteins. 
Specific goal 2 was addressed in Chapter 5. The changes in structure and activity or 
antigenicity of ovalbumin, lysozyme, and tetanus toxoid were studied after the proteins were 
incubated with the monomers (degradation products) of polyanhydrides (poly(SA) and 
poly(CPH)) and polyesters (poly(lactic acid) and poly(glycolic acid)). The results of this 
work demonstrated the importance of understanding the effect of the polymer degradation 
environment on the structure of the protein. Ovalbumin and tetanus toxoid were least stable 
in the presence of the ester monomers. However, ovalbumin was more stable in the presence 
of the SA monomer while tetanus toxoid was more stable in the presence of the CPH 
monomer. Lysozyme, an acid stabilized protein, was found to be stable in the presence of 
either ester or anhydride monomers. These experiments demonstrated a rational approach for 
selecting compatible protein/polymer systems prior to encapsulating proteins in polymer 
microspheres. 
Though specific goal 2 answered a lot of questions, it has raised new questions that 
should be addressed in future investigations. The work demonstrated a protocol for 
determining protein/monomer compatibility. Future investigations should address how well 
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the described protocol predicts the stability of proteins in in vitro and in vivo release 
experiments. These experiments should first be done with proteins encapsulated in polymer 
tablets to ensure that any instability of the protein is a result of the polymer/protein 
interactions and not a result of a fabrication technique (e.g., microsphere fabrication). The 
work could then be repeated with polyester and polyanhydride microspheres to obtain an in-
depth comparison of the two types of polymer delivery systems. 
Chapter 6 addressed specific goal 3. Four different microsphere fabrication 
techniques were used to examine the stability of ovalbumin released from poly(SA) and 
20:80 (CPH:SA) microspheres. Poly(SA) and 20:80 (CPH:SA) were used because these 
were the polyanhydrides that stabilized the encapsulated and released protein in specific goal 
1. The methods used to fabricate the poly(SA) and 20:80 (CPH:SA) microspheres were: 
water-oil-water (w/o/w), water-oil-oil (w/o/o), solid-oil-oil (s/o/o), and a cryogenic 
atomization procedure. The ovalbumin released from the poly(SA) and 20:80 (CPH:SA) 
microspheres made by each of the four fabrication methods maintained its primary structure. 
The only case in which the protein secondary structure deviated (i.e., reduced a-helix 
content) from that of the native protein was 20:80 (CPH:SA) microspheres fabricated via the 
water-oil-water method. This decrease was a combination of the increased hydrophobicity of 
the copolymer and the presence of two water-oil interfaces during the microsphere 
fabrication process. It is well known that in the presence of a water-oil interface, ovalbumin 
is more susceptible to aggregation than BSA [1]. 
By directly comparing the yield, protein loading efficiency, protein stability, and 
protein release kinetics it was possible to determine the preferred microsphere fabrication 
method for different delivery applications. When the protein was encapsulated as a 
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lyophilized powder (s/o/o and cryogenic atomization) the initial burst was larger than when it 
was encapsulated in an aqueous solution (w/o/w and w/o/o). In all cases, after the initial 
burst, the release of ovalbumin followed zero order kinetics. The cryogenic atomization 
method should be used for future applications (in which the delivery application requires a 
substantial burst followed by a zero order release) because it had the highest loading 
efficiency (it did have the lowest yield but this was later improved in specific goal 4), 
eliminated any water-oil interfaces, stabilized the encapsulated protein, and provided a 
controlled release with a moderate initial burst. 
Because each protein is different, future investigations should repeat the above 
studies with different proteins to determine the preferred fabrication method for each protein 
(e.g., low molecular weight proteins, or proteins with a free thiol group). Future applications 
should also test how the different microsphere fabrication methods affect the biological 
activity of the released protein. 
Chapter 7 addressed specific goal 4. In this work, uterocalin was encapsulated in 
poly(SA) and 20:80 (CPH:SA) microspheres using the cryogenic atomization method. The 
primary structure of the released protein was conserved and the protein was biologically 
active as determined by a cell migration assay. The uterocalin released from polyanhydride 
microspheres was added to a monolayer of wounded human colon epithelial cells (HT29) and 
its ability to increase the rate of cell migration was studied. The uterocalin released from 
poly(SA) and 20:80 (CPH:SA) microspheres maintained its biological activity, providing 
evidence that polyanhydrides are suitable protein carriers. 
Future therapeutic applications of protein-loaded polyanhydride microspheres should 
focus on diseases that require prolonged drug therapy (e.g. cancer, chronic diseases, and 
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preventative medicines). Once an appropriate alignment is identified further research should 
focus on identifying the most appropriate delivery route to the body and how the body 
uptakes the device and the encapsulated drug. One area that should be considered is 
targeting macrophages with drug-loaded nanoparticles (< 1 pm). Macrophages are excellent 
targets for drug delivery devices because they not only can remove nanoparticles from the 
blood within minutes of injection but they also contribute to inflammation (e.g. rheumatoid 
arthritis) and serve as hosts to infectious diseases (e.g HIV) [2], Because human 
macrophages typically have a lifespan of 1-3 months, similar to the amount of time needed to 
degrade a polyanhydride, polyanhydride nanoparticles may make excellent drug carriers for 
macrophage drug targeting. This work would require the fabrication of nanoparticles, which 
could be obtained by altering the fabrication techniques discussed in this work. 
Besides targeting macrophages, polyanhydrides should be investigated as vehicles for 
targeted drug delivery. By functionalizing a polymer (e.g., by chemically attaching an 
antibody or peptide chain) it can be made to specifically target specific tissues or organs in 
the body. Specifically targeting a tissue or organ in the body and localizing the drug delivery 
there maximizes the drug potential while minimizing the side effects. Polyanhydrides are 
end-capped with carboxylic acid groups, thus enabling the chemical attachment of antibodies 
or peptide chains. Previous work done with polyester (PLGA) microspheres/nanospheres has 
shown that by covalently linking ligands to the carboxylic end groups of the polymer, it is 
possible to deliver a drug-loaded polymeric particle to a specific site [3, 4], 
This work has provided evidence that polyanhydrides stabilize proteins (BSA, 
ovalbumin, and uterocalin) and that the degradation products of polyanhydrides do not 
reduce the antigenic response of proteins (e.g. ovalbumin and tetanus toxoid). Previous work 
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in our research group showed the potential of polyanhydride microspheres loaded with 
tetanus toxoid to modulate the immune response of mice [5]. This novel trait of 
polyanhydrides should be further investigated with other antigenic proteins. 
In summary, this work has demonstrated the ability of polyanhydride microspheres to 
stabilize and provide a controlled release of proteins. This work has addressed questions 
raised in previous research and voids in the literature including the design of a rational 
approach for selecting compatible polymer/protein systems and the direct comparison of 
microsphere fabrication methods. This work has also laid the groundwork for future 
applications of protein-loaded polyanhydride microspheres. 
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